US20200247885A1 - P2x4 antibodies & uses thereof - Google Patents

P2x4 antibodies & uses thereof Download PDF

Info

Publication number
US20200247885A1
US20200247885A1 US16/840,910 US202016840910A US2020247885A1 US 20200247885 A1 US20200247885 A1 US 20200247885A1 US 202016840910 A US202016840910 A US 202016840910A US 2020247885 A1 US2020247885 A1 US 2020247885A1
Authority
US
United States
Prior art keywords
prt
chain variable
variable region
antibody
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/840,910
Inventor
Wendy A. WILLIAMS
Clare Jones
James BUTTON
John LINLEY
Harm Jan SNIJDER
Ling Huang
Yoko Shibata
Sudharsan SRIDHARAN
Maria Groves
Claire Dobson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Priority to US16/840,910 priority Critical patent/US20200247885A1/en
Assigned to MEDIMMUNE LIMITED reassignment MEDIMMUNE LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ASTRAZENCA AB
Assigned to ASTRAZENECA AB reassignment ASTRAZENECA AB ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SNIJDER, Harm Jan
Assigned to MEDIMMUNE LIMITED reassignment MEDIMMUNE LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HUANG, LING, WILLIAMS, WENDY A., BUTTON, James, DOBSON, CLAIRE, GROVES, MARIA, JONES, CLARE, LINLEY, John, SHIBATA, YOKO, SRIDHARAN, Sudharsan
Publication of US20200247885A1 publication Critical patent/US20200247885A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Definitions

  • Chronic pain serves no beneficial purpose, but arises from pathological alterations in nociceptive neural networks.
  • Neuropathic pain is a form of chronic pain that arises after nerve injury caused by trauma, infection, or pathology. Neuropathic pain persists long after the initiating event has healed. While neurons are involved in neuropathic pain, they are unlikely to be the sole cell type mediating this condition.
  • the ion channel P2X4 is one of seven members of a family of purinergic, cation permeable channels. Each P2X4 subunit has two transmembrane domains, separated by a large ⁇ 280 amino acid extracellular domain. Functional channels are formed of a trimeric arrangement of subunits with a central pore.
  • the P2X4 channel is activated by binding of the ligand adenosine 5′-triphosphate (ATP) to residues contained within its extracellular domain. Activation of these receptors instigates a series of conformational changes that allow cations, such as Ca 2+ and Na + , entry into the cell through a cation selective channel.
  • ATP adenosine 5′-triphosphate
  • P2X4 activation and upregulation is thought to be a key driver of neuropathic pain.
  • microglia Downstream of P2X4 activation, microglia release brain derived neurotrophic factor (BDNF), which acts on spinal lamina I neurons to reduce expression of a neuronal chloride transporter KCC2, thereby altering the electrochemical gradient for chloride and rendering one of the main inhibitory neurotransmitters GABA excitatory. Therefore, P2X4-mediated BDNF release in spinal cord is thought to be a key driver of neuropathic pain.
  • BDNF brain derived neurotrophic factor
  • Neuropathic pain fails to respond to currently available analgesics, and is considered to be one of the most debilitating chronic pain conditions. Accordingly, improved methods for treating neuropathic pain, particularly pain mediated by P2X4 are urgently required.
  • the present invention provides antibodies that specifically bind a P2X4 polypeptide and modulate P2X4 channel activity, recombinant P2X4 polypeptides and methods for generating such polypeptides, as well as compositions and methods for generating anti-P2X4 antibodies, and methods of using P2X4 antibodies for the treatment of neuropathic pain and other indications.
  • the invention provides an antibody or antigen binding fragment thereof that specifically binds a human P2X4 polypeptide and modulates channel activity.
  • the antibody is a P2X4 potentiator.
  • the antibody is a P2X4 antagonist.
  • the antibody is a P2X4 modulator.
  • the antibody is a P2X4 antagonist that reduces P2X4 biological activity by at least about 10, 25, 50, 75, 85, 90 or 95%.
  • the antibody binds an epitope containing human P2X4 amino acids 110-166.
  • the antibody binds an epitope containing one or more human P2X4 amino acids selected from any one or more of amino acids 118, 122-139, 145, 159, 180, 183, 184, 231, and 244.
  • an amino acid substitution at position 131 of P2X4 reduces or eliminates antibody binding to a human P2X4 polypeptide.
  • the serine at position 131 of human P2X4 is substituted by Asparagine.
  • the antibody or fragment thereof contains:
  • a heavy chain variable region CDR2 containing a sequence X 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 X 13 X 14 X 15 X 6 (SEQ ID NO: 1029), where X 1 is A, R, I, T, E, S, A, V, W, N, G, E, R, or Y; X 2 is I or M; X 3 is S, K, Y, D, N, W, or I; X 4 is S, D, G, H, N, R, Y, or V; X 5 is G, D, S, F, N, R, F, D, or T; X 6 is G, S, N, or T; X 7 is S, T, D, Y, N, A, E, M, F, or D; X 8 is T, I, K, or A; X 9 is Y, D, R, N, G, Q, E, H,
  • a heavy chain variable region CDR3 containing a sequence X 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 (SEQ ID NO: 1011), where X 1 is E, N, D, R, K, G, S, A, Y, V, P, or H; X 2 is E, L, R, Q, T, G, F, P, Y, K, A, S, V, or F; X 3 is R, A, T, G, V, S, M, W, Y, D, H, N, E, L, or I; X 4 is G, L, R, D, T, G, Y, S, E, F, Q, C, I, M, V, N, K, or P; X 5 is S, G, Y, D, W, T, S, N, I, D, V, E, or C; X 6 is Y, A, S, W, T, L, G, E, F, K, V, I, or
  • the heavy chain variable region CDR2 optionally contains an insertion of 1-3 amino acids, X a X b X c between amino acids X 3 and X 4 , where X a is G, S, P, W, Y, E, A, R, or N; and X b X c are KT, respectively.
  • the heavy chain variable region CDR3 optionally contains an insertion of 1-14 amino acids Xa-Xn (SEQ ID NO: 1012), where X a is F, R, S, Y, L, D, G, V, I, T, or A; X b is G, R, Y, F, T, D, S, G, V, M, D, or R; X c is F, W, A, G, T, I, S, F, Y, C, L, V, R, or N; X d is S, F, M, G, Y, L, S, A, D, L, R, V, C, or S, X e is G, Y, S, T, P, F, Y, R, A, E, G, Q, N, or L; X f is Y, N, G, T, R, F, A, M, W, P, or V; X g is Y, M, S, V, F, A, P, S, S,
  • the heavy chain variable region CDR1 contains the sequence SYX 1 MX 2 (SEQ ID NO: 1063), where X 1 is A, W, Y, S, G, F, E, D, or P and X 2 is S, G, T, H, or N.
  • the heavy chain variable region CDR1 contains the sequence XYAMS (SEQ ID NO: 1064), where X is S, D, G, N or R; SXAMS (SEQ ID NO: 1065), where X is Y, A, H, F, or S; SYXMS (SEQ ID NO: 1066), where X is A, W, Y, S, G, F, E, D, or P; SYAXS (SEQ ID NO: 1067), where X is M, I, W, L, F, or V; SYAMX (SEQ ID NO: 1068), where X is S, G, T, H, or N.
  • the heavy chain variable region CDR1 contains amino acids SYAMS (SEQ ID NO: 57).
  • the heavy chain variable region CDR2 contains the sequence AISGSGGSTYYADSVKG (SEQ ID NO: 1069); or AISGSGGSTYYADSVEG (SEQ ID NO: 1070).
  • the heavy chain variable region CDR3 contains the sequence DWYFDL (SEQ ID NO: 1071) or NWYLDL (SEQ ID NO: 1072).
  • the antibody or fragment thereof contains, a.
  • a light chain variable region CDR1 containing a sequence X 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 X 11 (SEQ ID NO: 1013), where X 1 is T, G, R, S, or Q; X 2 is G, A, or L; X 3 is S, T, D, or H; X 4 is S, N, K, A, Q, T, or V; X 5 is G, I, L, S, or D; X 6 is A, G, R, P, I, D, S, E, T; X 7 is G, N, M, D, K, S, R, Y, or T; X 8 is Y, K, F, Q, S, N, Y, D, H, or R; X 9 is D, N, Y, W, F, M, G, or S; X 10 is V, A, L, I, G, or P; X 11 is H, T, S, Y
  • a light chain variable region CDR2 containing a sequence: X 1 X 2 X 3 X 4 X 5 X 6 X 7 (SEQ ID NO: 1014), where X 1 is G, Y, Q, K, N, D, R, A, or E; X 2 is N, D, K, A, V, G, or T, X 3 is N, S, T, I, K, Y, or D; X 4 is N, D, Y, K, E, T, N, S, or Q, X 8 is R, or L; X 6 is P, E, A, S, or Q; X 7 is S, P, or T;
  • a light chain variable region CDR3 containing a sequence X 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 X 9 (SEQ ID NO: 1015), where X 1 is Q, N, A, G, D, S, or L; X 2 is S, V, A, Q, T, L, or H; X 3 is Y, W, R, A, S, Q, T, or G; X 4 is D, Y, I, N, M, or H, X 5 is T, M, S, N, D, R, G, or K, X 6 is N, T, S, G, F, L or D; X 7 is L, T, G, P, A, I, or N; X 8 is K, W, V, I, P, G, L, R, or Y; X 9 is V, L, or T.
  • the light chain variable region CDR1 optionally contains an insertion of between 1 and 3 amino acids X a -X c between X 4 and X 5 , where X a is S or G; X b is N, D or S; and X c is I or V.
  • the light chain variable region CDR3 optionally contains an insertion of between 1 and 3 amino acids X a -X c between X 7 and X 8 , where X a is D, N, A, T, S, I or H; X b is H, Y, G, A, R, L, S, or P; X c is S.
  • the light chain variable region CDR1 contains one of the following sequences: S G D K L (SEQ ID NO: 1034); S G S S SNIG (SEQ ID NO: 1035); SG DAL (SEQ ID NO: 1036); RASQ GISSW LA (SEQ ID NO: 1037); and R A S Q G I S R W L A (SEQ ID NO: 1038).
  • the light chain variable region CDR2 contains one of the following sequences: G X X Y R P S (SEQ ID NO: 1039), where X is T, S, K or K D S E R P S (SEQ ID NO: 1040); K A S T L E S (SEQ ID NO: 1041); Q D X K R P S (SEQ ID NO: 1042), where X is D or T; and Q D I E R P S (SEQ ID NO: 1043).
  • the light chain variable region CDR3 contains one of the following sequences: Q Q S Y S T P W T (SEQ ID NO: 1044) or S S G T Y V V (SEQ ID NO: 1045).
  • the antibody contains a heavy chain variable region CDR1, CDR2, and CDR3. In other embodiments of the above aspects, the antibody contains a light chain variable region CDR1, CDR2, and CDR3. In other embodiments of the above aspects the antibody contains a heavy chain variable region CDR1, CDR2, and CDR3, and a light chain variable region CDR1, CDR2, and CDR3. In other embodiments of the above aspects the antibody is a phage display derived antibody selected from any one or more of Antibody Nos. 1-34. In particular embodiments, the antibody is Antibody No. 5, 8, 11, 18, 29, or 33.
  • the antibody or fragment thereof contains:
  • a heavy chain variable region CDR1 containing a sequence: X 1 X 2 X 3 X 4 X 5 (SEQ ID NO: 1022), where X 1 is S, N, D, T, A, or R; X 2 is G, Y, or F; X 3 is Y, H, S, G, D, or F; X 4 is D, V, or I; X 5 is N, H, C, R, S or is absent;
  • a heavy chain variable region CDR2 containing a sequence: X 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 X 13 X 14 X 15 X 16 (SEQ ID NO: 1023), where X 1 is M, V, L, I, A, G, or T; X 2 is G or I; X 3 is Y, W, N, or C; X 4 is Y, G, D, or W; X 5 is S, D, or E; X 6 is G or D; X 7 is S, Y, N, or I; X 8 is T, P, or K; X 9 is N, A, G, D, or V; X 10 is Y or F; X 11 is N; X 12 is P, S, or E; X 13 is S, A, or N; X 14 is L or F; X 15 is K; X 16 is S, G, or N;
  • a heavy chain variable region CDR3 containing a sequence: X 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 (SEQ ID NO: 1024), where X 1 is G, S, A, or R; X 2 is M, G, Y, S, L, R, or V; X 3 is M, D, I, V, H, M, or S; X 4 is V, Y, M, W, or S; X 5 is L, Y, S or absent; X 6 is I, D, V, T, G, S or absent; X 7 is P, G, D, S, or A; and X 8 is N, Y, or T.
  • the heavy chain variable region CDR1 optionally contains amino acids X 6 and X 7 , which are V and S, respectively.
  • the heavy chain variable region CDR2 optionally contains an insertion of amino acids X a and X b between X 3 and X 4 , where X a is I or P and X b is S.
  • the heavy chain variable region CDR3 optionally contains an insertion of between 1 and 6 amino acids X a -X f (SEQ ID NO: 1025) between X 6 and X 7 , where X a is G, T, D, or Y; X b is S, A, G, or F; X c is Y, V, P, or F; X d is Y or F; X e is Y; and X f is E, F, or G.
  • the heavy chain variable region CDR1 contains the sequence S G Y D (SEQ ID NO: 1046); S G S D (SEQ ID NO: 1047); or S G F D (SEQ ID NO: 1048).
  • the heavy chain variable region CDR2 contains the sequence: M G Y I S Y S (SEQ ID NO: 1049); V I W G D G STA (SEQ ID NO: 1050); S T A Y N S (SEQ ID NO: 1051); or STNY NP (SEQ ID NO: 1052).
  • the heavy chain variable region CDR3 contains the sequence G M M V L I (SEQ ID NO: 1053); G V S S L S (SEQ ID NO: 1054); or G S Y Y Y X (SEQ ID NO: 1055), where X is E, G, or F.
  • the antibody or fragment thereof contains:
  • a light chain variable region CDR1 containing a sequence: X 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 X 11 (SEQ ID NO: 1026), where X 1 is K, Q, or R; X 2 is A or T; X 3 is S, R, or N; X 4 is K or Q; X 5 is S, D, R, N, L, or I; X 6 is I or S; X 7 is T, G, V, or N; X 8 is N, S, H, or K; X 9 is Y or W; X 10 is L, M, or I; X 11 is A, S, or Y;
  • a light chain variable region CDR2 containing a sequence: X 1 X 2 X 3 X 4 X 5 X 6 X 7 (SEQ ID NO: 1027), where X 1 is S, D, E, or Y; X 2 is G, A, or T; X 3 is S or T; X 4 is T, S, K, or A; X 5 is L; X 6 is Q, A, or V; X 7 is S or D;
  • a light chain variable region CDR3 containing a sequence: X 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 X 9 (SEQ ID NO: 1028), where X 1 is Q, L, or H; X 2 is Q or K; X 3 is Y, A, W, or T; X 4 is Y, H, S, or D; X 5 is E, S, R, T, or N; X 6 is K, N, T, L, or H; X 7 is P; X 8 is Y, W, L, N, P, or R; and X 9 is T.
  • the light chain variable region CDR1 contains the sequence K A S K X I T (SEQ ID NO: 1056), where X is X, L, or I; or Q A S Q D I G N W L (SEQ ID NO: 1057).
  • the light chain variable region CDR2 contains the sequence S G S T L Q S (SEQ ID NO: 1058); DATSLAD (SEQ ID NO: 1059); or DATTLAD (SEQ ID NO: 1060).
  • the light chain variable region CDR3 contains the sequence Q Q Y Y E K P X T (SEQ ID NO: 1061) or Q Q Y Y E N P X T (SEQ ID NO: 1062) where X is Y or L.
  • the antibody contains a heavy chain variable region CDR1, CDR2, and CDR3. In other embodiments of the above aspects, the antibody contains a light chain variable region CDR1, CDR2, and CDR3. In still other embodiments of the above aspects, the antibody contains a heavy chain variable region CDR1, CDR2, and CDR3, and a light chain variable region CDR1, CDR2, and CDR3. In particular embodiments, the antibody is a hybridoma derived antibody selected from any one or more of Antibody Nos. 35-48.
  • the antigen binding fragment thereof is a single chain antibody, a single chain variable fragment (scFv), a Fab fragment, or a F(ab′)2 fragment.
  • the invention provides a polynucleotide encoding the antibody or antigen binding fragment thereof of any of the above aspects.
  • the invention provides a vector containing the polynucleotide of the previous aspect.
  • the invention provides a host cell containing the vector of the previous aspect.
  • the invention provides a method for treating neuropathic pain, the method involving administering to a patient in need thereof an antibody or antigen binding fragment thereof according to any of the above aspects.
  • the antibody or antigen binding fragment thereof is administered by intrathecal delivery.
  • the invention provides a method for the large scale production of a recombinant P2X4 polypeptide, the method involving expressing a human P2X4 protein in an SF9 cell at 27° C. for 72 hours; extracting the P2X4 protein by solubilizing in a buffer containing n-Dodecyl-beta-D-Maltoside, n-Dodecyl thio-Maltoside, CHAPS, and the Cholesteryl Hemisuccinate; then isolating the solubilized protein.
  • the SF9 cells were infected with baculovirus particles with a multiplicity of infection of 2 at a cell density of 2 ⁇ 10E6 cells/ml.
  • the proteins are purified using affinity and size exclusion chromatography.
  • the purified protein is maintained in a buffer containing 50 mM Tris-HCl pH 8.0, 600 mM NaCl, 10% glycerol, 0.025% n-Dodecyl-beta-D-Maltoside, 0.0125% n-Dodecyl thio-Maltoside, 0.0075% CHAPS, and 0.0015% Cholesteryl Hemisuccinate.
  • the method generates milligram quantities of purified P2X4 human polypeptide.
  • the majority of the P2X4 protein is in the trimeric form.
  • the invention provides a recombinant human P2X4 polypeptide produced according to the method of any previous aspect. In one embodiment, at least about 65%-75% of the polypeptide is in the trimeric form.
  • P2X purinoceptor 4 (P2RX4 or P2X4) polypeptide is meant a purinergic receptor protein or fragment thereof having at least about 85% or greater amino acid identity to the amino acid sequence provided at NCBI Accession No. Q99571 and having P2X4 biological activity.
  • P2X4 biological activity includes Ca 2+ /Na + conducting activity in response to ATP binding and/or P2X4 antibody binding.
  • An exemplary human P2X4 sequence is provided below:
  • a human P2X4 polypeptide has at least about 65%, 70%, 80%, 85%, 90%, 95%, or even 100% identity to NCBI Accession No. Q99571.
  • the invention provides P2X4 polypeptides comprising one or more amino acid substitutions relative to the Q99571 reference sequence, including for example: E95Q, V105M, G114D, A122V, S131N, A151P, G154R, L303P, and N306K.
  • An exemplary murine P2X purinoceptor 4 is provided at NCBI Accession No. Q9JJX6, which has the following sequence:
  • rat P2X purinoceptor 4 sequence is provided at NCBI Accession No. P51577, which has the following sequence:
  • An exemplary cynomologus monkey (e.g. macaque) P2X purinoceptor 4 sequence which has the following sequence:
  • P2X4 nucleic acid molecule is meant a polynucleotide encoding a P2X4 polypeptide or fragment thereof.
  • An exemplary human P2X4 polynucleotide sequence is provided at NCBI Accession No. NM_002560, the sequence of which follows:
  • P2X4 biological activity is meant ion channel conducting activity or ion channel mediated changes in cytosolic calcium levels.
  • ameliorate is meant decrease, suppress, attenuate, diminish, arrest, or stabilize the development or progression of a disease.
  • antibody refers to an immunoglobulin or a fragment or a derivative thereof, and encompasses any polypeptide comprising an antigen-binding site, regardless of whether it is produced in vitro or in vivo.
  • the term includes, but is not limited to, polyclonal, monoclonal, monospecific, polyspecific, non-specific, humanized, single-chain, chimeric, synthetic, recombinant, hybrid, mutated, and grafted antibodies.
  • antibody also includes antibody fragments such as Fab, F(ab′)2, Fv, scFv, Fd, dAb, and other antibody fragments that retain antigen-binding function, i.e., the ability to bind a P2X4 polypeptide specifically. Typically, such fragments would comprise an antigen-binding domain.
  • an antigen-binding domain refers to a part of an antibody molecule that comprises amino acids responsible for the specific binding between the antibody and the antigen. In instances, where an antigen is large, the antigen-binding domain may only bind to a part of the antigen. A portion of the antigen molecule that is responsible for specific interactions with the antigen-binding domain is referred to as “epitope” or “antigenic determinant.”
  • an antigen-binding domain comprises an antibody light chain variable region (V L ) and an antibody heavy chain variable region (V H ), however, it does not necessarily have to comprise both. For example, a so-called Fd antibody fragment consists only of a VH domain, but still retains some antigen-binding function of the intact antibody.
  • Binding fragments of an antibody are produced by recombinant DNA techniques, or by enzymatic or chemical cleavage of intact antibodies. Binding fragments include Fab, Fab′, F(ab′)2, Fv, and single-chain antibodies.
  • An antibody other than a “bispecific” or “bifunctional” antibody is understood to have each of its binding sites identical. Digestion of antibodies with the enzyme, papain, results in two identical antigen-binding fragments, known also as “Fab” fragments, and a “Fc” fragment, having no antigen-binding activity but having the ability to crystallize.
  • Fv when used herein refers to the minimum fragment of an antibody that retains both antigen-recognition and antigen-binding sites.
  • Fab when used herein refers to a fragment of an antibody that comprises the constant domain of the light chain and the CHI domain of the heavy chain.
  • mAb refers to monoclonal antibody.
  • Antibodies of the invention comprise without limitation whole native antibodies, bispecific antibodies; chimeric antibodies; Fab, Fab′, single chain V region fragments (scFv), fusion polypeptides, and unconventional antibodies.
  • Detect refers to identifying the presence, absence or amount of the analyte to be detected.
  • an antibody of the invention or fragment thereof is used to detect the presence or level of a P2X4 polypeptide.
  • detectable label is meant a composition that when linked to a molecule of interest renders the latter detectable, via spectroscopic, photochemical, biochemical, immunochemical, or chemical means.
  • useful labels include radioactive isotopes, magnetic beads, metallic beads, colloidal particles, fluorescent dyes, electron-dense reagents, enzymes (for example, as commonly used in an ELISA), biotin, digoxigenin, or haptens.
  • disease is meant any condition or disorder that damages or interferes with the normal function of a cell, tissue, or organ.
  • diseases include neuropathic pain, particularly pain associated with P2X4 channel activity or the activity of a pathway responsive to P2X4.
  • the term “effective amount” refers to a dosage or amount of an agent that is sufficient to reduce the activity of a P2X4 polypeptide to result in amelioration of symptoms in a patient or to achieve a desired biological outcome. Desired biological outcomes include, for example, the amelioration of chronic pain or a symptom thereof, modulation of P2X4 biological activity, or the modulation of a pathway responsive to P2X4 activity.
  • isolated refers to a molecule that is substantially free of other elements present in its natural environment.
  • an isolated protein is substantially free of cellular material or other proteins from the cell or tissue source from which it is derived.
  • isolated also refers to preparations where the isolated protein is sufficiently pure to be administered as a pharmaceutical composition, or at least 70-80% (w/w) pure, more preferably, at least 80-90% (w/w) pure, even more preferably, 90-95% pure; and, most preferably, at least 95%, 96%, 97%, 98%, 99%, or 100% (w/w) pure.
  • fragment is meant a portion of a polypeptide or nucleic acid molecule. This portion contains, preferably, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the entire length of the reference nucleic acid molecule or polypeptide.
  • a fragment of a P2X4 polypeptide may contain 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, or 300 amino acids.
  • a “reference sequence” is a defined sequence used as a basis for sequence comparison.
  • a reference sequence may be a subset of or the entirety of a specified sequence; for example, a segment of a full-length cDNA or gene sequence, or the complete cDNA or gene sequence.
  • the length of the reference polypeptide sequence will generally be at least about 16 amino acids, preferably at least about 20 amino acids, more preferably at least about 25 amino acids, and even more preferably about 35 amino acids, about 50 amino acids, or about 100 amino acids.
  • the length of the reference nucleic acid sequence will generally be at least about 50 nucleotides, preferably at least about 60 nucleotides, more preferably at least about 75 nucleotides, and even more preferably about 100 nucleotides or about 300 nucleotides or any integer thereabout or therebetween.
  • the term “repertoire” refers to a genetically diverse collection of nucleotides derived wholly or partially from sequences that encode expressed immunoglobulins.
  • the sequences are generated by in vivo rearrangement of, e.g., V, D, and J segments for H chains and, e.g., V and J segment for L chains.
  • the sequences may be generated from a cell line by in vitro stimulation, in response to which the rearrangement occurs.
  • part or all of the sequences may be obtained by combining, e.g., unrearranged V segments with D and J segments, by nucleotide synthesis, randomised mutagenesis, and other methods, e.g., as disclosed in U.S. Pat. No. 5,565,332.
  • binding is meant an agent (e.g., antibody) that recognizes and binds a molecule (e.g., polypeptide), but which does not substantially recognize and bind other molecules in a sample, for example, a biological sample.
  • an agent e.g., antibody
  • two molecules that specifically bind form a complex that is relatively stable under physiologic conditions.
  • Specific binding is characterized by a high affinity and a low to moderate capacity as distinguished from nonspecific binding which usually has a low affinity with a moderate to high capacity.
  • binding is considered specific when the affinity constant K A is higher than 10 7 M ⁇ 1 , or more preferably higher than 10 8 M ⁇ 1 .
  • the strength of the binding between P2X4 and an antibody can be measured using, for example, an enzyme-linked immunoadsorption assay (ELISA), radio-immunoassay (RIA), or surface plasmon resonance-based technology (e.g., Biacore), all of which are techniques well known in the art. If necessary, non-specific binding can be reduced without substantially affecting specific binding by varying the binding conditions.
  • the appropriate binding conditions such as concentration of antibodies, ionic strength of the solution, temperature, time allowed for binding, concentration of a blocking agent (e.g., serum albumin, milk casein), etc., may be optimized by a skilled artisan using routine techniques.
  • the term “about” is understood as within a range of normal tolerance in the art, for example within 2 standard deviations of the mean. About can be understood as within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05%, or 0.01% of the stated value. Unless otherwise clear from context, all numerical values provided herein are modified by the term about.
  • compositions or methods provided herein can be combined with one or more of any of the other compositions and methods provided herein.
  • FIG. 1A-1D shows an analysis of Antibody Nos. 1, 11, 29, and 33 binding to human P2X4 variants.
  • FIG. 2 provides the VH & VL sequences of Antibody Nos. 1-34, which were identified using phage display technology.
  • FIG. 3 provides a summary of P2X4 orthologue binding properties of antibodies identified using phage display selection (antibodies 1 to 34) and a summary of their functional effects measured by electrophysiology assays and reported as fraction of control current. Key: + indicates that binding was observed in FMAT assay;
  • ⁇ indicates that no binding was observed in FMAT assay; NT indicates that the antibody was not tested in the assay.
  • FIG. 4 shows results of the antibodies 5, 8, 11, 18, 29, and 33 screened in electrophysiology assays. Each of these antibodies was identified as a P2X4 antagonist. Peak agonist induced inward current in response to 3 ⁇ M ATP in the presence of antibody is indicated as a fraction of control current in the absence of antibody at human or cynomolgus (cyno) P2X4.
  • FIG. 5 provides a summary of P2X4 orthologue binding properties of antibodies isolated from hybridomas (Antibody Nos. 35-48) and a summary of their functional effects measured by electrophysiology assays and reported as fraction of control current.
  • FIG. 6 provides the VH & VL sequences of Antibody Nos. 35-48.
  • FIG. 7 provides a summary of results of binding assays for 252 antibodies (Antibody Nos. 35-286) isolated using hybridoma technology and a summary of their functional effects measured by electrophysiology assays and reported as fraction of control current.
  • FIG. 8A-8F shows whole cell current traces obtained using QPatch 16X showing the agonist response (indicated temporally by the grey bar) before (black trace) and after (grey trace) addition of antibodies. Traces are superimposed for comparison. Dotted line indicates zero current. P2X4 species investigated is indicated where appropriate by (m, mouse) (hu, human).
  • FIG. 8A, 8D, 8E, 8F show activity against huP2X4.
  • FIGS. 8B and 8C show activity against mP2X4.
  • FIG. 9 shows schematically an extracellular view of predicted P2X4 trimer-Antibody No. 11 Fv complex structure.
  • FIG. 9 illustrates the bipartite epitope-paratope interface—Antibody No. 11 VHCDRs-P2X4 protomer 1 head (major interface—large dotted circle); Antibody No. 11 VLCDRs-P2X4 protomer 2 right flipper (minor interface—small dotted circle).
  • Three Antibody No. 11 molecules can potentially bind the same P2X4 trimer molecule.
  • the two Fab arms of Antibody No. 11 are not likely to engage the same P2X4 trimer molecule.
  • Antibody No. 11 is predicted to bind a P2X heteromer across the epitope formed by two P2X4 subunits.
  • FIG. 10 provides alignments of human, cyno, mouse and rat P2X4 sequences. The head region of the protein is indicated. Amino acids within the predicted epitope are also indicated.
  • NIP228 TM isotype control antibody
  • FIG. 12 provides an alignment of the VH & VL sequences of Antibody Nos. 287 to 315, which are derived from Antibody 11.
  • FIG. 13 provides the VH & VL sequences of Antibody Nos. 208 and 316 to 321
  • FIG. 14 shows the effect of antibody Nos. 11, 300 and 312 on huP2X4 currents recorded on Qpatch 16X.
  • the black trace indicates the ATP response prior to IgG addition whereas the grey trace indicates the ATP response after incubation with IgG.
  • FIG. 15 summarises IC 50 values for optimised versions of Antibody 11 at huP2X4 using either FLIPR or Qpatch 16X. Values are geometric means.
  • FIG. 16 summarises IC 50 values for antibodies 38, 43, 46 & 208 at murineP2X4 and/or huP2X4 expressed in HEK 293F cells obtained on Qpatch 16X.
  • FIG. 17 summarises the effect of antibodies 38, 43, 46 & 208 on mouse microglial P2X4 currents measured on Qpatch 16X.
  • FIG. 18 shows exemplary electrophysiology current traces from mouse microglia pretreated with either the control antibody NIP 228 or antibody 208 (0.33 mg/ml).
  • the grey bar indicates the time at which ATP (30 ⁇ M) was added to the cells and the dotted line indicates the zero current level.
  • FIG. 19 shows example IC 50 curves obtained with two of the anti-P2X4 antibodies in the ATP stimulated calcium response assay.
  • FIG. 20 shows IC 50 curves (mean+/ ⁇ SEM) for antibodies 46, 38 and 208 obtained from mouse microglia assayed on FLIPR. Mean IC 50 values are presented below.
  • FIG. 21 shows exemplar electrophysiology current traces from human monocyte derived macrophages. Time at which ATP was added to the cells is indicated by the open box. Dotted line indicates zero current.
  • FIG. 22 summarises the steady state inward current from human monocyte derived macrophages in response to ATP (30 ⁇ M).
  • the present invention provides antibodies that specifically bind a P2X4 polypeptide and modulate P2X4 channel activity, recombinant P2X4 polypeptides and methods for generating such polypeptides, as well as compositions and methods for generating anti-P2X4 antibodies, and methods of using P2X4 antibodies for the treatment of neuropathic pain and other indications.
  • the present invention provides purified isolated recombinant P2X4 polypeptides that form stable trimeric complexes.
  • the invention further provides methods for the large scale production of purified and isolated human and murine P2X4 polypeptides, which is sufficient to produce milligram quantities of P2X4 protein, where the isolated and purified recombinant proteins are predominantly present as stable trimers.
  • the total quantities of P2X4 that were produced for the selection and screening experiments described herein included 6.2 mg hP2X4 and 3.2 mg mP2X4.
  • the production level of purified protein was 0.2 mg/L insect cell culture. As assayed by fluorescent size exclusion chromatography the protein preparation contains 50-75% trimer.
  • trimer rat P2X channels (subtypes 2, 4 and 7) has been performed (Antonio et al., Br. J. Pharmacol. 163 (2011) 1069-1077).
  • Rat P2X4 receptors having a C-terminal Hemaglutinin tag were expressed transiently in tsA 201 cells (a sub-clone of HEK293 cells stably expressing the SV40 large T-antigen). Receptors were solubilized in CHAPS detergent and affinity purified. Compared to expression of P2X2 and P2X7, expression of P2X4 was relatively low.
  • the purified receptors were used in AFM imaging, which showed trimeric arrangement of the receptors and also double trimers (dimers of trimers).
  • the methods present in the prior art uniformly failed to isolate substantial quantities of recombinant P2X4 polypeptides. Moreover, the prior art failed to isolate human P2X4 complexes in milligram quantities where the majority of the isolated proteins were present in trimeric form. In contrast, the methods of the invention, which are suitable for scale up, have allowed milligram scale production of purified recombinant P2X4 polypeptide. The yield of purified P2X4 obtained was 0.2 mg/L insect cell culture medium, corresponding to approximately 8 ⁇ g per 1 ⁇ 10 8 cells.
  • the human P2X4 and mouse P2X4 receptors were expressed in Sf9 insect cells using a baculovirus expression system.
  • Expression and protein production are not limited to Sf9 insect cell lines, other insect cell and cell lines that support protein production include Spodoptera fugiperda Sf21 cells or Trichoplusia ni derived cell lines Tn-368 and High-FiveTM BTI-TN-5B1-4.
  • P2X4 expression levels were monitored at the time of harvest, and the quality and homogeneity of the receptors was assessed using a modified size-exclusion chromatography while detecting fluorescence (FSEC) method as described by Backmark et al., (Protein Sci.
  • FSEC fluorescence
  • anti-P2X4 antibodies that comprise novel antigen-binding fragments.
  • the anti-P2X4 antibody is an anti-P2X4 antibody described herein (e.g., Antibodies 1-48) or a fragment thereof.
  • antibodies can be made, for example, using traditional hybridoma techniques (Kohler and Milstein (1975) Nature, 256: 495-499), recombinant DNA methods (U.S. Pat. No. 4,816,567), or phage display performed with antibody libraries (Clackson, T. and Lowman, H. B. Phage Display—A Practical Approach, 2004. Oxford University Press; (2) Thompson, J. et al. J Mol Biol. 256(1):77-88, 1996; (3) Osbourn, J. K. et al. Immunotechnology, 2(3):181-96, 1996).
  • Exemplary antibodies 35-48 were obtained using hybridoma techniques as described herein.
  • Exemplary antibodies 1-34 were obtained using phage display as described herein.
  • Antibodies A Laboratory Manual, eds. Harlow et al., Cold Spring Harbor Laboratory, 1988.
  • the invention is not limited to any particular source, species of origin, or method of production.
  • Intact antibodies also known as immunoglobulins, are typically tetrameric glycosylated proteins composed of two light (L) chains of approximately 25 kDa each and two heavy (H) chains of approximately 50 kDa each. Two types of light chain, designated as the ⁇ chain and the x chain, are found in antibodies.
  • immunoglobulins can be assigned to five major classes: A, D, E, G, and M, and several of these may be further divided into subclasses (isotypes), e.g., IgG 1 , IgG 2 , IgG 3 , IgG 4 , IgA 1 , and IgA 2 .
  • each light chain is composed of an N-terminal variable domain (V L ) and a constant domain (C L ).
  • Each heavy chain is composed of an N-terminal variable domain (V H ), three or four constant domains (C H ), and a hinge region.
  • the C H domain most proximal to V H is designated as C H 1.
  • the V H and V L domains consist of four regions of relatively conserved sequence called framework regions (FR1, FR2, FR3, and FR4), which form a scaffold for three regions of hypervariable sequence called complementarity determining regions (CDRs).
  • the CDRs contain most of the residues responsible for specific interactions with the antigen.
  • the three CDRs are referred to as CDR1, CDR2, and CDR3.
  • CDR constituents on the heavy chain are referred to as H1, H2, and H3, while CDR constituents on the light chain are referred to as L1, L2, and L3, accordingly.
  • CDR3 and, particularly H3, are the greatest source of molecular diversity within the antigen-binding domain.
  • H3, for example, can be as short as two amino acid residues or greater than 26.
  • a heavy chain CDR3 (H3) comprises between about 4 amino acids (see, for example, Ab No. 2) and 22 amino acids (see, for example, Ab Nos. 20 and 34).
  • the Fab fragment (Fragment antigen-binding) consists of the V H -C H 1 and V L -C L domains covalently linked by a disulfide bond between the constant regions.
  • a so-called single chain (sc) Fv fragment (scFv) can be constructed.
  • a scFv a flexible and adequately long polypeptide links either the C-terminus of the V H to the N-terminus of the V L or the C-terminus of the V L to the N-terminus of the V H .
  • a 15-residue (Gly 4 Ser) 3 peptide is used as a linker, but other linkers are also known in the art.
  • Antibody diversity is a result of combinatorial assembly of multiple germline genes encoding variable regions and a variety of somatic events.
  • the somatic events include recombination of variable gene segments with diversity (D) and joining (J) gene segments to make a complete V H region and the recombination of variable and joining gene segments to make a complete V L region.
  • D diversity
  • J joining
  • the recombination process itself is imprecise, resulting in the loss or addition of amino acids at the V(D)J junctions.
  • the disclosure provides novel CDRs derived from human immunoglobulin gene libraries.
  • the structure for carrying a CDR will generally be an antibody heavy or light chain or a portion thereof, in which the CDR is located at a location corresponding to the CDR of naturally occurring V H and V L .
  • the structures and locations of immunoglobulin variable domains may be determined, for example, as described in Kabat et al., Sequences of Proteins of Immunological Interest, No. 91-3242, National Institutes of Health Publications, Bethesda, Md., 1991.
  • amino acid sequences of anti-P2X4 antibodies 1-48, 208, and 287 to 321, including their V H and V L domains are set forth in the Figures and described herein.
  • Anti-P2X4 antibodies may optionally comprise antibody constant regions or parts thereof.
  • a V L domain may have attached, at its C terminus, antibody light chain constant domains including human C ⁇ or C ⁇ chains.
  • a specific antigen-binding domain based on a V H domain may have attached all or part of an immunoglobulin heavy chain derived from any antibody isotope, e.g., IgG, IgA, IgE, and IgM and any of the isotope subclasses, which include but are not limited to, IgG 1 and IgG 4 .
  • Certain embodiments comprise a V H and/or V L domain of an Fv fragment from a P2X4 antibody. Further embodiments comprise at least one CDR of any of these V H and V L domains.
  • Antibodies, comprising at least one of the CDR sequences set forth for Antibody Nos. 1-48 are encompassed within the scope of this invention.
  • an antibody of the invention comprises CDR3 of V H .
  • the V H and/or V L domains may be germlined, i.e., the framework regions (FRs) of these domains are mutated using conventional molecular biology techniques to match those produced by the germline cells.
  • the framework sequences remain diverged from the consensus germline sequences.
  • the antibodies specifically bind an epitope within the extracellular domain of human P2X4. In certain embodiments, the antibodies specifically bind an epitope within the extracellular domain of human or mouse P2X4, with an affinity of more than 10 6 M ⁇ 1 , more than 10 7 M ⁇ 1 , or more than 108 M ⁇ 1 .
  • antibodies of the invention may also bind with other proteins, including, for example, recombinant proteins comprising all or a portion of the P2X4 extracellular domain.
  • the antibodies of this invention may be used to detect, measure, and inhibit proteins that differ somewhat from P2X4.
  • the antibodies are expected to retain the specificity of binding so long as the target protein comprises a sequence which is at least about 60%, 70%, 80%, 90%, 95%, or more identical to any sequence of at least 100, 80, 60, 40, or 20 of contiguous amino acids of P2X4 (NCBI Ref. No. Q99571).
  • the percent identity is determined by standard alignment algorithms such as, for example, Basic Local Alignment Tool (BLAST) described in Altshul et al. (1990) J. Mol. Biol., 215: 403-410, the algorithm of Needleman et al. (1970) J. Mol. Biol., 48: 444-453, or the algorithm of Meyers et al. (1988) Comput. Appl. Biosci., 4: 11-17.
  • BLAST Basic Local Alignment Tool
  • epitope mapping see, e.g., Epitope Mapping Protocols, ed. Morris, Humana Press, 1996) and secondary and tertiary structure analyses can be carried out to identify specific 3D structures assumed by the disclosed antibodies and their complexes with antigens.
  • An example of such a 3D structure is provided for Antibody No. 11.
  • Such methods include, but are not limited to, X-ray crystallography (Engstom (1974) Biochem. Exp. Biol., 11:7-13) and computer modeling of virtual representations of the presently disclosed antibodies (Fletterick et al. (1986) Computer Graphics and Molecular Modeling, in Current Communications in Molecular Biology, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.).
  • CDRs in such antibodies are not limited to the specific sequences of V H and V L identified herein, and may include variants of these sequences that retain the ability to specifically bind P2X4. Such variants may be derived from the sequences listed herein by a skilled artisan using techniques well known in the art. For example, amino acid substitutions, deletions, or additions, can be made in the FRs and/or in the CDRs. While changes in the FRs are usually designed to improve stability and immunogenicity of the antibody, changes in the CDRs are typically designed to increase affinity of the antibody for its target. Variants of FRs also include naturally occurring immunoglobulin allotypes.
  • affinity-increasing changes may be determined empirically by routine techniques that involve altering the CDR and testing the affinity of the antibody for its target. For example, conservative amino acid substitutions can be made within any one of the disclosed CDRs.
  • Various alterations can be made according to the methods described in Antibody Engineering, 2 nd ed., Oxford University Press, ed. Borrebaeck, 1995. These include, but are not limited to, nucleotide sequences that are altered by the substitution of different codons that encode a functionally equivalent amino acid residue within the sequence, thus producing a “silent” change.
  • the nonpolar amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine.
  • the polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine.
  • the positively charged (basic) amino acids include arginine, lysine, and histidine.
  • the negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Substitutes for an amino acid within the sequence may be selected from other members of the class to which the amino acid belongs (see Table 1).
  • any native residue in the polypeptide may also be substituted with alanine (see, e.g., MacLennan et al. (1998) Acta Physiol. Scand. Suppl. 643:55-67; Sasaki et al. (1998) Adv. Biophys. 35:1-24).
  • Derivatives and analogs of antibodies of the invention can be produced by various techniques well known in the art, including recombinant and synthetic methods (Maniatis (1990) Molecular Cloning, A Laboratory Manual, 2 nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., and Bodansky et al. (1995) The Practice of Peptide Synthesis, 2nd ed., Spring Verlag, Berlin, Germany).
  • a method for making a V H domain which is an amino acid sequence variant of a V H domain of the invention comprises a step of adding, deleting, substituting, or inserting one or more amino acids in the amino acid sequence of the presently disclosed V H domain, optionally combining the V H domain thus provided with one or more V L domains, and testing the V H domain or V H /V L combination or combinations for a specific binding to P2X4 or and, optionally, testing the ability of such antigen-binding domain to modulate P2X4 activity, for example, using an electrophysiology assay described herein.
  • the V L domain may have an amino acid sequence that is identical or is substantially identical to a polypeptide of the invention.
  • An analogous method can be employed in which one or more sequence variants of a V L domain disclosed herein are combined with one or more V H domains.
  • a further aspect of the disclosure provides a method of preparing an antigen-binding fragment that specifically binds with P2X4.
  • the method comprises:
  • V L CDR3 i.e., L3
  • the donor nucleic acid may be selected from nucleic acids encoding an amino acid sequence substantially as set out in Antibody Nos. 1-48.
  • a sequence encoding a CDR of the invention may be introduced into a repertoire of variable domains lacking the respective CDR (e.g., CDR3), using recombinant DNA technology, for example, using methodology described by Marks et al. (Bio/Technology (1992) 10: 779-783).
  • consensus primers directed at or adjacent to the 5′ end of the variable domain area can be used in conjunction with consensus primers to the third framework region of human V H genes to provide a repertoire of V H variable domains lacking a CDR3.
  • the repertoire may be combined with a CDR3 of a particular antibody.
  • the CDR3-derived sequences may be shuffled with repertoires of V H or V L domains lacking a CDR3, and the shuffled complete V H or V L domains combined with a cognate V L or V H domain to make the P2X4-specific antibodies of the invention.
  • the repertoire may then be displayed in a suitable host system such as the phage display system described herein or as described in WO92/01047 so that suitable antigen-binding fragments can be selected.
  • One such technique, error-prone PCR is described by Gram et al. (Proc. Nat. Acad. Sci. U.S.A. (1992) 89: 3576-3580).
  • Another method that may be used is to direct mutagenesis to CDRs of V H or V L genes.
  • Such techniques are disclosed by Barbas et al. (Proc. Nat. Acad. Sci. U.S.A. (1994) 91: 3809-3813) and Schier et al. (J. Mol. Biol. (1996) 263: 551-567).
  • one or more, or all three CDRs may be grafted into a repertoire of V H or V L domains, which are then screened for an antigen-binding fragment specific for P2X4.
  • a portion of an immunoglobulin variable domain will comprise at least one of the CDRs substantially as set out herein and, optionally, intervening framework regions from the scFv fragments as set out herein.
  • the portion may include at least about 50% of either or both of FR1 and FR4, the 50% being the C-terminal 50% of FR1 and the N-terminal 50% of FR4. Additional residues at the N-terminal or C-terminal end of the substantial part of the variable domain may be those not normally associated with naturally occurring variable domain regions.
  • construction of antibodies by recombinant DNA techniques may result in the introduction of N- or C-terminal residues encoded by linkers introduced to facilitate cloning or other manipulation steps.
  • Other manipulation steps include the introduction of linkers to join variable domains to further protein sequences including immunoglobulin heavy chain constant regions, other variable domains (for example, in the production of diabodies), or proteinaceous labels as discussed in further detail below.
  • the embodiments illustrated in the Examples comprise a “matching” pair of V H and V L domains
  • alternative embodiments may comprise antigen-binding fragments containing only a single CDR from either V L or V H domain.
  • the antigen-binding fragment is CDR3 of V H (H3).
  • Either one of the single chain specific binding domains can be used to screen for complementary domains capable of forming a two-domain specific antigen-binding fragment capable of, for example, binding to P2X4.
  • the screening may be accomplished by phage display screening methods using the so-called hierarchical dual combinatorial approach disclosed in WO92/01047, in which an individual colony containing either an H or L chain clone is used to infect a complete library of clones encoding the other chain (L or H) and the resulting two-chain specific binding domain is selected in accordance with phage display techniques as described.
  • Anti-P2X4 antibodies described herein can be linked to another functional molecule, e.g., another peptide or protein (albumin, another antibody, etc.).
  • another functional molecule e.g., another peptide or protein (albumin, another antibody, etc.).
  • the antibodies can be linked by chemical cross-linking or by recombinant methods.
  • the disclosed antibodies may also be altered to have a glycosylation pattern that differs from the native pattern.
  • one or more carbohydrate moieties can be deleted and/or one or more glycosylation sites added to the original antibody.
  • Addition of glycosylation sites to the presently disclosed antibodies may be accomplished by altering the amino acid sequence to contain glycosylation site consensus sequences known in the art.
  • Another means of increasing the number of carbohydrate moieties on the antibodies is by chemical or enzymatic coupling of glycosides to the amino acid residues of the antibody. Such methods are described in WO 87/05330 and in Aplin et al. (1981) CRC Crit. Rev. Biochem., 22: 259-306.
  • the antibodies may also be tagged with a detectable, or functional, label.
  • Detectable labels include radiolabels such as 131 I or 99 Tc, which may also be attached to antibodies using conventional chemistry.
  • Detectable labels also include enzyme labels such as horseradish peroxidase or alkaline phosphatase.
  • Detectable labels further include chemical moieties such as biotin, which may be detected via binding to a specific cognate detectable moiety, e.g., labeled avidin.
  • an amino acid is substituted by a related amino acid having similar charge, hydrophobic, or stereochemical characteristics. Such substitutions would be within the ordinary skills of an artisan. Unlike in CDRs, more substantial changes can be made in FRs without adversely affecting the binding properties of an antibody. Changes to FRs include, but are not limited to, humanizing a non-human derived or engineering certain framework residues that are important for antigen contact or for stabilizing the binding site, e.g., changing the class or subclass of the constant region, changing specific amino acid residues which might alter the effector function such as Fc receptor binding, e.g., as described in U.S. Pat. Nos. 5,624,821 and 5,648,260 and Lund et al. (1991) J. Immun. 147: 2657-2662 and Morgan et al. (1995) Immunology 86: 319-324, or changing the species from which the constant region is derived.
  • the present disclosure provides the amino acid sequence of the disclosed antibodies. Once provided with this information, one of skill in the art could readily obtain nucleic acid molecules encoding the disclosed antibodies.
  • the nucleic acids may comprise DNA or RNA and may be wholly or partially synthetic or recombinant. Reference to a nucleotide sequence encompasses a DNA molecule with the specified sequence, and encompasses a RNA molecule with the specified sequence in which U is substituted for T, unless context requires otherwise.
  • the nucleic acids molecules of the invention comprise a coding sequence for a CDR, a V H domain, and/or a V L domain disclosed herein.
  • the present disclosure also provides constructs in the form of plasmids, vectors, phagemids, transcription or expression cassettes which comprise at least one nucleic acid molecule encoding a CDR, a V H domain, and/or a V L domain disclosed herein.
  • the disclosure further provides a host cell which comprises one or more constructs as above.
  • nucleic acids encoding any CDR (H1, H2, H3, L1, L2, or L3), V H or V L domain, as well as methods of making of the encoded products.
  • the method comprises expressing the encoded product from the encoding nucleic acid. Expression may be achieved by culturing under appropriate conditions recombinant host cells containing the nucleic acid. Following production by expression a V H or V L domain, or specific binding member may be isolated and/or purified using any suitable technique, then used as appropriate.
  • Antigen-binding fragments, V H and/or V L domains and encoding nucleic acid molecules and vectors may be isolated and/or purified from their natural environment, in substantially pure or homogeneous form, or, in the case of nucleic acid, free or substantially free of nucleic acid or genes of origin other than the sequence encoding a polypeptide with the required function.
  • suitable host cells include bacteria, plant cells, mammalian cells, and yeast and baculovirus systems.
  • Mammalian cell lines available in the art for expression of a heterologous polypeptide include Chinese hamster ovary cells, HeLa cells, baby hamster kidney cells, NS0 mouse myeloma cells, and many others.
  • a common bacterial host is E. coli .
  • Any protein expression system compatible with the invention may be used to produce the disclosed antibodies. Suitable expression systems include transgenic animals described in Gene Expression Systems, Academic Press, eds. Fernandez et al., 1999.
  • Suitable vectors can be chosen or constructed, so that they contain appropriate regulatory sequences, including promoter sequences, terminator sequences, polyadenylation sequences, enhancer sequences, marker genes and other sequences as appropriate.
  • Vectors may be plasmids or viral, e.g., phage, or phagemid, as appropriate.
  • phage e.g., phagemid
  • a further aspect of the disclosure provides a host cell comprising a nucleic acid as disclosed here.
  • a still further aspect provides a method comprising introducing such nucleic acid into a host cell.
  • the introduction may employ any available technique.
  • suitable techniques may include calcium phosphate transfection, DEAE-Dextran, electroporation, liposome-mediated transfection and transduction using retrovirus or other virus, e.g., vaccinia or, for insect cells, baculovirus.
  • suitable techniques may include calcium chloride transformation, electroporation and transfection using bacteriophage.
  • the introduction of the nucleic acid into the cells may be followed by causing or allowing expression from the nucleic acid, e.g., by culturing host cells under conditions for expression of the gene.
  • the disclosed anti-P2X4 antibodies are capable of modulating the electrophysiological activity of P2X4.
  • antibodies provided herein may be used to inhibit or potentiate P2X4 channel conductance.
  • Such antibodies can be used to treat P2X4-associated medical disorders in mammals, especially, in humans.
  • antibodies that inhibit P2X4 activity are useful for the treatment of neuropathic pain.
  • Antibodies that potentiate P2X4 activity are useful in other therapeutic methods, including but not limited to microglia-mediated diseases and disorders and macrophage-mediated diseases and disorders.
  • Antibodies of the invention can also be used for isolating P2X4 or P2X4-expressing cells.
  • binding of P2X4 with an anti-P2X4 antibody modulates P2X4 biological activity by potentiating or reducing passage of ions through the P2X4 channel.
  • the antibodies or antibody compositions of the present invention are administered in therapeutically effective amounts.
  • a therapeutically effective amount may vary with the subject's age, condition, and sex, as well as the severity of the medical condition of the subject.
  • the appropriate dose is chosen based on clinical indications by a treating physician.
  • the antibodies may be given as a bolus dose, to maximize the circulating levels of antibodies for the greatest length of time after the dose. Continuous infusion may also be used after the bolus dose.
  • Anti-P2X4 antibodies of the invention may be used to detect the presence of P2X4 in biological samples. Detection methods that employ antibodies are well known in the art and include, for example, ELISA, radioimmunoassay, immunoblot, Western blot, immunofluorescence, and immunoprecipitation. If desired, an anti-P2X4 antibody is modified, for example, with a ligand group (such as biotin) or a detectable marker group (such as a fluorescent group, a radioisotope or an enzyme). If desired, the antibodies of the invention may be labeled using conventional techniques.
  • a ligand group such as biotin
  • a detectable marker group such as a fluorescent group, a radioisotope or an enzyme
  • Suitable detectable labels include, for example, fluorophores, chromophores, radioactive atoms, electron-dense reagents, enzymes, and ligands having specific binding partners. Enzymes are typically detected by their activity. For example, horseradish peroxidase can be detected by its ability to convert tetramethylbenzidine (TMB) to a blue pigment, quantifiable with a spectrophotometer.
  • suitable binding partners include, but are not limited to, biotin and avidin or streptavidin, IgG and protein A, and the numerous receptor-ligand couples known in the art. Other permutations and possibilities will be readily apparent to those of ordinary skill in the art, and are considered as equivalents within the scope of the invention.
  • compositions comprising anti-P2X4 antibodies (e.g., Antibody Nos. 1-48). Such compositions are likely suitable for pharmaceutical use and administration to patients.
  • the compositions typically comprise one or more antibodies of the present invention and a pharmaceutically acceptable excipient.
  • pharmaceutically acceptable excipient includes any and all solvents, dispersion media, coatings, antibacterial agents and antifungal agents, isotonic agents, and absorption delaying agents, and the like, that are compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art.
  • the compositions may also contain other active compounds providing supplemental, additional, or enhanced therapeutic functions.
  • the pharmaceutical compositions may also be included in a container, pack, or dispenser together with instructions for administration.
  • a pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Methods to accomplish the administration are known to those of ordinary skill in the art.
  • the administration may, for example, be intravenous, intraperitoneal, intramuscular, intracavity, subcutaneous or transdermal.
  • neuropathic pain is treated by intrathecal administration. It may also be possible to obtain compositions which may be topically or orally administered, or which may be capable of transmission across mucous membranes.
  • Solutions or suspensions used for intradermal or subcutaneous application typically include one or more of the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerin, propylene glycol, or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates; and agents for the adjustment of tonicity such as sodium chloride or dextrose.
  • the pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.
  • Such preparations may be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
  • compositions suitable for injection include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
  • suitable carriers include physiological saline, bacteriostatic water, Cremophor EL (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS).
  • the composition must be sterile and should be fluid to the extent that easy syringability exists. It should be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyetheylene glycol, and the like), and suitable mixtures thereof.
  • the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and/or by the use of surfactants.
  • Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate, and gelatin.
  • Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For oral administration, the antibodies can be combined with excipients and used in the form of tablets, troches, or capsules. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.
  • the tablets, pills, capsules, troches, and the like can contain any of the following ingredients, or compounds of a similar nature; a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
  • a binder such as microcrystalline cellulose, gum tragacanth or gelatin
  • an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch
  • a lubricant such as magnesium stearate or Sterotes
  • a glidant such as colloidal silicon dioxide
  • Systemic administration can also be by transmucosal or transdermal means.
  • penetrants appropriate to the barrier to be permeated are used in the formulation.
  • penetrants are generally known in the art, and include, for example, detergents, bile salts, and fusidic acid derivatives.
  • Transmucosal administration may be accomplished, for example, through the use of lozenges, nasal sprays, inhalers, or suppositories.
  • compositions may be capable of transmission across mucous membranes in intestine, mouth, or lungs (e.g., via the FcRn receptor-mediated pathway as described in U.S. Pat. No.
  • the active compounds may be formulated into ointments, salves, gels, or creams as generally known in the art.
  • the antibodies may be delivered in the form of an aerosol spray from pressured container or dispenser, which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.
  • the presently disclosed antibodies are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems.
  • a controlled release formulation including implants and microencapsulated delivery systems.
  • Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art.
  • Liposomal suspensions containing the presently disclosed antibodies can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811.
  • dosage unit form refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • Toxicity and therapeutic efficacy of the composition of the invention can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD 50 (the dose lethal to 50% of the population) and the ED 50 (the dose therapeutically effective in 50% of the population).
  • the dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD 50 /ED 50 .
  • Compositions that exhibit large therapeutic indices are preferred.
  • a dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC 50 (i.e., the concentration of the antibody which achieves a half-maximal inhibition of symptoms). Circulating levels in plasma may be measured, for example, by high performance liquid chromatography. The effects of any particular dosage can be monitored by a suitable bioassay.
  • the dosage lies preferably within a range of circulating concentrations with little or no toxicity. The dosage may vary depending upon the dosage form employed and the route of administration utilized.
  • kits for modulating P2X4 activity are useful for the treatment of indications mediated by decreased P2X4 activity as described herein.
  • Antibodies that inhibit P2X4 activity are useful for the treatment or prevention of neuropathic pain and/or microglia-mediated diseases and disorders and/or macrophage-mediated diseases and disorders.
  • the kit includes a therapeutic or prophylactic composition containing an effective amount of an anti-P2X4 antibody that modulates P2X4 activity in unit dosage form.
  • the kit comprises a sterile container which contains a therapeutic or prophylactic cellular composition; such containers can be boxes, ampules, bottles, vials, tubes, bags, pouches, blister-packs, or other suitable container forms known in the art. Such containers can be made of plastic, glass, laminated paper, metal foil, or other materials suitable for holding medicaments.
  • an antibody of the invention is provided together with instructions for administering the antibody or agent to a subject having or at risk of developing neuropathic pain.
  • the instructions will generally include information about the use of the composition for the treatment or prevention of such indications.
  • the instructions include at least one of the following: description of the therapeutic agent; dosage schedule and administration for treatment or prevention of an immune disorder or symptoms thereof; precautions; warnings; indications; counter-indications; overdosage information; adverse reactions; animal pharmacology; clinical studies; and/or references.
  • the instructions may be printed directly on the container (when present), or as a label applied to the container, or as a separate sheet, pamphlet, card, or folder supplied in or with the container.
  • Human P2X purinoceptor 4 (Q99571), a natural variant of human P2X purinoceptor 4 with an S to G mutation at position 242 (Corresponds to variant rs25644) and murine P2 ⁇ purinoceptor 4 (Q9JJX6) proteins were designed with a C-terminal AVI tag (Avidity LLC) and a C-terminal Histidine tag.
  • the constructs were cloned into pFASTBAC1 vectors (Life Technologies). Bacmids were generated in DH10Bac (Life Technologies) E. coli cells.
  • Sf9 insect cells Sf9 insect cells (Spodopterafrugiperda Sf9 cells from Life Technologies, cat no 11496-015) for production of recombinant baculovirus particles, which in turn were used to infect Sf9 cells for protein expression.
  • FSEC Fluorescence-detection size-exclusion chromatography
  • Membranes were prepared from SF9 cells. Membrane proteins were extracted from the membranes by detergent solubilization, using combinations of detergents, salts, buffers and additives, including n-Dodecyl-beta-D-Maltoside CAS 69227-93-6 (0-2% (w/v)), n-Dodecyl thio-Maltoside CAS 148565-58-6 (0-1% (w/v)), (3-[(3-Cholamidopropyl)-Dimethylammonio]-1-Propane Sulfonate/N,N-Dimethyl-3-Sulfo-N-[3-[[3 ⁇ ,5 ⁇ ,7 ⁇ ,12 ⁇ )-3,7,12-Trihydroxy-24-Oxocholan-24-yl]Amino]propyl]-1-Propanaminium Hydroxide abbreviated to CHAPS CAS 75621-03-3 (0-0.6% (w
  • the proteins underwent standard affinity and size exclusion chromatography purification.
  • the purified protein was formulated in a buffer which contained 50 mM Tris-HCl pH 8.0, 600 mM NaCl, 10% (v/v) glycerol, 0.025 (w/v) % n-Dodecyl-beta-D-Maltoside CAS 69227-93-6, 0.0125% (w/v), n-Dodecyl thio-Maltoside CAS 148565-58-6, 0.0075% (w/v) (3-[(3-Cholamidopropyl)-Dimethylammonio]-1-Propane Sulfonate/N,N-Dimethyl-3-Sulfo-N-[3-[[3 ⁇ ,5 ⁇ ,7 ⁇ ,12 ⁇ )-3,7,12-Trihydroxy-24-Oxocholan-24-
  • the purified protein was formulated under alternative conditions, including phosphate buffers and HEPES buffers 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid buffers CAS 7365-45-9.
  • the pH of the various buffers has ranged from 7.0-8.0.
  • Salt (NaCl) has been varied between 120-600 mM.
  • Glycerol can be excluded from the protein formulation.
  • P2X receptors form functional trimeric ion channels.
  • the solubilised and purified P2X4 proteins are typically present in a range of oligomeric states, including monomers, dimers, trimers, and hexamers (i.e., dimers of trimers).
  • This range of oligomeric states is described for example, by references (Backmark et al., Protein Sci. 22 (2013) 1124-1132; Kawate et al., Structure 14 (2006) 673-681; Kawate et al., Nature 460 (2009) 592-598; Nakazawa et al., European Journal of Pharmacology 518 (2005) 107-110; Nicke et al., Mol. Pharmacol. 63 (2003) 243-252). To obtain a stable predominantly trimeric arrangement, solubilization conditions were adjusted.
  • Optimal solubilization was obtained in buffers containing combinations of the detergents including n-Dodecyl-beta-D-Maltoside CAS 69227-93-6, n-Dodecyl thio-Maltoside CAS 148565-58-6, (3-[(3-Cholamidopropyl)-Dimethylammonio]-1-Propane Sulfonate/N,N-Dimethyl-3-Sulfo-N-[3-[[3 ⁇ ,5 ⁇ ,7 ⁇ ,12 ⁇ )-3,7,12-Trihydroxy-24-Oxocholan-24-yl]Amino]propyl]-1-Propanaminium Hydroxide abbreviated to CHAPS CAS 75621-03-3, and the additive Cholesteryl Hemisuccinate CAS 102601-49-0.
  • the purified protein was formulated in a buffer which contained 50 mM Tris-HCl pH 8.0, 600 mM NaCl, 10% (v/v) glycerol, 0.025 (w/v) % n-Dodecyl-beta-D-Maltoside CAS 69227-93-6, 0.0125% (w/v), n-Dodecyl thio-Maltoside CAS 148565-58-6, 0.0075% (w/v) (3-[(3-Cholamidopropyl)-Dimethylammonio]-1-Propane Sulfonate/N,N-Dimethyl-3-Sulfo-N-[3-[[3 ⁇ ,5 ⁇ ,7 ⁇ ,12 ⁇ )-3,7,12-Trihydroxy-24-Oxocholan-24-yl]Amino]propyl]-1-Propanaminium Hydroxide abbreviated to CHAPS CAS 75621-03-3, and 0.0015% (w/
  • Na ⁇ ve human single chain Fv (scFv) phage display libraries were cloned into a phagemid vector based on the filamentous phage M13 were used for selections (Lloyd (2009) Protein Eng Des Sel 22, 159-168; Vaughan et al., Nature biotechnology 14, 309-314, 1996).
  • Anti-P2X4 specific antibodies were isolated from the phage display libraries using a series of selection cycles on recombinant human P2X4 (hu P2X4), essentially as previously described by Vaughan et al (Vaughan et al., supra).
  • human P2X4 in PBS (Dulbecco's PBS, pH7.4) was immobilised onto wells of a MaxiSorpL microtitre plate (Nunc) overnight at 4° C. Wells were washed with PBS then blocked for 1 hour with PBS-Marvel dried skimmed milk (3% w/v). Purified phage in PBS-Marvel (3% w/v) were added to the wells and allowed to bind coated antigen for 1 hour at room temperature. Unbound phage was removed by a series of wash cycles using PBS. Bound phage particles were eluted with trypsin for 30 minutes at 37° C., infected into E.
  • anti-P2X4 antibodies were isolated as described above except deselection of the purified phage library against the C-terminal peptide huP2X4370-388 (Alomone Labs # APR-002) or phenyl hydrophobic interaction chromatography (HIC) beads was performed prior to selection with the antigen.
  • Purified recombinant murine P2X4 protein and murine P2X4 transfected HEK 293F cells were used to immunise Sprague Dawley rats in three groups. For group 1, rats were immunised with murine P2X4 protein; for group 2, rats were immunised with murine P2X4 transfected HEK 293F cells; and for group 3, rats were immunised by alternating murine P2X4 protein and murine P2X4 transfected HEK 293F cells.
  • a twenty eight day immunization protocol was used with a priming immunization on day 0, followed by four subsequent booster immunizations on days 7, 15, 22 and 24.
  • group 1 equal volumes of complete Freund's adjuvant and murine P2X4 protein (total protein: 100 ⁇ g) were emulsified together, and delivered to the rats subcutaneously at two sites (200 ⁇ L per site).
  • total protein 100 ⁇ g
  • the same amount of protein was used, emulsified in Freund's incomplete adjuvant.
  • murine P2X4 transfected HEK 293F cells were resuspended at 5E7 cells per mL in PBS and emulsified with equal volumes of complete Freund's adjuvant.
  • the cells were injected into rats at two sites (200 ⁇ L per site). For the subsequent three booster injections, the same number of cells was used, emulsified in Freund's incomplete adjuvant.
  • group 3 the priming immunization was with murine P2X4 protein as per group 1 above, followed by three booster immunizations with murine P2X4 transfected HEK 293F cells, murine P2X4 protein, and murine P2X4 transfected HEK 293F cells.
  • group 1 and group 3 rats received murine P2X4 protein (400 ⁇ L at 50 ⁇ g/mL in Tris buffer), and group 2 rats received murine transfected HEK 293F cells (400 ⁇ L at 5E7/mL).
  • Tail vein bleeds were obtained from the rats before immunisation, on day 13 after the first immunization, and on day 20 after second immunisation.
  • the IgG titres to anti-murine P2X4 were determined by a cell-based DELFIA (dissociation-enhanced lanthanide fluorescence immunoassay) assay.
  • the IgG titres to murine P2X4 in sera were determined by a cell based DELFIA using both mP2X4 transfected HEK 293F and parental HEK cells.
  • the serum samples from rats immunised with either cells alone or the alternating protein and cells strategy were incubated with non-transfected HEK 293F cells.
  • the sera from rats immunised with protein were assayed without this pre-adsorption step.
  • Murine P2X4 transfected HEK 293F and parental HEK cells were plated in culture media onto black collagen coated 96 well microtitre plates at a density of 30,000 cells per well. After overnight incubation at 37° C. in a 5% CO 2 incubator, the culture supernatant was removed and the cells were fixed with 3.7% formaldehyde solution at 50 ⁇ L per well. All subsequent incubations were carried out at room temperature. After 5 minutes fixation, the formaldehyde solution was discarded and replaced with 200 ⁇ L of 3%witz/PBS blocking buffer. After one hour, the blocking buffer was removed and the serum samples added in a 3-fold dilution series (50 ⁇ L per well starting from a 1:200 dilution).
  • the reaction was allowed to develop for 10 minutes, and then the plate was then read using a PerkinElmer EnVision 2103 multilabel plate reader.
  • the TRF (time-resolved fluorescence) signal in each well was measured (excitation 340 nm, emission 615 nm).
  • the serum titration curves for murine P2X4 transfected HEK 293F cells and parental HEK 293F cells were plotted and the respective area under the curves (AUC) calculated.
  • AUC area under the curves
  • specific mP2X4 IgG titres were derived by subtracting the AUC values from parental HEK cells from the AUC values for the murine P2X4 transfected cells.
  • lymph nodes were aseptically harvested and cells were isolated by mechanical disruption and counted. These cells were mixed with SP2/0 myeloma cells and fused using an electrofusion apparatus. The resultant fusions were mixed with a methylcellulose-based semi-solid media and plated out into OmniTray plates.
  • the semi-solid media comprised CloneMatrix and DMEM supplemented with 20% FCS, 10% BM Condimed H1, 1 mM sodium pyruvate and OPI media supplement, 2% hypoxanthine azaserine and FITC conjugated goat anti-rat IgG.
  • the cells in semi-solid media were cultured for 13 days at 37° C. in a 5% CO 2 incubator.
  • the supernatants of the picked colonies were harvested and screened for murine P2X4 specificity by comparing binding to murine P2X4 transfected HEK 293F cells and parental HEK 293F cells by a cell-based fluorornetric microvolumne assay technology (FMAT) assay.
  • FMAT fluorornetric microvolumne assay technology
  • mRNA Messenger RNA
  • dT magnetic oligo
  • PCR amplification was performed using poly-C and constant region V H /V L primers.
  • the hybridomas Prior to purification, the hybridomas were tested by ELISA using a goat anti-rat IgG2a coated microtitre plate to determine which clones secreted Rat IgG2a, as this isotype is purified using a different purification matrix to rat IgG1, IgG2b and IgG2c isotypes.
  • the captured rat IgGs were eluted with 75 ⁇ L of 100 mM HEPES, 140 mM NaCl pH 3.0 then neutralised with an equal volume of 200 mM HEPES pH 8.0.
  • the purified IgGs were quantified using an absorbance reading at 280 nm in UV-Star 384 well plate.
  • Rat hybridoma IgG clones were molecularly reformatted to generate chimeric constructs expressing rat V H and V L domains and human IgG1 constant domains essentially as described by Persic et al., 1997 (Gene 187, 9-18) with the following modifications.
  • An OriP fragment was included in the expression vectors to facilitate use with CHO-transient cells and to allow episomal replication.
  • the VH domain was cloned into a vector (pEU1.4) containing the human heavy chain constant domains and regulatory elements to express whole IgG1 heavy chain in mammalian cells.
  • This constant region contained the triple mutations (TM) L234F/L235E/P331S resulting in an effector null human IgG1 (Oganesyan et al., (2008) Acta Crystallogr D Biol Crystallogr. 64, 700-704).
  • the VL domain was cloned into a vector (pEU4.4) for the expression of the human light chain (lambda) constant domains and regulatory elements to express whole IgG light chain in mammalian cells.
  • the heavy and light chain IgG expressing vectors were transfected into CHO-transient mammalian cells. IgGs were expressed and secreted into the medium.
  • IgG was purified using Protein A chromatography. Culture supernatants were loaded on a column of appropriate size of Ceramic Protein A (Pall 20078-036) and washed with 50 mM Tris-HCl pH 8.0, 250 mM NaCl. Bound IgG was eluted from the column using 0.1 M Sodium Citrate (pH 3.0) and neutralised by the addition of Tris-HCl (pH 9.0).
  • the eluted material was buffer exchanged into PBS using Nap 10 columns (GE Lifesciences 17-0854-02) and the concentration of IgG was determined spectrophotometrically using an extinction coefficient based on the amino acid sequence of the IgG (Pace et al., (1995) Protein Sci. 4, 2411-23).
  • the purified IgG were analysed for purity using SDS-PAGE.
  • ScFv antibodies identified from the phage display method described in Example 3 were expressed in bacteria and screened as unpurified bacterial periplasmic extracts (which contain scFv), prepared in: 0.2M HEPES buffer pH7.4, 0.5 mM EDTA and 0.5 M sucrose.
  • the heavy and light chain variable regions were amplified by PCR and cloned into a vector for expression as human IgG1 antibodies in HEK293F cells.
  • Assay buffer was prepared as follows: 1 ⁇ Hanks Balanced Salt Solution (HBSS) (Sigma H8264), 0.1% (v/v) BSA (PAA K05-013), 20 mM HEPES (Gibco 15630) and 1 U/ml Apyrase (Sigma A6535) and 5 ⁇ l added to the assay plate with the bacterial scFv extract.
  • Anti-myc detection reagent (Serotec MCA2200) and anti-mouse DyLight649 (Jackson Immuno Research Labs 115-495-071) were diluted in assay buffer to 15.6 nM and 24 nM respectively in the same solution and 5 ⁇ l added to the assay plate with the scFv sample.
  • HEK293F cells expressing human P2X4 (huP2X4) (Q99571, ENSP00000336607) were diluted to 2.6e 5 cells/ml in assay buffer and 15l added to the assay plate.
  • parallel scFv samples were also tested for binding to HEK293F cells that did not express huP2X4.
  • HEK293F expressed IgG samples 2.5 ⁇ l of cell culture supernatant was added to the 384 well assay plate (Corning 3655). Assay buffer was prepared as described above and 7.5 ⁇ l was added to the assay plate with the IgG sample. Anti-human AlexaFluor 647 (Life Technologies A21445) was diluted in assay buffer to 6 nM and 10 ⁇ l added to the assay plate with the IgG sample.
  • HEK293F cells expressing huP2X4 (Q99571, ENSP00000336607) were diluted to 4e 5 cells/ml in assay buffer and 10l added to the assay plate.
  • IgG samples were also tested for binding to HEK293F cells that did not express huP2X4.
  • Assay plates set up to screen both types of samples were sealed with a Topseal plate sealer (Perkin Elmer 6005250) and incubated at room temperature for at least 4 hours before reading on the Fluorescence Microvolume Assay Technology (FMAT), a fluorescence based platform that detects fluorescence localized to bead or cells settled at the bottom of a microwell (Dietz et al., Cytometry 23:177-186 (1996), Miraglia et al., J. Biomol. Screening 4:193-204 (1999)).
  • FMAT Fluorescence Microvolume Assay Technology
  • Purified IgG antibodies were tested for functional activity in the electrophysiology assay and for binding to cells expressing mouse and cynomologus P2X4 using the same method described for the human P2X4 cells described above except a titration of purified IgG sample was used. Results of electrophysiology assays are provided at FIGS. 3 and 4 .
  • Supernatants generated from the immunisations were screened to identify IgGs with specific binding to mP2X4. Briefly supernatants were diluted 10 fold into assay buffer (HBSS, 0.1% (v/v) BSA, 20 mM HEPES and 1 U/ml Apyrase) and 5 ⁇ l added to the assay plate. Anti-rat detection antibody labeled with Alexa Fluor 647 (Jackson Immuno Research labs) was diluted to 6 nM and 10 ⁇ l added to the assay plate. HEK293F cells expressing mP2X4 were diluted to 2.6e 5 /ml and 15 ⁇ l added to the assay plate.
  • IgG samples were also tested for non-specific binding in parallel by testing the samples for binding to HEK293F cells.
  • IgGs demonstrating specific binding to mP2X4 and no binding to HEK293F cells were identified as hits and selected for antibody purification and analysis by electrophysiology. Results of the electrophysiology screen are provided in FIG. 7 together with the binding results for these samples against human and cyno P2X4 expressing cell lines using the same assay described previously
  • DNA vectors containing huP2X4 sequences with these changes were generated using standard molecular biology techniques. DNA vectors were transfected into HEK293F cells using 293-fectin (Life Technologies 12347019) following the manufacturers guidelines. Cells expressing the huP2X4 variants were incubated with Antibody Nos. 1, 11, 29, and 33 together with the anti-human AlexaFluor 647 (Life Technologies A21445) detection reagent.
  • FIGS. 1A-1D show the results of FMAT assays characterizing binding of P2X4 antibodies to HEK293F cells expressing variants of human P2X4.
  • QEB QPatch extracellular buffer
  • KCl KCl
  • MgCl 2 MgCl 2
  • CaCl 2 KCl
  • HEPES HEPES
  • pH of extracellular buffers was adjusted to 7.4 with NaOH (1 M), osmolarity was adjusted to 300 mOsm with sucrose and the solutions were 0.2 m filtered.
  • Compound plate extracellular buffer was supplemented with 0.1% bovine serum albumin.
  • the QPatch intracellular buffer contained (in mM) CsF (140), NaCl (10), EGTA (1), HEPES (10). pH of the intracellular buffer was adjusted to 7.3 with CsOH (1 M) and the solution was 0.2 ⁇ m filtered. IgGs were titrated to pH 7.4 with NaOH (1 M).
  • FIG. 8A whereas an example of a potentiating IgG can be seen in FIG. 8D .
  • Electrophysiology data presented in FIG. 3 and FIG. 4 were leak subtracted by subtracting the current in the absence of ligand and the magnitude of the P2X4 response measured as the peak inward current in the presence of ligand. Peak inward current in the presence of IgG+ATP after 5 minutes IgG incubation was expressed as a fraction of the 4 th control ATP response.
  • I norm I IgG *(1/I isotype )
  • I IgG fraction of control current for the test IgG
  • I isotype fraction of control current for the isotype control IgG.
  • Six IgGs were found to significantly inhibit human P2X4 currents; Antibody Nos. 5, 8, 11, 18, 29, and 33 ( FIGS. 3, 4, 8A ). Inhibition of P2X4 currents was rapid, occurring at the first time point following IgG addition, whereas the isotype control IgG NIP 228 had no significant effect.
  • FIG. 2 Sequences for phage display antibodies are provided in FIG. 2 .
  • FIG. 9 provides a structural analysis of the epitope/paratope interface.
  • FIG. 10 provides the sequence of the predicted P2X4 epitope.
  • HEK 293F cells stably expressing either mouse P2X4 (Uniprot # Q9JJX6) or human P2X4 (Uniprot # Q99571) were harvested at 50% confluency using accutase.
  • QEB QPatch extracellular buffer
  • CPEB2 compound plate extracellular buffer
  • pH of extracellular buffers was adjusted to 7.4 with NaOH (1 M) and the solutions were 0.2 ⁇ m filtered.
  • the QPatch intracellular buffer contained (in mM) CsF (140), NaCl (10), EGTA (1), HEPES (10). pH of the intracellular buffer was adjusted to 7.3 with CsOH (1 M) and the solution was 0.2 ⁇ m filtered.
  • IgGs were titrated to pH 7.4 with NaOH (1 M). After obtaining whole cell configuration, cells were voltage clamped at ⁇ 50 mV with 70% series resistance compensation employed.
  • CPEB2+IgG was then incubated for 3 minutes followed by a second ATP addition. Data were leak subtracted by subtracting the current in the absence of ligand and the magnitude of the P2X4 response measured as the peak inward current in the presence of ligand.
  • the ATP response after IgG addition was expressed as a fraction of the ATP response prior to IgG addition.
  • the hIgG1 NIP 228 TM was used as a control antibody to determine the cutoff for defining functional antibodies.
  • mice 50 female C57BL/6 mice were used for the studies. All mice underwent insertion of transponders for identification purposes at least 5 days before the start of the study. Mechanical hyperalgesia was determined using an analgysemeter (Randall & Selitto 1957) (Ugo Basile). An increasing force was applied to the dorsal surface of each hind paw in turn until a withdrawal response was observed. The application of force was halted at this point and the weight in grams recorded. Data was expressed as withdrawal threshold in grams for ipsilateral and contralateral paws. Following the establishment of baseline readings mice were divided into 2 groups with approximately equal ipsilateral/contralateral ratios which underwent surgery to partially ligate the sciatic nerve or served as sham operated controls.
  • mice were anaesthetised with isoflurane. Following this approximately 1 cm of the left sciatic nerve was exposed by blunt dissection through an incision at the level of the mid thigh. A suture (9/0 Virgin Silk: Ethicon) was then passed through the dorsal third of the nerve and tied tightly. The incision was then closed using glue and the mice were allowed to recover for at least six days prior to commencement of testing. Sham operated mice underwent the same protocol but following exposure of the nerve the mice were sutured and allowed to recover. Mice were tested for onset of hyperalgesia on days 7 and 10 post surgery. Any mice showing an ipsilateral/contralateral ratio of greater than 80% were classed as non-responders and removed from the study. Following testing on day 10 mice were further sub-divided into groups giving the final treatment groups;
  • mice were administered NIP 228 TM (Isotype control) or test molecules on day 13 and were re-tested for changes in mechanical hyperalgesia at 4 hrs post dose and also on 1, 2, 4 and 7 days post dose.
  • mice were anaesthetised with isoflurane.
  • Ipsilateral and contralateral readings were taken for each animal at each test time and were entered into EXCEL for calculation of ipsilateral/contralateral ratios. Summary data was transferred into PRISM for graphical and statistical analysis.
  • Results were analysed using 2-way ANOVA. Pairwise comparisons where appropriate were made using Tukey's test. Analysis of the results showed that partial ligation of the sciatic nerve caused a mechanical hyperalgesia which manifested as a significant reduction in the ipsilateral/contralateral ratio on day 7 and 10 when compared to sham operated controls. Following treatment with NIP228, operated mice did not show any change in the level of mechanical hyperalgesia from pre-dose levels indicating a lack of effect of the isotype control on mechanical hyperalgesia. The administration of Antibody No. 208 produced a significant reversal which was significant for up to 4 days post dose after which the response returned to baseline levels. Similar effects were seen with Antibody No. 38 ( FIG. 13 ).
  • mice Human P2X4 (hP2X4) transfected HEK 293F and XS63 cells were used to immunise CD1 mice in three groups.
  • group 1 mice were immunised with hP2X4 transfected HEK 293F cells
  • group 2 mice were immunised with hP2X4 transfected XS63 cells
  • group 3 mice were immunised by alternating hP2X4 transfected XS63 cells and hP2X4 transfected HEK 293F cells.
  • hP2X4 transfected cells were re-suspended at 1E8/mL and emulsified with equal volumes of complete Freund's adjuvant, and injected into mice at two sites, 100 ⁇ L per site.
  • Lymphoid cells isolated from spleens and lymph nodes were fused with SP2/0 myeloma cells using an electrofusion method.
  • the fusions were plated out into semi-solid selection media containing FITC conjugated goat anti-mouse IgG.
  • Supernatants were initially screened for IgGs that specifically bound to hP2X4 using both the hP2X4 expressing HEK 293F and XS63 cells, and parental HEK 293F cells.
  • the IgGs that showed specific binding to hP2X4, and no binding to parental HEK293F cells, were selected for further specificity testing on mouse P2X4 (mP2X4) HEK 293F cells.
  • IgGs which specifically bound to hP2X4 or to both hP2X4 and mP2X4 were selected for antibody purification and functional analysis by electrophysiology.
  • mRNA Messenger RNA
  • mRNA was extracted from hybridoma cells using magnetic oligo (dT) particles and reverse transcribed into cDNA.
  • Polymerase chain reaction (PCR) amplification was performed using poly-C and constant region VH or VL primers specific to all mouse IgG subclasses.
  • Mouse IgGs of all subclasses (IgG1, IgG2a, IgG2b and IgG3) were purified from overgrown cell culture supernatants on ProPlus resin (Phynexus).
  • QEB QPatch extracellular buffer
  • CPEB2 compound plate extracellular buffer
  • pH of extracellular buffers was adjusted to 7.4 with NaOH (1 M) and the solutions were 0.2 ⁇ m filtered.
  • the QPatch intracellular buffer contained (in mM) CsF (140), NaCl (10), EGTA (1), HEPES (10). pH of the intracellular buffer was adjusted to 7.3 with CsOH (1 M) and the solution was 0.2 m filtered.
  • IgGs were titrated to pH 7.4 with NaOH (1 M). After obtaining whole cell configuration, cells were voltage clamped at ⁇ 50 mV with 70% series resistance compensation employed. The ligand agonist adenosine 5′-triphosphate disodium salt (ATP, 3 ⁇ M) in QEB was applied for 3 seconds then washed off with QEB+apyrase (1 U/ml). CPEB2+IgG was then incubated for 3 minutes followed by a second ATP addition. Data were leak subtracted by subtracting the current in the absence of ligand and the magnitude of the P2X4 response measured as the peak inward current in the presence of ligand.
  • ATP adenosine 5′-triphosphate disodium salt
  • the ATP response after IgG addition was expressed as a fraction of the ATP response prior to IgG addition.
  • the hIgG1 NIP 228 TM was used as a control antibody to determine the cutoff for defining functional antibodies.
  • Antibody sequences are provided in FIG. 13 .
  • Antibody No. 11 was optimised for affinity via two approaches either; targeted or random mutagenesis followed by affinity-based phage display selections.
  • targeted approach large scFv-phage libraries derived from the lead clone were created by oligonucleotide-directed mutagenesis of the variable heavy (VH) complementarity determining regions 3 (CDR3) and light (VL) chain CDR3 using standard molecular biology techniques as described (Clackson, T and Lowman, H. B. Phage Display A Practical Approach, 2004. Oxford University Press).
  • the libraries were subjected to affinity-based phage display selections in order to select variants with higher affinity for human P2X4.
  • Antibody 11 was also optimised using a random mutagenesis approach to identify key residues within the entire variable domain that may improve binding to human P2X4. Such a technique is described by Gram et al. [Gram et al., 1992 , Proc. Natl. Acad. Sci., USA, 89:3576-3580], who used error-prone PCR. In some embodiments one or two amino acid substitutions are made within an entire variable domain or set of CDRs.
  • the generated library was subjected to affinity-based selections as described for the targeted selections outlined above. Exemplary antibodies from this selection method are disclosed herein as Antibodies 287 to 315, and an alignment of their sequences is shown in FIG. 12 .
  • assay buffer HBSS, 0.1% BSA, 1 U/ml apyrase, either with or without 20 mM HEPES.
  • Antibody 11-Dylight® 650 was added to each well except the wells used to define the background binding, to a final concentration of 2 nM.
  • HEK293F huP2X4 cells were added to each well at a final density of approximately 2000 cells per well. Plates were covered and incubated at room temperature for 2 to 3 hours before reading on a Mirrorball® plate reader (TTP Labtech, Ltd) and determining the total FL3 fluorescence per well (Median (mean intensity) fluorescence multiplied by the number of objects). Individual events were gated on size and fluorescence and a minimum object number of greater than 25 was used to determine wells with sufficient events to report a FL3 total value. % specific binding was calculated for each well using the following equation, maximal FL3 total values were defined from wells that did not receive any scFv but did receive peri plasmic sample buffer:
  • % ⁇ ⁇ specific ⁇ ⁇ binding sample ⁇ ⁇ FL ⁇ ⁇ 3 ⁇ ⁇ total - background ⁇ ⁇ FL ⁇ ⁇ 3 ⁇ ⁇ total maximal ⁇ ⁇ FL ⁇ ⁇ 3 ⁇ ⁇ total - background ⁇ ⁇ FL ⁇ ⁇ 3 ⁇ ⁇ total ⁇ 100
  • Example 13 Identification of Antibodies with Improved Potency against Human P2X4 Using the Human P2X4 1321N1 Cell Line FLIPR® Assay
  • Antibodies identified in the Antibody 11 competition assay described in example 12 were generated as purified IgG and titrated to generate a dilution series. These antibodies were diluted in assay buffer containing HBSS and 0.1% BSA and pre-incubated with 1321N1 cells expressing huP2X4 for 30 mins where the cells had previously been loaded with Fluo-4 NW calcium dye (Molecular ProbesTM, Life Technologies) following the manufacturer's instructions. P2X4 was activated by the addition of 1 ⁇ M ATP diluted in assay buffer and the resulting rise in intracellular calcium was detected by the calcium dye and measured by an increase in fluorescence using the FLIPR® Tetra plate reader (Molecular Devices, LLC). Data was calculated to determine the maximum fluorescence observed over the background fluorescence for the duration of the assay. These data were then analysed to determine % maximal response over the buffer response alone seen in wells where ATP was omitted, using the following equation:
  • Example 14 Identification of Antibodies with Improved Potency against Human P2X4 Using the HEK 293F huP2 ⁇ 4 Cell Line on the Automated Electrophysiology Platform Qpatch 16X
  • HEK 293F cells stably expressing human P2X4, were harvested at 50% confluency using accutase. Cells were then resuspended in 10 ml Freestyle 293F media supplemented with HEPES (10 mM)+apyrase (1 U/ml, ATPase/ADPase activity 1) at a density of 2-3e 6 cells/ml. P2X4 function was assayed using the automated electrophysiology platform QPatch 16X (Sophion) in population patch configuration. Composition of QPatch extracellular buffer (QEB) was (in mM) NaCl (140), KCl (2), MgCl 2 (1) CaCl 2 (2), HEPES (10).
  • QEB QPatch extracellular buffer
  • the QPatch intracellular buffer contained (in mM) CsF (140), NaCl (10), EGTA (1), HEPES (10). pH of the intracellular buffer was adjusted to 7.3 with CsOH (1 M) and the solution was 0.2 m filtered. IgGs were titrated to pH 7.4 with NaOH (1 M).
  • IgGs were serially diluted in QEB+0.1% bovine serum albumin and tested for function on Qpatch 16X in population patch configuration.
  • Extracellular buffer was QEB
  • intracellular buffer was QIB
  • ATP wash buffer was QEB+apyrase (1 U/ml).
  • ATP 3 ⁇ M was applied every 10 mins for 3 s with a total of 5 applications per experiment.
  • the first two ATP additions (ATP 1 & ATP 2) were preceded by preincubation for 5 mins with QEB buffer+0.1% BSA whereas the following three ATP additions were preceded by 5 mins incubation with ascending doses of IgG.
  • HEK 293F cells expressing P2X4 were handled as in example 8. Potency of hybridoma derived IgGs was assayed on Qpatch 16X in population patch configuration. For determination of IgG potency, IgGs were serially diluted in PBS+0.1% bovine serum albumin and tested for function on Qpatch 16X in population patch configuration. IgGs were then diluted 1:3 in QEB+0.1% BSA resulting in a final buffer composition of NaCl (137.6), KCl (2.2), MgCl 2 (0.66), CaCl 2 (1.3), HEPES (6.6), KH 2 PO 4 (0.49), NaH 2 PO 4 (2.66), BSA (0.1%) equivalent to CPEB1.
  • Extracellular buffer was QEB, intracellular buffer was QIB and ATP wash buffer was QEB+apyrase (1 U/ml).
  • ATP 3 ⁇ M was applied every 10 mins for 3 s with a total of 5 applications per experiment.
  • the first two ATP additions (ATP 1 & ATP 2) were preceded by preincubation for 5 mins with CPEB1+0.1% BSA whereas the following three ATP additions were preceded by 5 mins incubation with ascending doses of IgG.
  • Log and half log doses were interleaved in post analysis to generate 6 point dose response curves.
  • Microglia were removed by shaking overnight in an orbital shaker incubator (no CO 2 ) with HEPES supplemented in the media (20 mM). Purified microglia were centrifuged at 1200 rpm for 5 mins and resuspended in 20 ml DMEM+10% FCS+pen/strep growth media. Cells were counted and seeded in ultra low bind T75 cell culture flasks (Corning) at 7e6 cells/flask. Microglia were then maintained in culture for 1-7 days before being used for Qpatch 16X electrophysiology assays or FLIPR calcium imaging assays.
  • 1 ⁇ T75 flask was washed twice with dPBS and cells were harvested using accutase treatment for 5-10 mins. Cells were then resuspended in 293F Freestyle media+20 mM HEPES+1 U/ml accutase (10 ml) and spun down at 800 rpm for 5 mins. Cells were then resuspended in 3 ml 293F Freestyle media+20 mM HEPES+1 U/ml accutase and 1 ml of cell suspension used per experiment. Qpatch 16X was used in population patch configuration and cells voltage clamped at ⁇ 70 mV.
  • Microglia were plated in Cell Coat Poly-D-Lysine coated 384 well plates (black, uclear) with 30 ⁇ l per well and cultured in a humidified incubator at 37° C. for 48 hours. Media was removed and replaced with 20 ul per well of HBSS buffer+20 mM HEPES+0.1% BSA, supplemented with Screen QuestTM Fluo-8 No Wash Calcium Assay Kit (AAT Bioquest, Inc.) as per the manufacturers instructions. Cells were then incubated at 37° C. for 30 mins then returned to room temperature for 15 mins before assaying on FLIPR (Molecular devices). Ivermectin (12 ⁇ M) was made up in a further 384 well compound plate (Compound plate 1).
  • IgGs were made up in PBS+0.1% BSA (compound plate 2).
  • ATP (30 uM) was made up in HBSS+20 mM HEPES+0.1% BSA in a separate 384 well compound plate (Compound plate 3). Fluo-8 was excited at a wavelength of 470-495 nm and the emitted light measured at a wavelength of 515-575 nm. Camera gain was adjusted to give 1000 counts at rest with an exposure of 0.4 s. 10 ul of solution from compound plate 1 was added to the cells and the fluorescence measured. After 5 mins incubation, 10 ul of solution from compound plate 2 was added. 15 min later, ATP (5 uM final) was added and the peak end fluorescence measured between 200-300 sec post ATP addition.
  • Fluorescence counts were normalised to the ATP response in the absence of antibody (minus background fluorescence) and plotted as % of ATP response (See FIG. 21 ).
  • 10 point dose response curves for each IgG were constructed from duplicate wells and the data fit in Prism using a log (inhibitor) vs. response ⁇ Variable slope (four parameters) equation.
  • Y Bottom+(Top ⁇ Bottom)/(1+10 ⁇ circumflex over ( ) ⁇ ((LogIC50 ⁇ X)*Hill Slope)). See FIG. 20 .
  • Human monocytes were isolated from the mononuclear fraction of peripheral blood by centrigugation on a Ficoll-Paque gradient. Cells were then purified by incubating in a T175 cell culture flask in cell culture media in the absence of serum for 1 hour. Non-adherent cells were removed and the remaining cells grown in RPMI Glutamax I media supplemented with 10% FCS (HI/GI)+1% P/S+100 ng/ml M-CSF for 7 days. Cells were fed on day 2-3 by adding an additional 10 ml of media. Macrophage were harvested by accutase treatment for 10 mins followed by cell scraping and replated in ultra-low bind T75 flasks at 6e6 cells per flask.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention provides antibodies that specifically bind a P2X4 polypeptide and modulate P2X4 channel activity, recombinant P2X4 polypeptides and methods for generating such polypeptides, as well as compositions and methods for generating anti-P2X4 antibodies, and methods of using P2X4 antibodies for the treatment of neuropathic pain and other indications.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a continuation of U.S. patent application Ser. No. 15/308,294, filed on Nov. 1, 2016, which application is a U.S. National Stage application of International Application No. PCT/EP2015/059633, filed on May 2, 2015. International Application No. PCT/EP2015/059633 claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Application No. 61/987,929, filed on May 2, 2014. Each of the above listed applications is incorporated by reference herein in its entirety for all purposes.
    • REFERENCE TO THE SEQUENCE LISTING
  • This application incorporates by reference a Sequence Listing submitted with this application as a text file entitled “P2X4-100-US-CNT-SequenceListing”, created on Mar. 30, 2020, and having a size of 379,453 bytes.
    • BACKGROUND OF THE INVENTION
  • Chronic pain serves no beneficial purpose, but arises from pathological alterations in nociceptive neural networks. Neuropathic pain is a form of chronic pain that arises after nerve injury caused by trauma, infection, or pathology. Neuropathic pain persists long after the initiating event has healed. While neurons are involved in neuropathic pain, they are unlikely to be the sole cell type mediating this condition. There is a growing body of evidence that supports a role for glia-neuron interactions in establishing and maintaining neuropathic pain. Microglia, in particular, have emerged as key players in neuropathic pain. The microglial P2X4 receptor appears to be important in the development and maintenance of neuropathic pain.
  • The ion channel P2X4 is one of seven members of a family of purinergic, cation permeable channels. Each P2X4 subunit has two transmembrane domains, separated by a large ˜280 amino acid extracellular domain. Functional channels are formed of a trimeric arrangement of subunits with a central pore. The P2X4 channel is activated by binding of the ligand adenosine 5′-triphosphate (ATP) to residues contained within its extracellular domain. Activation of these receptors instigates a series of conformational changes that allow cations, such as Ca2+ and Na+, entry into the cell through a cation selective channel. P2X4 activation and upregulation is thought to be a key driver of neuropathic pain. Downstream of P2X4 activation, microglia release brain derived neurotrophic factor (BDNF), which acts on spinal lamina I neurons to reduce expression of a neuronal chloride transporter KCC2, thereby altering the electrochemical gradient for chloride and rendering one of the main inhibitory neurotransmitters GABA excitatory. Therefore, P2X4-mediated BDNF release in spinal cord is thought to be a key driver of neuropathic pain.
  • Neuropathic pain fails to respond to currently available analgesics, and is considered to be one of the most debilitating chronic pain conditions. Accordingly, improved methods for treating neuropathic pain, particularly pain mediated by P2X4 are urgently required.
    • SUMMARY OF THE INVENTION
  • As described below, the present invention provides antibodies that specifically bind a P2X4 polypeptide and modulate P2X4 channel activity, recombinant P2X4 polypeptides and methods for generating such polypeptides, as well as compositions and methods for generating anti-P2X4 antibodies, and methods of using P2X4 antibodies for the treatment of neuropathic pain and other indications.
  • In a first aspect, the invention provides an antibody or antigen binding fragment thereof that specifically binds a human P2X4 polypeptide and modulates channel activity. In one embodiment, the antibody is a P2X4 potentiator. In another embodiment, the antibody is a P2X4 antagonist. In another embodiment, the antibody is a P2X4 modulator. In another embodiment, the antibody is a P2X4 antagonist that reduces P2X4 biological activity by at least about 10, 25, 50, 75, 85, 90 or 95%. In another embodiment, the antibody binds an epitope containing human P2X4 amino acids 110-166. In another embodiment, the antibody binds an epitope containing one or more human P2X4 amino acids selected from any one or more of amino acids 118, 122-139, 145, 159, 180, 183, 184, 231, and 244. In another embodiment, an amino acid substitution at position 131 of P2X4 reduces or eliminates antibody binding to a human P2X4 polypeptide. In another embodiment, the serine at position 131 of human P2X4 is substituted by Asparagine.
  • In one embodiment of the previous aspect, the antibody or fragment thereof contains:
  • a. a heavy chain variable region CDR1 containing a sequence X1X2X3X4X5 (SEQ ID NO: 1009), where X1 is G, N, S, D, or R; X2 is Y, A, H, F, or S; X3 is A, W, Y, S, G, F, W, E, D, or P; X4 is M, I, W, L, I, F, or V; X5 is S, G, T, H, or N; and/or
  • b. a heavy chain variable region CDR2 containing a sequence X1X2X3X4X5X6X7X8X9X10X11X12X13X14X15X6 (SEQ ID NO: 1029), where X1 is A, R, I, T, E, S, A, V, W, N, G, E, R, or Y; X2 is I or M; X3 is S, K, Y, D, N, W, or I; X4 is S, D, G, H, N, R, Y, or V; X5 is G, D, S, F, N, R, F, D, or T; X6 is G, S, N, or T; X7 is S, T, D, Y, N, A, E, M, F, or D; X8 is T, I, K, or A; X9 is Y, D, R, N, G, Q, E, H, or K; X10 is Y, Q, S, or V; X11 is A, S, N, or V; X12 is D, A, P, R, or Q; X13 is S, P, K, or N; X14 is V, F, L, or A; X15 is K, Q, or E; X16 is G, S, A, or D; and/or
  • c. a heavy chain variable region CDR3 containing a sequence X1X2X3X4X5X6X7X8 (SEQ ID NO: 1011), where X1 is E, N, D, R, K, G, S, A, Y, V, P, or H; X2 is E, L, R, Q, T, G, F, P, Y, K, A, S, V, or F; X3 is R, A, T, G, V, S, M, W, Y, D, H, N, E, L, or I; X4 is G, L, R, D, T, G, Y, S, E, F, Q, C, I, M, V, N, K, or P; X5 is S, G, Y, D, W, T, S, N, I, D, V, E, or C; X6 is Y, A, S, W, T, L, G, E, F, K, V, I, or D; X7 is D, E, or G; and X8 is Y, S, V, L, M, Q, I, S, I, H, F, or D. In one embodiment, the heavy chain variable region CDR2 optionally contains an insertion of 1-3 amino acids, XaXbXc between amino acids X3 and X4, where Xa is G, S, P, W, Y, E, A, R, or N; and XbXc are KT, respectively. In another embodiment, the heavy chain variable region CDR3 optionally contains an insertion of 1-14 amino acids Xa-Xn (SEQ ID NO: 1012), where Xa is F, R, S, Y, L, D, G, V, I, T, or A; Xb is G, R, Y, F, T, D, S, G, V, M, D, or R; Xc is F, W, A, G, T, I, S, F, Y, C, L, V, R, or N; Xd is S, F, M, G, Y, L, S, A, D, L, R, V, C, or S, Xe is G, Y, S, T, P, F, Y, R, A, E, G, Q, N, or L; Xf is Y, N, G, T, R, F, A, M, W, P, or V; Xg is Y, M, S, V, F, A, P, S, D, R, H, P, E, or R Xh is Y, G, M, F, G, P, V, F, H, T, or G, Xi is T, I, G, R, or F; Xj is Y, G, H, or E; XK is Y, G, F, or N; XL is F, or N; Xm is Y; and Xn is F. In one embodiment, the heavy chain variable region CDR1 contains the sequence SYX1MX2 (SEQ ID NO: 1063), where X1 is A, W, Y, S, G, F, E, D, or P and X2 is S, G, T, H, or N. In another embodiment, the heavy chain variable region CDR1 contains the sequence XYAMS (SEQ ID NO: 1064), where X is S, D, G, N or R; SXAMS (SEQ ID NO: 1065), where X is Y, A, H, F, or S; SYXMS (SEQ ID NO: 1066), where X is A, W, Y, S, G, F, E, D, or P; SYAXS (SEQ ID NO: 1067), where X is M, I, W, L, F, or V; SYAMX (SEQ ID NO: 1068), where X is S, G, T, H, or N. In another embodiment, the heavy chain variable region CDR1 contains amino acids SYAMS (SEQ ID NO: 57). In another embodiment, the heavy chain variable region CDR2 contains the sequence AISGSGGSTYYADSVKG (SEQ ID NO: 1069); or AISGSGGSTYYADSVEG (SEQ ID NO: 1070). In yet another embodiment, the heavy chain variable region CDR3 contains the sequence DWYFDL (SEQ ID NO: 1071) or NWYLDL (SEQ ID NO: 1072). In still another embodiment, the antibody or fragment thereof contains, a. a light chain variable region CDR1 containing a sequence X1X2X3X4X5X6X7X8X9X10X11 (SEQ ID NO: 1013), where X1 is T, G, R, S, or Q; X2 is G, A, or L; X3 is S, T, D, or H; X4 is S, N, K, A, Q, T, or V; X5 is G, I, L, S, or D; X6 is A, G, R, P, I, D, S, E, T; X7 is G, N, M, D, K, S, R, Y, or T; X8 is Y, K, F, Q, S, N, Y, D, H, or R; X9 is D, N, Y, W, F, M, G, or S; X10 is V, A, L, I, G, or P; X11 is H, T, S, Y, A, Q, Y, N, or F,
  • b. a light chain variable region CDR2 containing a sequence: X1X2X3X4X5X6X7 (SEQ ID NO: 1014), where X1 is G, Y, Q, K, N, D, R, A, or E; X2 is N, D, K, A, V, G, or T, X3 is N, S, T, I, K, Y, or D; X4 is N, D, Y, K, E, T, N, S, or Q, X8 is R, or L; X6 is P, E, A, S, or Q; X7 is S, P, or T;
  • c. a light chain variable region CDR3 containing a sequence X1X2X3X4X5X6X7X8X9 (SEQ ID NO: 1015), where X1 is Q, N, A, G, D, S, or L; X2 is S, V, A, Q, T, L, or H; X3 is Y, W, R, A, S, Q, T, or G; X4 is D, Y, I, N, M, or H, X5 is T, M, S, N, D, R, G, or K, X6 is N, T, S, G, F, L or D; X7 is L, T, G, P, A, I, or N; X8 is K, W, V, I, P, G, L, R, or Y; X9 is V, L, or T. In one embodiment, the light chain variable region CDR1 optionally contains an insertion of between 1 and 3 amino acids Xa-Xc between X4 and X5, where Xa is S or G; Xb is N, D or S; and Xc is I or V. In another embodiment, the light chain variable region CDR3 optionally contains an insertion of between 1 and 3 amino acids Xa-Xc between X7 and X8, where Xa is D, N, A, T, S, I or H; Xb is H, Y, G, A, R, L, S, or P; Xc is S. In still another embodiment, the light chain variable region CDR1 contains one of the following sequences: S G D K L (SEQ ID NO: 1034); S G S S SNIG (SEQ ID NO: 1035); SG DAL (SEQ ID NO: 1036); RASQ GISSW LA (SEQ ID NO: 1037); and R A S Q G I S R W L A (SEQ ID NO: 1038). In another embodiment, the light chain variable region CDR2 contains one of the following sequences: G X X Y R P S (SEQ ID NO: 1039), where X is T, S, K or K D S E R P S (SEQ ID NO: 1040); K A S T L E S (SEQ ID NO: 1041); Q D X K R P S (SEQ ID NO: 1042), where X is D or T; and Q D I E R P S (SEQ ID NO: 1043). In another embodiment, the light chain variable region CDR3 contains one of the following sequences: Q Q S Y S T P W T (SEQ ID NO: 1044) or S S G T Y V V (SEQ ID NO: 1045).
  • In various embodiments of the above aspects, the antibody contains a heavy chain variable region CDR1, CDR2, and CDR3. In other embodiments of the above aspects, the antibody contains a light chain variable region CDR1, CDR2, and CDR3. In other embodiments of the above aspects the antibody contains a heavy chain variable region CDR1, CDR2, and CDR3, and a light chain variable region CDR1, CDR2, and CDR3. In other embodiments of the above aspects the antibody is a phage display derived antibody selected from any one or more of Antibody Nos. 1-34. In particular embodiments, the antibody is Antibody No. 5, 8, 11, 18, 29, or 33.
  • In another embodiment of the above aspect, the antibody or fragment thereof contains:
  • a. a heavy chain variable region CDR1 containing a sequence: X1X2X3X4X5 (SEQ ID NO: 1022), where X1 is S, N, D, T, A, or R; X2 is G, Y, or F; X3 is Y, H, S, G, D, or F; X4 is D, V, or I; X5 is N, H, C, R, S or is absent;
  • b. a heavy chain variable region CDR2 containing a sequence: X1X2X3X4X5X6X7X8X9X10X11X12X13X14X15X16 (SEQ ID NO: 1023), where X1 is M, V, L, I, A, G, or T; X2 is G or I; X3 is Y, W, N, or C; X4 is Y, G, D, or W; X5 is S, D, or E; X6 is G or D; X7 is S, Y, N, or I; X8 is T, P, or K; X9 is N, A, G, D, or V; X10 is Y or F; X11 is N; X12 is P, S, or E; X13 is S, A, or N; X14 is L or F; X15 is K; X16 is S, G, or N;
  • c. a heavy chain variable region CDR3 containing a sequence: X1X2X3X4X5X6X7X8 (SEQ ID NO: 1024), where X1 is G, S, A, or R; X2 is M, G, Y, S, L, R, or V; X3 is M, D, I, V, H, M, or S; X4 is V, Y, M, W, or S; X5 is L, Y, S or absent; X6 is I, D, V, T, G, S or absent; X7 is P, G, D, S, or A; and X8 is N, Y, or T. In one embodiment, the heavy chain variable region CDR1 optionally contains amino acids X6 and X7, which are V and S, respectively. In another embodiment, the heavy chain variable region CDR2 optionally contains an insertion of amino acids Xa and Xb between X3 and X4, where Xa is I or P and Xb is S. In another embodiment, the heavy chain variable region CDR3 optionally contains an insertion of between 1 and 6 amino acids Xa-Xf (SEQ ID NO: 1025) between X6 and X7, where Xa is G, T, D, or Y; Xb is S, A, G, or F; Xc is Y, V, P, or F; Xd is Y or F; Xe is Y; and Xf is E, F, or G. In another embodiment, the heavy chain variable region CDR1 contains the sequence S G Y D (SEQ ID NO: 1046); S G S D (SEQ ID NO: 1047); or S G F D (SEQ ID NO: 1048). In another embodiment, the heavy chain variable region CDR2 contains the sequence: M G Y I S Y S (SEQ ID NO: 1049); V I W G D G STA (SEQ ID NO: 1050); S T A Y N S (SEQ ID NO: 1051); or STNY NP (SEQ ID NO: 1052). In one embodiment, the heavy chain variable region CDR3 contains the sequence G M M V L I (SEQ ID NO: 1053); G V S S L S (SEQ ID NO: 1054); or G S Y Y Y X (SEQ ID NO: 1055), where X is E, G, or F.
  • In another embodiment of the above aspect, the antibody or fragment thereof contains:
  • a. a light chain variable region CDR1 containing a sequence: X1X2X3X4X5X6X7X8X9X10X11 (SEQ ID NO: 1026), where X1 is K, Q, or R; X2 is A or T; X3 is S, R, or N; X4 is K or Q; X5 is S, D, R, N, L, or I; X6 is I or S; X7 is T, G, V, or N; X8 is N, S, H, or K; X9 is Y or W; X10 is L, M, or I; X11 is A, S, or Y;
  • b. a light chain variable region CDR2 containing a sequence: X1X2X3X4X5X6X7 (SEQ ID NO: 1027), where X1 is S, D, E, or Y; X2 is G, A, or T; X3 is S or T; X4 is T, S, K, or A; X5 is L; X6 is Q, A, or V; X7 is S or D;
  • c. a light chain variable region CDR3 containing a sequence: X1X2X3X4X5X6X7X8X9 (SEQ ID NO: 1028), where X1 is Q, L, or H; X2 is Q or K; X3 is Y, A, W, or T; X4 is Y, H, S, or D; X5 is E, S, R, T, or N; X6 is K, N, T, L, or H; X7 is P; X8 is Y, W, L, N, P, or R; and X9 is T.
  • In one embodiment, the light chain variable region CDR1 contains the sequence K A S K X I T (SEQ ID NO: 1056), where X is X, L, or I; or Q A S Q D I G N W L (SEQ ID NO: 1057). In another embodiment, the light chain variable region CDR2 contains the sequence S G S T L Q S (SEQ ID NO: 1058); DATSLAD (SEQ ID NO: 1059); or DATTLAD (SEQ ID NO: 1060). In another embodiment, the light chain variable region CDR3 contains the sequence Q Q Y Y E K P X T (SEQ ID NO: 1061) or Q Q Y Y E N P X T (SEQ ID NO: 1062) where X is Y or L.
  • In another series of embodiments the antibody or fragment thereof comprises a VH comprising:
      • a. a heavy chain variable region CDR1 containing a sequence: SX1AMS (SEQ ID NO: 1016), where X1 is Y or F;
      • b. a heavy chain variable region CDR2 containing a sequence: AISGSG XISTYYADSVKG (SEQ ID NO: 1017), where X1 is S or G;
      • c. a heavy chain variable region CDR3 containing a sequence: X1X2DX3WSX4X5X6X7X8TAFDL (SEQ ID NO: 1018), where X1 is H, D or Q; X2 is W, M, F, H, or R; X3 is W, Y or F; X4 is T, N, G, or P; X5 is R, A, S, G, or Y; X6 is S, P, N or T; and X7 is G, S, R, or K: X8 is P, M, A or L optionally in combination with a VL comprising
      • a. a light chain variable region CDR1 comprising the sequence SGDALPRQYAY (SEQ ID NO: 1019)
      • b. a light chain variable region CDR2 comprising the sequence KDSXRPS (SEQ ID NO: 1020), where X is E or F
      • c. a light chain variable region CDR3 comprising the sequence QSADSSGTYXV (SEQ ID NO: 1021), where X is V or A.
  • In various embodiments of the above aspects, the antibody contains a heavy chain variable region CDR1, CDR2, and CDR3. In other embodiments of the above aspects, the antibody contains a light chain variable region CDR1, CDR2, and CDR3. In still other embodiments of the above aspects, the antibody contains a heavy chain variable region CDR1, CDR2, and CDR3, and a light chain variable region CDR1, CDR2, and CDR3. In particular embodiments, the antibody is a hybridoma derived antibody selected from any one or more of Antibody Nos. 35-48.
  • In various embodiments of the above aspects, the antigen binding fragment thereof is a single chain antibody, a single chain variable fragment (scFv), a Fab fragment, or a F(ab′)2 fragment.
  • In another aspect, the invention provides a polynucleotide encoding the antibody or antigen binding fragment thereof of any of the above aspects.
  • In another aspect, the invention provides a vector containing the polynucleotide of the previous aspect.
  • In still another aspect, the invention provides a host cell containing the vector of the previous aspect.
  • In another aspect, the invention provides a method for treating neuropathic pain, the method involving administering to a patient in need thereof an antibody or antigen binding fragment thereof according to any of the above aspects. In one embodiment, the antibody or antigen binding fragment thereof is administered by intrathecal delivery.
  • In another aspect, the invention provides a method for the large scale production of a recombinant P2X4 polypeptide, the method involving expressing a human P2X4 protein in an SF9 cell at 27° C. for 72 hours; extracting the P2X4 protein by solubilizing in a buffer containing n-Dodecyl-beta-D-Maltoside, n-Dodecyl thio-Maltoside, CHAPS, and the Cholesteryl Hemisuccinate; then isolating the solubilized protein. In one embodiment, the SF9 cells were infected with baculovirus particles with a multiplicity of infection of 2 at a cell density of 2×10E6 cells/ml. In another embodiment, the proteins are purified using affinity and size exclusion chromatography. In another embodiment, the purified protein is maintained in a buffer containing 50 mM Tris-HCl pH 8.0, 600 mM NaCl, 10% glycerol, 0.025% n-Dodecyl-beta-D-Maltoside, 0.0125% n-Dodecyl thio-Maltoside, 0.0075% CHAPS, and 0.0015% Cholesteryl Hemisuccinate.
  • In another embodiment, the method generates milligram quantities of purified P2X4 human polypeptide. In another embodiment, the majority of the P2X4 protein is in the trimeric form.
  • In another aspect, the invention provides a recombinant human P2X4 polypeptide produced according to the method of any previous aspect. In one embodiment, at least about 65%-75% of the polypeptide is in the trimeric form.
  • Other features and advantages of the invention will be apparent from the detailed description, and from the claims.
    • Definitions
  • Unless defined otherwise, all technical and scientific terms used herein have the meaning commonly understood by a person skilled in the art to which this invention belongs. The following references provide one of skill with a general definition of many of the terms used in this invention: Singleton et al., Dictionary of Microbiology and Molecular Biology (2nd ed. 1994); The Cambridge Dictionary of Science and Technology (Walker ed., 1988); The Glossary of Genetics, 5th Ed., R. Rieger et al. (eds.), Springer Verlag (1991); and Hale & Marham, The Harper Collins Dictionary of Biology (1991). As used herein, the following terms have the meanings ascribed to them below, unless specified otherwise.
  • By “P2X purinoceptor 4 (P2RX4 or P2X4) polypeptide” is meant a purinergic receptor protein or fragment thereof having at least about 85% or greater amino acid identity to the amino acid sequence provided at NCBI Accession No. Q99571 and having P2X4 biological activity. P2X4 biological activity includes Ca2+/Na+ conducting activity in response to ATP binding and/or P2X4 antibody binding. An exemplary human P2X4 sequence is provided below:
  • (SEQ ID NO: 1029)
    magccaalaa flfeydtpri vlirsrkvgl mnravqllil ayvigwvfvw ekgyqetdsv  61
    vssvttkvkg vavtntsklg friwdvadyv ipaqeenslf vmtnviltmn qtqglcpeip 121
    dattvcksda sctagsagth sngvstgrcv afngsvktce vaawcpvedd thvpqpaflk 181
    aaenftllvk nniwypkfnf skrnilpnit ttylksciyd aktdpfcpif rlgkivenag 241
    hsfqdmaveg gimgiqvnwd cnldraaslc lprysfrrld trdvehnvsp gynfrfakyy 301
    rdlagneqrt likaygirfd iivfgkagkf diiptminig sglallgmat vlcdiivlyc 361
    mkkrlyyrek kykyvedyeq glaseldq
  • In embodiments of the invention, a human P2X4 polypeptide has at least about 65%, 70%, 80%, 85%, 90%, 95%, or even 100% identity to NCBI Accession No. Q99571. In other embodiments, the invention provides P2X4 polypeptides comprising one or more amino acid substitutions relative to the Q99571 reference sequence, including for example: E95Q, V105M, G114D, A122V, S131N, A151P, G154R, L303P, and N306K.
  • An exemplary murine P2X purinoceptor 4 is provided at NCBI Accession No. Q9JJX6, which has the following sequence:
  • (SEQ ID NO: 1030)
    magccsvlgs flfeydtpri vlirsrkvgl mnrvvqllil ayvigwvfvw ekgyqetdsv  61
    vssvttkakg vavtntsqlg friwdvadyv vpaqeenslf imtnmivtvn qtqgtcpeip 121
    dktsicdsda nctlgssdth ssgigtgrcv pfnasvktce vaawcpvend agvptpaflk 181
    aaenftllvk nniwypkfnf skrnilpnit tsylksciyn artdpfcpif rlgqivadag 241
    hsfqemaveg gimgiqikwd cnldraashc lprysfrrld trdlehnvsp gynfrfakyy 301
    rdlagneqrt ltkaygirfd iivfgkagkf diiptminvg sglallgvat vlcdvivlyc 361
    mkkryyyrdk kykyvedyeq glsgemnq
  • An exemplary rat P2X purinoceptor 4 sequence is provided at NCBI Accession No. P51577, which has the following sequence:
  • (SEQ ID NO: 1031)
    magccsvlgs flfeydtpri vlirsrkvgl mnravqllil ayvigwvfvw ekgyqetdsv  61
    vssvttkakg vavtntsqlg friwdvadyv ipaqeenslf imtnmivtvn qtqstcpeip 121
    dktsicnsda dctpgsvdth ssgvatgrcv pfnesvktce vaawcpvend vgvptpaflk 181
    aaenftllvk nniwypkfnf skrnilpnit tsylksciyn aqtdpfcpif rlgtivedat 241
    hsfqemaveg gimgiqikwd cnldraaslc lprysfrrld trdlehnvsp gynfrfakyy 301
    rdlagkeqrt ltkaygirfd iivfgkagkf diiptminvg sglallgvat vlcdvivlyc 361
    mkkkyyyrdk kykyvedyeq glsgemnq
  • An exemplary cynomologus monkey (e.g. macaque) P2X purinoceptor 4 sequence, which has the following sequence:
  • (SEQ ID NO: 1032)
    magccaalaa flfeydtpri vlirsrkvgl mnravqllil ayvigwvfvw ekgyqetdsv  61
    vssvttkvkg vavtntsklg friwdvadyv ipaqqenslf vmtnmiltmn qtqdlcpeip 121
    dvttvcksda nctagsagth sngvstgrcv pfnrsvktce vaawcpvedd thvpqpaflk 181
    aaenftllvk nniwypkfnf skrnilpnit ttylksciyd aktdpfcpif rlgkivenag 241
    hsfqdmaveg gimgiqvnwd cnldraaslc lprysfrrld trdvehnvsp gynfrfakyy 301
    rdpagkeqrt likaygirfd iivfgkagkf diiptminig sglallgmat vlcdiivlyc 361
    mkkrlyyrek kykyvedyeq glaseldp
  • By “P2X4 nucleic acid molecule” is meant a polynucleotide encoding a P2X4 polypeptide or fragment thereof. An exemplary human P2X4 polynucleotide sequence is provided at NCBI Accession No. NM_002560, the sequence of which follows:
  • (SEQ ID NO: 1033)
       1 aagtgctggg atgacaggtg tgagccaccg cccccggccc ctcgcccgcc ttttgaagga
      61 gcctttcgtc ctcaagggcg aggccactcc ccccccgcga gttccatgcc ccctagaggg
     121 tcatcgttcc cgacggggag gtggcgccct cccccgggcc ccgggccccg accgcccgtg
     181 ctgcctcctt ccgggccctc ctccgcgatg acggcgccgc cagcaggcca ggcggactgg
     241 gcggggctcc gagcggggac tgggacccag accgactagg ggactgggag cgggcggcgc
     301 ggccatggcg ggctgctgcg ccgcgctggc ggccttcctg ttcgagtacg acacgccgcg
     361 catcgtgctc atccgcagcc gcaaagtggg gctcatgaac cgcgccgtgc aactgctcat
     421 cctggcctac gtcatcgggt gggtgtttgt gtgggaaaag ggctaccagg aaactgactc
     481 cgtggtcagc tccgttacga ccaaggtcaa gggcgtggct gtgaccaaca cttctaaact
     541 tggattccgg atctgggatg tggcggatta tgtgatacca gctcaggagg aaaactccct
     601 cttcgtcatg accaacgtga tcctcaccat gaaccagaca cagggcctgt gccccgagat
     661 tccagatgcg accactgtgt gtaaatcaga tgccagctgt actgccggct ctgccggcac
     721 ccacagcaac ggagtctcaa caggcaggtg cgtagctttc aacgggtctg tcaagacgtg
     781 tgaggtggcg gcctggtgcc cggtggagga tgacacacac gtgccacaac ctgctttttt
     841 aaaggctgca gaaaacttca ctcttttggt taagaacaac atctggtatc ccaaatttaa
     901 tttcagcaag aggaatatcc ttcccaacat caccactact tacctcaagt cgtgcattta
     961 tgatgctaaa acagatccct tctgccccat attccgtctt ggcaaaatag tggagaacgc
    1021 aggacacagt ttccaggaca tggccgtgga gggaggcatc atgggcatcc aggtcaactg
    1081 ggactgcaac ctggacagag ccgcctccct ctgcttgccc aggtactcct tccgccgcct
    1141 cgatacacgg gacgttgagc acaacgtatc tcctggctac aatttcaggt ttgccaagta
    1201 ctacagagac ctggctggca acgagcagcg cacgctcatc aaggcctatg gcatccgctt
    1261 cgacatcatt gtgtttggga aggcagggaa atttgacatc atccccacta tgatcaacat
    1321 cggctctggc ctggcactgc taggcatggc gaccgtgctg tgtgacatca tagtcctcta
    1381 ctgcatgaag aaaagactct actatcggga gaagaaatat aaatatgtgg aagattacga
    1441 gcagggtctt gctagtgagc tggaccagtg aggcctaccc cacacctggg ctctccacag
    1501 ccccatcaaa gaacagagag gaggaggagg gagaaatggc caccacatca ccccagagaa
    1561 atttctggaa tctgattgag tctccactcc acaagcactc agggttcccc agcagctcct
    1621 gtgtgttgtg tgcaggatct gtttgcccac tcggcccagg aggtcagcag tctgttcttg
    1681 gctgggtcaa ctctgctttt cccgcaacct ggggttgtcg ggggagcgct ggcccgacgc
    1741 agtggcactg ctgtggcttt cagggctgga gctggctttg ctcagaagcc tcctgtctcc
    1801 agctctctcc aggacaggcc cagtcctctg aggcacggcg gctctgttca agcactttat
    1861 gcggcagggg aggccgcctg gctgcagtca ctagacttgt agcaggcctg ggctgcaggc
    1921 ttccccccga ccattccctg cagccatgcg gcagagctgg catttctcct cagagaagcg
    1981 ctgtgctaag gtgatcgagg accagacatt aaagcgtgat tttcttaaaa aaaaaaaaaa
    2041 aaa
  • By “P2X4 biological activity” is meant ion channel conducting activity or ion channel mediated changes in cytosolic calcium levels.
  • By “ameliorate” is meant decrease, suppress, attenuate, diminish, arrest, or stabilize the development or progression of a disease.
  • The term “antibody,” as used in this disclosure, refers to an immunoglobulin or a fragment or a derivative thereof, and encompasses any polypeptide comprising an antigen-binding site, regardless of whether it is produced in vitro or in vivo. The term includes, but is not limited to, polyclonal, monoclonal, monospecific, polyspecific, non-specific, humanized, single-chain, chimeric, synthetic, recombinant, hybrid, mutated, and grafted antibodies. Unless otherwise modified by the term “intact,” as in “intact antibodies,” for the purposes of this disclosure, the term “antibody” also includes antibody fragments such as Fab, F(ab′)2, Fv, scFv, Fd, dAb, and other antibody fragments that retain antigen-binding function, i.e., the ability to bind a P2X4 polypeptide specifically. Typically, such fragments would comprise an antigen-binding domain.
  • The terms “antigen-binding domain,” “antigen-binding fragment,” and “binding fragment” refer to a part of an antibody molecule that comprises amino acids responsible for the specific binding between the antibody and the antigen. In instances, where an antigen is large, the antigen-binding domain may only bind to a part of the antigen. A portion of the antigen molecule that is responsible for specific interactions with the antigen-binding domain is referred to as “epitope” or “antigenic determinant.” In particular embodiments, an antigen-binding domain comprises an antibody light chain variable region (VL) and an antibody heavy chain variable region (VH), however, it does not necessarily have to comprise both. For example, a so-called Fd antibody fragment consists only of a VH domain, but still retains some antigen-binding function of the intact antibody.
  • Binding fragments of an antibody are produced by recombinant DNA techniques, or by enzymatic or chemical cleavage of intact antibodies. Binding fragments include Fab, Fab′, F(ab′)2, Fv, and single-chain antibodies. An antibody other than a “bispecific” or “bifunctional” antibody is understood to have each of its binding sites identical. Digestion of antibodies with the enzyme, papain, results in two identical antigen-binding fragments, known also as “Fab” fragments, and a “Fc” fragment, having no antigen-binding activity but having the ability to crystallize. Digestion of antibodies with the enzyme, pepsin, results in the a F(ab′)2 fragment in which the two arms of the antibody molecule remain linked and comprise two-antigen binding sites. The F(ab′)2 fragment has the ability to crosslink antigen. “Fv” when used herein refers to the minimum fragment of an antibody that retains both antigen-recognition and antigen-binding sites. “Fab” when used herein refers to a fragment of an antibody that comprises the constant domain of the light chain and the CHI domain of the heavy chain.
  • The term “mAb” refers to monoclonal antibody. Antibodies of the invention comprise without limitation whole native antibodies, bispecific antibodies; chimeric antibodies; Fab, Fab′, single chain V region fragments (scFv), fusion polypeptides, and unconventional antibodies.
  • In this disclosure, “comprises,” “comprising,” “containing” and “having” and the like can have the meaning ascribed to them in U.S. Patent law and can mean “includes,” “including,” and the like; “consisting essentially of” or “consists essentially” likewise has the meaning ascribed in U.S. Patent law and the term is open-ended, allowing for the presence of more than that which is recited so long as basic or novel characteristics of that which is recited is not changed by the presence of more than that which is recited, but excludes prior art embodiments.
  • “Detect” refers to identifying the presence, absence or amount of the analyte to be detected. In one embodiment, an antibody of the invention or fragment thereof is used to detect the presence or level of a P2X4 polypeptide.
  • By “detectable label” is meant a composition that when linked to a molecule of interest renders the latter detectable, via spectroscopic, photochemical, biochemical, immunochemical, or chemical means. For example, useful labels include radioactive isotopes, magnetic beads, metallic beads, colloidal particles, fluorescent dyes, electron-dense reagents, enzymes (for example, as commonly used in an ELISA), biotin, digoxigenin, or haptens.
  • By “disease” is meant any condition or disorder that damages or interferes with the normal function of a cell, tissue, or organ. Examples of diseases include neuropathic pain, particularly pain associated with P2X4 channel activity or the activity of a pathway responsive to P2X4.
  • The term “effective amount” refers to a dosage or amount of an agent that is sufficient to reduce the activity of a P2X4 polypeptide to result in amelioration of symptoms in a patient or to achieve a desired biological outcome. Desired biological outcomes include, for example, the amelioration of chronic pain or a symptom thereof, modulation of P2X4 biological activity, or the modulation of a pathway responsive to P2X4 activity.
  • The term “isolated” refers to a molecule that is substantially free of other elements present in its natural environment. For instance, an isolated protein is substantially free of cellular material or other proteins from the cell or tissue source from which it is derived. The term “isolated” also refers to preparations where the isolated protein is sufficiently pure to be administered as a pharmaceutical composition, or at least 70-80% (w/w) pure, more preferably, at least 80-90% (w/w) pure, even more preferably, 90-95% pure; and, most preferably, at least 95%, 96%, 97%, 98%, 99%, or 100% (w/w) pure.
  • By “fragment” is meant a portion of a polypeptide or nucleic acid molecule. This portion contains, preferably, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the entire length of the reference nucleic acid molecule or polypeptide. In a particular embodiment, a fragment of a P2X4 polypeptide may contain 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, or 300 amino acids.
  • By “reference” is meant a standard of comparison.
  • A “reference sequence” is a defined sequence used as a basis for sequence comparison. A reference sequence may be a subset of or the entirety of a specified sequence; for example, a segment of a full-length cDNA or gene sequence, or the complete cDNA or gene sequence. For polypeptides, the length of the reference polypeptide sequence will generally be at least about 16 amino acids, preferably at least about 20 amino acids, more preferably at least about 25 amino acids, and even more preferably about 35 amino acids, about 50 amino acids, or about 100 amino acids. For nucleic acids, the length of the reference nucleic acid sequence will generally be at least about 50 nucleotides, preferably at least about 60 nucleotides, more preferably at least about 75 nucleotides, and even more preferably about 100 nucleotides or about 300 nucleotides or any integer thereabout or therebetween.
  • The term “repertoire” refers to a genetically diverse collection of nucleotides derived wholly or partially from sequences that encode expressed immunoglobulins. The sequences are generated by in vivo rearrangement of, e.g., V, D, and J segments for H chains and, e.g., V and J segment for L chains. Alternatively, the sequences may be generated from a cell line by in vitro stimulation, in response to which the rearrangement occurs. Alternatively, part or all of the sequences may be obtained by combining, e.g., unrearranged V segments with D and J segments, by nucleotide synthesis, randomised mutagenesis, and other methods, e.g., as disclosed in U.S. Pat. No. 5,565,332.
  • By “specifically binds” is meant an agent (e.g., antibody) that recognizes and binds a molecule (e.g., polypeptide), but which does not substantially recognize and bind other molecules in a sample, for example, a biological sample. For example, two molecules that specifically bind form a complex that is relatively stable under physiologic conditions. Specific binding is characterized by a high affinity and a low to moderate capacity as distinguished from nonspecific binding which usually has a low affinity with a moderate to high capacity. Typically, binding is considered specific when the affinity constant KA is higher than 107 M−1, or more preferably higher than 108 M−1.
  • The strength of the binding between P2X4 and an antibody can be measured using, for example, an enzyme-linked immunoadsorption assay (ELISA), radio-immunoassay (RIA), or surface plasmon resonance-based technology (e.g., Biacore), all of which are techniques well known in the art. If necessary, non-specific binding can be reduced without substantially affecting specific binding by varying the binding conditions. The appropriate binding conditions such as concentration of antibodies, ionic strength of the solution, temperature, time allowed for binding, concentration of a blocking agent (e.g., serum albumin, milk casein), etc., may be optimized by a skilled artisan using routine techniques.
  • Unless specifically stated or obvious from context, as used herein, the term “about” is understood as within a range of normal tolerance in the art, for example within 2 standard deviations of the mean. About can be understood as within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05%, or 0.01% of the stated value. Unless otherwise clear from context, all numerical values provided herein are modified by the term about.
  • The recitation of a listing of chemical groups in any definition of a variable herein includes definitions of that variable as any single group or combination of listed groups. The recitation of an embodiment for a variable or aspect herein includes that embodiment as any single embodiment or in combination with any other embodiments or portions thereof.
  • Any compositions or methods provided herein can be combined with one or more of any of the other compositions and methods provided herein.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1A-1D shows an analysis of Antibody Nos. 1, 11, 29, and 33 binding to human P2X4 variants.
  • FIG. 2 provides the VH & VL sequences of Antibody Nos. 1-34, which were identified using phage display technology.
  • FIG. 3 provides a summary of P2X4 orthologue binding properties of antibodies identified using phage display selection (antibodies 1 to 34) and a summary of their functional effects measured by electrophysiology assays and reported as fraction of control current. Key: + indicates that binding was observed in FMAT assay;
  • − indicates that no binding was observed in FMAT assay; NT indicates that the antibody was not tested in the assay.
  • FIG. 4 shows results of the antibodies 5, 8, 11, 18, 29, and 33 screened in electrophysiology assays. Each of these antibodies was identified as a P2X4 antagonist. Peak agonist induced inward current in response to 3 μM ATP in the presence of antibody is indicated as a fraction of control current in the absence of antibody at human or cynomolgus (cyno) P2X4.
  • FIG. 5 provides a summary of P2X4 orthologue binding properties of antibodies isolated from hybridomas (Antibody Nos. 35-48) and a summary of their functional effects measured by electrophysiology assays and reported as fraction of control current.
  • FIG. 6 provides the VH & VL sequences of Antibody Nos. 35-48.
  • FIG. 7 provides a summary of results of binding assays for 252 antibodies (Antibody Nos. 35-286) isolated using hybridoma technology and a summary of their functional effects measured by electrophysiology assays and reported as fraction of control current.
  • FIG. 8A-8F shows whole cell current traces obtained using QPatch 16X showing the agonist response (indicated temporally by the grey bar) before (black trace) and after (grey trace) addition of antibodies. Traces are superimposed for comparison. Dotted line indicates zero current. P2X4 species investigated is indicated where appropriate by (m, mouse) (hu, human).
  • FIG. 8A, 8D, 8E, 8F show activity against huP2X4. FIGS. 8B and 8C show activity against mP2X4.
  • FIG. 9 shows schematically an extracellular view of predicted P2X4 trimer-Antibody No. 11 Fv complex structure. In particular, FIG. 9 illustrates the bipartite epitope-paratope interface—Antibody No. 11 VHCDRs-P2X4 protomer 1 head (major interface—large dotted circle); Antibody No. 11 VLCDRs-P2X4 protomer 2 right flipper (minor interface—small dotted circle). Three Antibody No. 11 molecules can potentially bind the same P2X4 trimer molecule. The two Fab arms of Antibody No. 11 are not likely to engage the same P2X4 trimer molecule. Antibody No. 11 is predicted to bind a P2X heteromer across the epitope formed by two P2X4 subunits.
  • FIG. 10 provides alignments of human, cyno, mouse and rat P2X4 sequences. The head region of the protein is indicated. Amino acids within the predicted epitope are also indicated.
  • FIG. 11 shows the effect of P2X4 antibody Nos. 38 and 208 and an isotype control antibody (NIP228 TM) dosed intra-thecally (5 μg per mouse) on reversal of peripheral nerve ligation (PNL)-induced mechanical hyperalgesia as measured by the ipsilateral/contralateral ratio of paw withdrawal threshold in response to paw pressure (n=9-10 per group). Data analysed using 2 way ANOVA with time and treatment as dependant factors. Subsequent statistical significance obtained using Tukey's Post Hoc test. * P<0.05; *** P<0.001−Op+NIP228 TM vs Op+Antibody 208: +P<0.05; ++P<0.01; +++P<0.001−Op+NIP228 TM vs Op+Antibody 38
  • FIG. 12 provides an alignment of the VH & VL sequences of Antibody Nos. 287 to 315, which are derived from Antibody 11.
  • FIG. 13 provides the VH & VL sequences of Antibody Nos. 208 and 316 to 321
  • FIG. 14 shows the effect of antibody Nos. 11, 300 and 312 on huP2X4 currents recorded on Qpatch 16X. The black trace indicates the ATP response prior to IgG addition whereas the grey trace indicates the ATP response after incubation with IgG. The dashed line indicates the zero current level and the grey bar indicates the time at which ATP was added to the cell bathing solution. Traces are overlayed for comparison. Dose response curves are plotted with normalised current values as described in Example 14 and represent mean+/−SEM, n=4.
  • FIG. 15 summarises IC50 values for optimised versions of Antibody 11 at huP2X4 using either FLIPR or Qpatch 16X. Values are geometric means.
  • FIG. 16 summarises IC50 values for antibodies 38, 43, 46 & 208 at murineP2X4 and/or huP2X4 expressed in HEK 293F cells obtained on Qpatch 16X.
  • FIG. 17 summarises the effect of antibodies 38, 43, 46 & 208 on mouse microglial P2X4 currents measured on Qpatch 16X.
  • FIG. 18 shows exemplary electrophysiology current traces from mouse microglia pretreated with either the control antibody NIP 228 or antibody 208 (0.33 mg/ml). The grey bar indicates the time at which ATP (30 μM) was added to the cells and the dotted line indicates the zero current level.
  • FIG. 19 shows example IC50 curves obtained with two of the anti-P2X4 antibodies in the ATP stimulated calcium response assay.
  • FIG. 20 shows IC50 curves (mean+/−SEM) for antibodies 46, 38 and 208 obtained from mouse microglia assayed on FLIPR. Mean IC50 values are presented below.
  • FIG. 21 shows exemplar electrophysiology current traces from human monocyte derived macrophages. Time at which ATP was added to the cells is indicated by the open box. Dotted line indicates zero current.
  • FIG. 22 summarises the steady state inward current from human monocyte derived macrophages in response to ATP (30 μM).
  • DESCRIPTION OF THE SEQUENCES
    SEQ
    ID Antibody Description
    1 1 VH
    DNA
    2 1 VH
    PRT
    3 1 CDR1
    PRT
    4 1 CDR2
    PRT
    5 1 CDR3
    PRT
    6 1 FW1
    PRT
    7 1 FW2
    PRT
    8 1 FW3
    PRT
    9 1 FW4
    PRT
    10 1 VL
    DNA
    11 1 VL
    PRT
    12 1 CDR1
    PRT
    13 1 CDR2
    PRT
    14 1 CDR3
    PRT
    15 1 FW1
    PRT
    16 1 FW2
    PRT
    17 1 FW3
    PRT
    18 1 FW4
    PRT
    19 5 VH
    DNA
    20 5 VH
    PRT
    21 5 CDR1
    PRT
    22 5 CDR2
    PRT
    23 5 CDR3
    PRT
    24 5 FW1
    PRT
    25 5 FW2
    PRT
    26 5 FW3
    PRT
    27 5 FW4
    PRT
    28 5 VL
    DNA
    29 5 VL
    PRT
    30 5 CDR1
    PRT
    31 5 CDR2
    PRT
    32 5 CDR3
    PRT
    33 5 FW1
    PRT
    34 5 FW2
    PRT
    35 5 FW3
    PRT
    36 5 FW4
    PRT
    37 8 VH
    DNA
    38 8 VH
    PRT
    39 8 CDR1
    PRT
    40 8 CDR2
    PRT
    41 8 CDR3
    PRT
    42 8 FW1
    PRT
    43 8 FW2
    PRT
    44 8 FW3
    PRT
    45 8 FW4
    PRT
    46 8 VL
    DNA
    47 8 VL
    PRT
    48 8 CDR1
    PRT
    49 8 CDR2
    PRT
    50 8 CDR3
    PRT
    51 8 FW1
    PRT
    52 8 FW2
    PRT
    53 8 FW3
    PRT
    54 8 FW4
    PRT
    55 11 VH
    DNA
    56 11 VH
    PRT
    57 11 CDR1
    PRT
    58 11 CDR2
    PRT
    59 11 CDR3
    PRT
    60 11 FW1
    PRT
    61 11 FW2
    PRT
    62 11 FW3
    PRT
    63 11 FW4
    PRT
    64 11 VL
    DNA
    65 11 VL
    PRT
    66 11 CDR1
    PRT
    67 11 CDR2
    PRT
    68 11 CDR3
    PRT
    69 11 FW1
    PRT
    70 11 FW2
    PRT
    71 11 FW3
    PRT
    72 11 FW4
    PRT
    73 18 VH
    DNA
    74 18 VH
    PRT
    75 18 CDR1
    PRT
    76 18 CDR2
    PRT
    77 18 CDR3
    PRT
    78 18 FW1
    PRT
    79 18 FW2
    PRT
    80 18 FW3
    PRT
    81 18 FW4
    PRT
    82 18 VL
    DNA
    83 18 VL
    PRT
    84 18 CDR1
    PRT
    85 18 CDR2
    PRT
    86 18 CDR3
    PRT
    87 18 FW1
    PRT
    88 18 FW2
    PRT
    89 18 FW3
    PRT
    90 18 FW4
    PRT
    91 29 VH
    DNA
    92 29 VH
    PRT
    93 29 CDR1
    PRT
    94 29 CDR2
    PRT
    95 29 CDR3
    PRT
    96 29 FW1
    PRT
    97 29 FW2
    PRT
    98 29 FW3
    PRT
    99 29 FW4
    PRT
    100 29 VL
    DNA
    101 29 VL
    PRT
    102 29 CDR1
    PRT
    103 29 CDR2
    PRT
    104 29 CDR3
    PRT
    105 29 FW1
    PRT
    106 29 FW2
    PRT
    107 29 FW3
    PRT
    108 29 FW4
    PRT
    109 33 VH
    DNA
    110 33 VH
    PRT
    111 33 CDR1
    PRT
    112 33 CDR2
    PRT
    113 33 CDR3
    PRT
    114 33 FW1
    PRT
    115 33 FW2
    PRT
    116 33 FW3
    PRT
    117 33 FW4
    PRT
    118 33 VL
    DNA
    119 33 VL
    PRT
    120 33 CDR1
    PRT
    121 33 CDR2
    PRT
    122 33 CDR3
    PRT
    123 33 FW1
    PRT
    124 33 FW2
    PRT
    125 33 FW3
    PRT
    126 33 FW4
    PRT
    127 35 VH
    DNA
    128 35 VH
    PRT
    129 35 CDR1
    PRT
    130 35 CDR2
    PRT
    131 35 CDR3
    PRT
    132 35 FW1
    PRT
    133 35 FW2
    PRT
    134 35 FW3
    PRT
    135 35 FW4
    PRT
    136 35 VL
    DNA
    137 35 VL
    PRT
    138 35 CDR1
    PRT
    139 35 CDR2
    PRT
    140 35 CDR3
    PRT
    141 35 FW1
    PRT
    142 35 FW2
    PRT
    143 35 FW3
    PRT
    144 35 FW4
    PRT
    163 37 VH
    DNA
    164 37 VH
    PRT
    165 37 CDR1
    PRT
    166 37 CDR2
    PRT
    167 37 CDR3
    PRT
    168 37 FW1
    PRT
    169 37 FW2
    PRT
    170 37 FW3
    PRT
    171 37 FW4
    PRT
    172 37 VL
    DNA
    173 37 VL
    PRT
    174 37 CDR1
    PRT
    175 37 CDR2
    PRT
    176 37 CDR3
    PRT
    177 37 FW1
    PRT
    178 37 FW2
    PRT
    179 37 FW3
    PRT
    180 37 FW4
    PRT
    181 38 VH
    DNA
    182 38 VH
    PRT
    183 38 CDR1
    PRT
    184 38 CDR2
    PRT
    185 38 CDR3
    PRT
    186 38 FW1
    PRT
    187 38 FW2
    PRT
    188 38 FW3
    PRT
    189 38 FW4
    PRT
    190 38 VL
    DNA
    191 38 VL
    PRT
    192 38 CDR1
    PRT
    193 38 CDR2
    PRT
    194 38 CDR3
    PRT
    195 38 FW1
    PRT
    196 38 FW2
    PRT
    197 38 FW3
    PRT
    198 38 FW4
    PRT
    217 40 VH
    DNA
    218 40 VH
    PRT
    219 40 CDR1
    PRT
    220 40 CDR2
    PRT
    221 40 CDR3
    PRT
    222 40 FW1
    PRT
    223 40 FW2
    PRT
    224 40 FW3
    PRT
    225 40 FW4
    PRT
    226 40 VL
    DNA
    227 40 VL
    PRT
    228 40 CDR1
    PRT
    229 40 CDR2
    PRT
    230 40 CDR3
    PRT
    231 40 FW1
    PRT
    232 40 FW2
    PRT
    233 40 FW3
    PRT
    234 40 FW4
    PRT
    253 42 VH
    DNA
    254 42 VH
    PRT
    255 42 CDR1
    PRT
    256 42 CDR2
    PRT
    257 42 CDR3
    PRT
    258 42 FW1
    PRT
    259 42 FW2
    PRT
    260 42 FW3
    PRT
    261 42 FW4
    PRT
    262 42 VL
    DNA
    263 42 VL
    PRT
    264 42 CDR1
    PRT
    265 42 CDR2
    PRT
    266 42 CDR3
    PRT
    267 42 FW1
    PRT
    268 42 FW2
    PRT
    269 42 FW3
    PRT
    270 42 FW4
    PRT
    271 43 VH
    DNA
    272 43 VH
    PRT
    273 43 CDR1
    PRT
    274 43 CDR2
    PRT
    275 43 CDR3
    PRT
    276 43 FW1
    PRT
    277 43 FW2
    PRT
    278 43 FW3
    PRT
    279 43 FW4
    PRT
    280 43 VL
    DNA
    281 43 VL
    PRT
    282 43 CDR1
    PRT
    283 43 CDR2
    PRT
    284 43 CDR3
    PRT
    285 43 FW1
    PRT
    286 43 FW2
    PRT
    287 43 FW3
    PRT
    288 43 FW4
    PRT
    289 44 VH
    DNA
    290 44 VH
    PRT
    291 44 CDR1
    PRT
    292 44 CDR2
    PRT
    293 44 CDR3
    PRT
    294 44 FW1
    PRT
    295 44 FW2
    PRT
    296 44 FW3
    PRT
    297 44 FW4
    PRT
    298 44 VL
    DNA
    299 44 VL
    PRT
    300 44 CDR1
    PRT
    301 44 CDR2
    PRT
    302 44 CDR3
    PRT
    303 44 FW1
    PRT
    304 44 FW2
    PRT
    305 44 FW3
    PRT
    306 44 FW4
    PRT
    307 45 VL
    DNA
    308 45 VL
    PRT
    309 45 CDR1
    PRT
    310 45 CDR2
    PRT
    311 45 CDR3
    PRT
    312 45 FW1
    PRT
    313 45 FW2
    PRT
    314 45 FW3
    PRT
    315 45 FW4
    PRT
    316 45 VL
    DNA
    317 45 VL
    PRT
    318 45 CDR1
    PRT
    319 45 CDR2
    PRT
    320 45 CDR3
    PRT
    321 45 FW1
    PRT
    322 45 FW2
    PRT
    323 45 FW3
    PRT
    324 45 FW4
    PRT
    325 46 VH
    DNA
    326 46 VH
    PRT
    327 46 CDR1
    PRT
    328 46 CDR2
    PRT
    329 46 CDR3
    PRT
    330 46 FW1
    PRT
    331 46 FW2
    PRT
    332 46 FW3
    PRT
    333 46 FW4
    PRT
    334 46 VL
    DNA
    335 46 VL
    PRT
    336 46 CDR1
    PRT
    337 46 CDR2
    PRT
    338 46 CDR3
    PRT
    339 46 FW1
    PRT
    340 46 FW2
    PRT
    341 46 FW3
    PRT
    342 46 FW4
    PRT
    343 47 VH
    DNA
    344 47 VH
    PRT
    345 47 CDR1
    PRT
    346 47 CDR2
    PRT
    347 47 CDR3
    PRT
    348 47 FW1
    PRT
    349 47 FW2
    PRT
    350 47 FW3
    PRT
    351 47 FW4
    PRT
    352 47 VL
    DNA
    353 47 VL
    PRT
    354 47 CDR1
    PRT
    355 47 CDR2
    PRT
    356 47 CDR3
    PRT
    357 47 FW1
    PRT
    358 47 FW2
    PRT
    359 47 FW3
    PRT
    360 47 FW4
    PRT
    361 48 VH
    DNA
    362 48 VH
    PRT
    363 48 CDR1
    PRT
    364 48 CDR2
    PRT
    365 48 CDR3
    PRT
    366 48 FW1
    PRT
    367 48 FW2
    PRT
    368 48 FW3
    PRT
    369 48 FW4
    PRT
    370 48 VL
    DNA
    371 48 VL
    PRT
    372 48 CDR1
    PRT
    373 48 CDR2
    PRT
    374 48 CDR3
    PRT
    375 48 FW1
    PRT
    376 48 FW2
    PRT
    377 48 FW3
    PRT
    378 48 FW4
    PRT
    379 287 VH
    DNA
    380 287 VH
    PRT
    381 287 CDR1
    PRT
    382 287 CDR2
    PRT
    383 287 CDR3
    PRT
    384 287 FW1
    PRT
    385 287 FW2
    PRT
    386 287 FW3
    PRT
    387 287 FW4
    PRT
    388 287 VL
    DNA
    389 287 VL
    PRT
    390 287 CDR1
    PRT
    391 287 CDR2
    PRT
    392 287 CDR3
    PRT
    393 287 FW1
    PRT
    394 287 FW2
    PRT
    395 287 FW3
    PRT
    396 287 FW4
    PRT
    397 288 VH
    DNA
    398 288 VH
    PRT
    399 288 CDR1
    PRT
    400 288 CDR2
    PRT
    401 288 CDR3
    PRT
    402 288 FW1
    PRT
    403 288 FW2
    PRT
    404 288 FW3
    PRT
    405 288 FW4
    PRT
    406 288 VL
    DNA
    407 288 VL
    PRT
    408 288 CDR1
    PRT
    409 288 CDR2
    PRT
    410 288 CDR3
    PRT
    411 288 FW1
    PRT
    412 288 FW2
    PRT
    413 288 FW3
    PRT
    414 288 FW4
    PRT
    415 289 VH
    DNA
    416 289 VH
    PRT
    417 289 CDR1
    PRT
    418 289 CDR2
    PRT
    419 289 CDR3
    PRT
    420 289 FW1
    PRT
    421 289 FW2
    PRT
    422 289 FW3
    PRT
    423 289 FW4
    PRT
    424 289 VL
    DNA
    425 289 VL
    PRT
    426 289 CDR1
    PRT
    427 289 CDR2
    PRT
    428 289 CDR3
    PRT
    429 289 FW1
    PRT
    430 289 FW2
    PRT
    431 289 FW3
    PRT
    432 289 FW4
    PRT
    433 290 VH
    DNA
    434 290 VH
    PRT
    435 290 CDR1
    PRT
    436 290 CDR2
    PRT
    437 290 CDR3
    PRT
    438 290 FW1
    PRT
    439 290 FW2
    PRT
    440 290 FW3
    PRT
    441 290 FW4
    PRT
    442 290 VL
    DNA
    443 290 VL
    PRT
    444 290 CDR1
    PRT
    445 290 CDR2
    PRT
    446 290 CDR3
    PRT
    447 290 FW1
    PRT
    448 290 FW2
    PRT
    449 290 FW3
    PRT
    450 290 FW4
    PRT
    451 291 VH
    DNA
    452 291 VH
    PRT
    453 291 CDR1
    PRT
    454 291 CDR2
    PRT
    455 291 CDR3
    PRT
    456 291 FW1
    PRT
    457 291 FW2
    PRT
    458 291 FW3
    PRT
    459 291 FW4
    PRT
    460 291 VL
    DNA
    461 291 VL
    PRT
    462 291 CDR1
    PRT
    463 291 CDR2
    PRT
    464 291 CDR3
    PRT
    465 291 FW1
    PRT
    466 291 FW2
    PRT
    467 291 FW3
    PRT
    468 291 FW4
    PRT
    469 292 VH
    DNA
    470 292 VH
    PRT
    471 292 CDR1
    PRT
    472 292 CDR2
    PRT
    473 292 CDR3
    PRT
    474 292 FW1
    PRT
    475 292 FW2
    PRT
    476 292 FW3
    PRT
    477 292 FW4
    PRT
    478 292 VL
    DNA
    479 292 VL
    PRT
    480 292 CDR1
    PRT
    481 292 CDR2
    PRT
    482 292 CDR3
    PRT
    483 292 FW1
    PRT
    484 292 FW2
    PRT
    485 292 FW3
    PRT
    486 292 FW4
    PRT
    487 293 VH
    DNA
    488 293 VH
    PRT
    489 293 CDR1
    PRT
    490 293 CDR2
    PRT
    491 293 CDR3
    PRT
    492 293 FW1
    PRT
    493 293 FW2
    PRT
    494 293 FW3
    PRT
    495 293 FW4
    PRT
    496 293 VL
    DNA
    497 293 VL
    PRT
    498 293 CDR1
    PRT
    499 293 CDR2
    PRT
    500 293 CDR3
    PRT
    501 293 FW1
    PRT
    502 293 FW2
    PRT
    503 293 FW3
    PRT
    504 293 FW4
    PRT
    505 294 VH
    DNA
    506 294 VH
    PRT
    507 294 CDR1
    PRT
    508 294 CDR2
    PRT
    509 294 CDR3
    PRT
    510 294 FW1
    PRT
    511 294 FW2
    PRT
    512 294 FW3
    PRT
    513 294 FW4
    PRT
    514 294 VL
    DNA
    515 294 VL
    PRT
    516 294 CDR1
    PRT
    517 294 CDR2
    PRT
    518 294 CDR3
    PRT
    519 294 FW1
    PRT
    520 294 FW2
    PRT
    521 294 FW3
    PRT
    522 294 FW4
    PRT
    523 295 VH
    DNA
    524 295 VH
    PRT
    525 295 CDR1
    PRT
    526 295 CDR2
    PRT
    527 295 CDR3
    PRT
    528 295 FW1
    PRT
    529 295 FW2
    PRT
    530 295 FW3
    PRT
    531 295 FW4
    PRT
    532 295 VL
    DNA
    533 295 VL
    PRT
    534 295 CDR1
    PRT
    535 295 CDR2
    PRT
    536 295 CDR3
    PRT
    537 295 FW1
    PRT
    538 295 FW2
    PRT
    539 295 FW3
    PRT
    540 295 FW4
    PRT
    541 296 VH
    DNA
    542 296 VH
    PRT
    543 296 CDR1
    PRT
    544 296 CDR2
    PRT
    545 296 CDR3
    PRT
    546 296 FW1
    PRT
    547 296 FW2
    PRT
    548 296 FW3
    PRT
    549 296 FW4
    PRT
    550 296 VL
    DNA
    551 296 VL
    PRT
    552 296 CDR1
    PRT
    553 296 CDR2
    PRT
    554 296 CDR3
    PRT
    555 296 FW1
    PRT
    556 296 FW2
    PRT
    557 296 FW3
    PRT
    558 296 FW4
    PRT
    559 297 VH
    DNA
    560 297 VH
    PRT
    561 297 CDR1
    PRT
    562 297 CDR2
    PRT
    563 297 CDR3
    PRT
    564 297 FW1
    PRT
    565 297 FW2
    PRT
    566 297 FW3
    PRT
    567 297 FW4
    PRT
    568 297 VL
    DNA
    569 297 VL
    PRT
    570 297 CDR1
    PRT
    571 297 CDR2
    PRT
    572 297 CDR3
    PRT
    573 297 FW1
    PRT
    574 297 FW2
    PRT
    575 297 FW3
    PRT
    576 297 FW4
    PRT
    577 298 VH
    DNA
    578 298 VH
    PRT
    579 298 CDR1
    PRT
    580 298 CDR2
    PRT
    581 298 CDR3
    PRT
    582 298 FW1
    PRT
    583 298 FW2
    PRT
    584 298 FW3
    PRT
    585 298 FW4
    PRT
    586 298 VL
    DNA
    587 298 VL
    PRT
    588 298 CDR1
    PRT
    589 298 CDR2
    PRT
    590 298 CDR3
    PRT
    591 298 FW1
    PRT
    592 298 FW2
    PRT
    593 298 FW3
    PRT
    594 298 FW4
    PRT
    595 299 VH
    DNA
    596 299 VH
    PRT
    597 299 CDR1
    PRT
    598 299 CDR2
    PRT
    599 299 CDR3
    PRT
    600 299 FW1
    PRT
    601 299 FW2
    PRT
    602 299 FW3
    PRT
    603 299 FW4
    PRT
    604 299 VL
    DNA
    605 299 VL
    PRT
    606 299 CDR1
    PRT
    607 299 CDR2
    PRT
    608 299 CDR3
    PRT
    609 299 FW1
    PRT
    610 299 FW2
    PRT
    611 299 FW3
    PRT
    612 299 FW4
    PRT
    613 300 VH
    DNA
    614 300 VH
    PRT
    615 300 CDR1
    PRT
    616 300 CDR2
    PRT
    617 300 CDR3
    PRT
    618 300 FW1
    PRT
    619 300 FW2
    PRT
    620 300 FW3
    PRT
    621 300 FW4
    PRT
    622 300 VL
    DNA
    623 300 VL
    PRT
    624 300 CDR1
    PRT
    625 300 CDR2
    PRT
    626 300 CDR3
    PRT
    627 300 FW1
    PRT
    628 300 FW2
    PRT
    629 300 FW3
    PRT
    630 300 FW4
    PRT
    631 302 VH
    DNA
    632 302 VH
    PRT
    633 302 CDR1
    PRT
    634 302 CDR2
    PRT
    635 302 CDR3
    PRT
    636 302 FW1
    PRT
    637 302 FW2
    PRT
    638 302 FW3
    PRT
    639 302 FW4
    PRT
    640 302 VL
    DNA
    641 302 VL
    PRT
    642 302 CDR1
    PRT
    643 302 CDR2
    PRT
    644 302 CDR3
    PRT
    645 302 FW1
    PRT
    646 302 FW2
    PRT
    647 302 FW3
    PRT
    648 302 FW4
    PRT
    649 303 VH
    DNA
    650 303 VH
    PRT
    651 303 CDR1
    PRT
    652 303 CDR2
    PRT
    653 303 CDR3
    PRT
    654 303 FW1
    PRT
    655 303 FW2
    PRT
    656 303 FW3
    PRT
    657 303 FW4
    PRT
    658 303 VL
    DNA
    659 303 VL
    PRT
    660 303 CDR1
    PRT
    661 303 CDR2
    PRT
    662 303 CDR3
    PRT
    663 303 FW1
    PRT
    664 303 FW2
    PRT
    665 303 FW3
    PRT
    666 303 FW4
    PRT
    667 304 VH
    DNA
    668 304 VH
    PRT
    669 304 CDR1
    PRT
    670 304 CDR2
    PRT
    671 304 CDR3
    PRT
    672 304 FW1
    PRT
    673 304 FW2
    PRT
    674 304 FW3
    PRT
    675 304 FW4
    PRT
    676 304 VL
    DNA
    677 304 VL
    PRT
    678 304 CDR1
    PRT
    679 304 CDR2
    PRT
    680 304 CDR3
    PRT
    681 304 FW1
    PRT
    682 304 FW2
    PRT
    683 304 FW3
    PRT
    684 304 FW4
    PRT
    685 305 VH
    DNA
    686 305 VH
    PRT
    687 305 CDR1
    PRT
    688 305 CDR2
    PRT
    689 305 CDR3
    PRT
    690 305 FW1
    PRT
    691 305 FW2
    PRT
    692 305 FW3
    PRT
    693 305 FW4
    PRT
    694 305 VL
    DNA
    695 305 VL
    PRT
    696 305 CDR1
    PRT
    697 305 CDR2
    PRT
    698 305 CDR3
    PRT
    699 305 FW1
    PRT
    700 305 FW2
    PRT
    701 305 FW3
    PRT
    702 305 FW4
    PRT
    703 306 VH
    DNA
    704 306 VH
    PRT
    705 306 CDR1
    PRT
    706 306 CDR2
    PRT
    707 306 CDR3
    PRT
    708 306 FW1
    PRT
    709 306 FW2
    PRT
    710 306 FW3
    PRT
    711 306 FW4
    PRT
    712 306 VL
    DNA
    713 306 VL
    PRT
    714 306 CDR1
    PRT
    715 306 CDR2
    PRT
    716 306 CDR3
    PRT
    717 306 FW1
    PRT
    718 306 FW2
    PRT
    719 306 FW3
    PRT
    720 306 FW4
    PRT
    721 307 VH
    DNA
    722 307 VH
    PRT
    723 307 CDR1
    PRT
    724 307 CDR2
    PRT
    725 307 CDR3
    PRT
    726 307 FW1
    PRT
    727 307 FW2
    PRT
    728 307 FW3
    PRT
    729 307 FW4
    PRT
    730 307 VL
    DNA
    731 307 VL
    PRT
    732 307 CDR1
    PRT
    733 307 CDR2
    PRT
    734 307 CDR3
    PRT
    735 307 FW1
    PRT
    736 307 FW2
    PRT
    737 307 FW3
    PRT
    738 307 FW4
    PRT
    739 308 VH
    DNA
    740 308 VH
    PRT
    741 308 CDR1
    PRT
    742 308 CDR2
    PRT
    743 308 CDR3
    PRT
    744 308 FW1
    PRT
    745 308 FW2
    PRT
    746 308 FW3
    PRT
    747 308 FW4
    PRT
    748 308 VL
    DNA
    749 308 VL
    PRT
    750 308 CDR1
    PRT
    751 308 CDR2
    PRT
    752 308 CDR3
    PRT
    753 308 FW1
    PRT
    754 308 FW2
    PRT
    755 308 FW3
    PRT
    756 308 FW4
    PRT
    757 309 VH
    DNA
    758 309 VH
    PRT
    759 309 CDR1
    PRT
    760 309 CDR2
    PRT
    761 309 CDR3
    PRT
    762 309 FW1
    PRT
    763 309 FW2
    PRT
    764 309 FW3
    PRT
    765 309 FW4
    PRT
    766 309 VL
    DNA
    767 309 VL
    PRT
    768 309 CDR1
    PRT
    769 309 CDR2
    PRT
    770 309 CDR3
    PRT
    771 309 FW1
    PRT
    772 309 FW2
    PRT
    773 309 FW3
    PRT
    774 309 FW4
    PRT
    775 310 VH
    DNA
    776 310 VH
    PRT
    777 310 CDR1
    PRT
    778 310 CDR2
    PRT
    779 310 CDR3
    PRT
    780 310 FW1
    PRT
    781 310 FW2
    PRT
    782 310 FW3
    PRT
    783 310 FW4
    PRT
    784 310 VL
    DNA
    785 310 VL
    PRT
    786 310 CDR1
    PRT
    787 310 CDR2
    PRT
    788 310 CDR3
    PRT
    789 310 FW1
    PRT
    790 310 FW2
    PRT
    791 310 FW3
    PRT
    792 310 FW4
    PRT
    793 311 VH
    DNA
    794 311 VH
    PRT
    795 311 CDR1
    PRT
    796 311 CDR2
    PRT
    797 311 CDR3
    PRT
    798 311 FW1
    PRT
    799 311 FW2
    PRT
    800 311 FW3
    PRT
    801 311 FW4
    PRT
    802 311 VL
    DNA
    803 311 VL
    PRT
    804 311 CDR1
    PRT
    805 311 CDR2
    PRT
    806 311 CDR3
    PRT
    807 311 FW1
    PRT
    808 311 FW2
    PRT
    809 311 FW3
    PRT
    810 311 FW4
    PRT
    811 312 VH
    DNA
    812 312 VH
    PRT
    813 312 CDR1
    PRT
    814 312 CDR2
    PRT
    815 312 CDR3
    PRT
    816 312 FW1
    PRT
    817 312 FW2
    PRT
    818 312 FW3
    PRT
    819 312 FW4
    PRT
    820 312 VL
    DNA
    821 312 VL
    PRT
    822 312 CDR1
    PRT
    823 312 CDR2
    PRT
    824 312 CDR3
    PRT
    825 312 FW1
    PRT
    826 312 FW2
    PRT
    827 312 FW3
    PRT
    828 312 FW4
    PRT
    829 313 VH
    DNA
    830 313 VH
    PRT
    831 313 CDR1
    PRT
    832 313 CDR2
    PRT
    833 313 CDR3
    PRT
    834 313 FW1
    PRT
    835 313 FW2
    PRT
    836 313 FW3
    PRT
    837 313 FW4
    PRT
    838 313 VL
    DNA
    839 313 VL
    PRT
    840 313 CDR1
    PRT
    841 313 CDR2
    PRT
    842 313 CDR3
    PRT
    843 313 FW1
    PRT
    844 313 FW2
    PRT
    845 313 FW3
    PRT
    846 313 FW4
    PRT
    847 314 VH
    DNA
    848 314 VH
    PRT
    849 314 CDR1
    PRT
    850 314 CDR2
    PRT
    851 314 CDR3
    PRT
    852 314 FW1
    PRT
    853 314 FW2
    PRT
    854 314 FW3
    PRT
    855 314 FW4
    PRT
    856 314 VL
    DNA
    857 314 VL
    PRT
    858 314 CDR1
    PRT
    859 314 CDR2
    PRT
    860 314 CDR3
    PRT
    861 314 FW1
    PRT
    862 314 FW2
    PRT
    863 314 FW3
    PRT
    864 314 FW4
    PRT
    865 315 VH
    DNA
    866 315 VH
    PRT
    867 315 CDR1
    PRT
    868 315 CDR2
    PRT
    869 315 CDR3
    PRT
    870 315 FW1
    PRT
    871 315 FW2
    PRT
    872 315 FW3
    PRT
    873 315 FW4
    PRT
    874 315 VL
    DNA
    875 315 VL
    PRT
    876 315 CDR1
    PRT
    877 315 CDR2
    PRT
    878 315 CDR3
    PRT
    879 315 FW1
    PRT
    880 315 FW2
    PRT
    881 315 FW3
    PRT
    882 315 FW4
    PRT
    883 316 VH
    DNA
    884 316 VH
    PRT
    885 316 CDR1
    PRT
    886 316 CDR2
    PRT
    887 316 CDR3
    PRT
    888 316 FW1
    PRT
    889 316 FW2
    PRT
    892 316 FW3
    PRT
    891 316 FW4
    PRT
    892 316 VL
    DNA
    893 316 VL
    PRT
    894 316 CDR1
    PRT
    895 316 CDR2
    PRT
    896 316 CDR3
    PRT
    897 316 FW1
    PRT
    898 316 FW2
    PRT
    899 316 FW3
    PRT
    900 316 FW4
    PRT
    901 317 VH
    DNA
    902 317 VH
    PRT
    903 317 CDR1
    PRT
    904 317 CDR2
    PRT
    905 317 CDR3
    PRT
    906 317 FW1
    PRT
    907 317 FW2
    PRT
    908 317 FW3
    PRT
    909 317 FW4
    PRT
    910 317 VL
    DNA
    911 317 VL
    PRT
    912 317 CDR1
    PRT
    913 317 CDR2
    PRT
    914 317 CDR3
    PRT
    915 317 FW1
    PRT
    916 317 FW2
    PRT
    917 317 FW3
    PRT
    918 317 FW4
    PRT
    919 318 VH
    DNA
    920 318 VH
    PRT
    921 318 CDR1
    PRT
    922 318 CDR2
    PRT
    923 318 CDR3
    PRT
    924 318 FW1
    PRT
    925 318 FW2
    PRT
    926 318 FW3
    PRT
    927 318 FW4
    PRT
    928 318 VL
    DNA
    929 318 VL
    PRT
    930 318 CDR1
    PRT
    931 318 CDR2
    PRT
    932 318 CDR3
    PRT
    933 318 FW1
    PRT
    934 318 FW2
    PRT
    935 318 FW3
    PRT
    936 318 FW4
    PRT
    937 319 VH
    DNA
    938 319 VH
    PRT
    939 319 CDR1
    PRT
    940 319 CDR2
    PRT
    941 319 CDR3
    PRT
    942 319 FW1
    PRT
    943 319 FW2
    PRT
    944 319 FW3
    PRT
    945 319 FW4
    PRT
    946 319 VL
    DNA
    947 319 VL
    PRT
    948 319 CDR1
    PRT
    949 319 CDR2
    PRT
    950 319 CDR3
    PRT
    951 319 FW1
    PRT
    952 319 FW2
    PRT
    953 319 FW3
    PRT
    954 319 FW4
    PRT
    955 320 VH
    DNA
    956 320 VH
    PRT
    957 320 CDR1
    PRT
    958 320 CDR2
    PRT
    959 320 CDR3
    PRT
    960 320 FW1
    PRT
    961 320 FW2
    PRT
    962 320 FW3
    PRT
    963 320 FW4
    PRT
    964 320 VL
    DNA
    965 320 VL
    PRT
    966 320 CDR1
    PRT
    967 320 CDR2
    PRT
    968 320 CDR3
    PRT
    969 320 FW1
    PRT
    970 320 FW2
    PRT
    971 320 FW3
    PRT
    972 320 FW4
    PRT
    973 321 VH
    DNA
    974 321 VH
    PRT
    975 321 CDR1
    PRT
    976 321 CDR2
    PRT
    977 321 CDR3
    PRT
    978 321 FW1
    PRT
    979 321 FW2
    PRT
    980 321 FW3
    PRT
    981 321 FW4
    PRT
    982 321 VL
    DNA
    983 321 VL
    PRT
    984 321 CDR1
    PRT
    985 321 CDR2
    PRT
    986 321 CDR3
    PRT
    987 321 FW1
    PRT
    988 321 FW2
    PRT
    989 321 FW3
    PRT
    990 321 FW4
    PRT
    991 208 VH
    DNA
    992 208 VH
    PRT
    993 208 CDR1
    PRT
    994 208 CDR2
    PRT
    995 208 CDR3
    PRT
    996 208 FW1
    PRT
    997 208 FW2
    PRT
    998 208 FW3
    PRT
    999 208 FW4
    PRT
    100 208 VL
    DNA
    1001 208 VL
    PRT
    1002 208 CDR1
    PRT
    1003 208 CDR2
    PRT
    1004 208 CDR3
    PRT
    1005 208 FW1
    PRT
    1006 208 FW2
    PRT
    1007 208 FW3
    PRT
    1008 208 FW4
    PRT
    • DETAILED DESCRIPTION OF THE INVENTION
  • As described below, the present invention provides antibodies that specifically bind a P2X4 polypeptide and modulate P2X4 channel activity, recombinant P2X4 polypeptides and methods for generating such polypeptides, as well as compositions and methods for generating anti-P2X4 antibodies, and methods of using P2X4 antibodies for the treatment of neuropathic pain and other indications.
    • Recombinant Expression of P2X4
  • The present invention provides purified isolated recombinant P2X4 polypeptides that form stable trimeric complexes. The invention further provides methods for the large scale production of purified and isolated human and murine P2X4 polypeptides, which is sufficient to produce milligram quantities of P2X4 protein, where the isolated and purified recombinant proteins are predominantly present as stable trimers. The total quantities of P2X4 that were produced for the selection and screening experiments described herein included 6.2 mg hP2X4 and 3.2 mg mP2X4. The production level of purified protein was 0.2 mg/L insect cell culture. As assayed by fluorescent size exclusion chromatography the protein preparation contains 50-75% trimer.
  • Expression and purification of human-P2X4 with a C-terminal deca Histidine tag in HEK293 cells has been described (Young et al., J. Biol. Chem. 283 (2008) 26241-26251). The purification involved solubilization using dodecylmaltoside detergent and Ni-immobilized metal affinity chromatography. A polyacrylamide gel electrophoretic purification step was required to isolate the trimeric form. Although a fully trimeric preparation of hP2X4 was claimed to have been isolated, the described yield was only 40 μg per 2.5×108 cells.
  • Another example of small scale expression and purification of trimer rat P2X channels ( subtypes 2, 4 and 7) has been performed (Antonio et al., Br. J. Pharmacol. 163 (2011) 1069-1077). Rat P2X4 receptors having a C-terminal Hemaglutinin tag were expressed transiently in tsA 201 cells (a sub-clone of HEK293 cells stably expressing the SV40 large T-antigen). Receptors were solubilized in CHAPS detergent and affinity purified. Compared to expression of P2X2 and P2X7, expression of P2X4 was relatively low. The purified receptors were used in AFM imaging, which showed trimeric arrangement of the receptors and also double trimers (dimers of trimers).
  • In another report Sf9 insect cell system was evaluated for expression of human P2X4 and Dictyostelium discoideum P2XA (Valente et al., Biochim. Biophys. Acta 1808 (2011) 2859-2866). While the D. discoideum P2XA could be obtained in a stable, purified and detergent soluble form, the human P2X4 was reported not to be amenable to be produced in a trimeric form.
  • The methods present in the prior art uniformly failed to isolate substantial quantities of recombinant P2X4 polypeptides. Moreover, the prior art failed to isolate human P2X4 complexes in milligram quantities where the majority of the isolated proteins were present in trimeric form. In contrast, the methods of the invention, which are suitable for scale up, have allowed milligram scale production of purified recombinant P2X4 polypeptide. The yield of purified P2X4 obtained was 0.2 mg/L insect cell culture medium, corresponding to approximately 8 μg per 1×108 cells.
  • For the large scale production of purified P2X4, the human P2X4 and mouse P2X4 receptors were expressed in Sf9 insect cells using a baculovirus expression system. Expression and protein production are not limited to Sf9 insect cell lines, other insect cell and cell lines that support protein production include Spodoptera fugiperda Sf21 cells or Trichoplusia ni derived cell lines Tn-368 and High-Five™ BTI-TN-5B1-4. To increase protein production, P2X4 expression levels were monitored at the time of harvest, and the quality and homogeneity of the receptors was assessed using a modified size-exclusion chromatography while detecting fluorescence (FSEC) method as described by Backmark et al., (Protein Sci. 22 (2013) 1124-1132). This method is similar to the basic FSEC concept as described by Kawate and Gouaux (Structure 14 (2006) 673-681), but applied a fluorescent probe that specifically interacts with a Histidine tag on the protein. To achieve the surprising yields reported herein, cells were innoculated at a density of 1.0×10e6/mL in SF900II medium. Cells were infected with a multiplicity of infection of 2 at a cell density of 2×10e6 cells/ml. Protein expression was performed at 27° C. and cells were harvested 72 hours post infection. These conditions permitted an optimal quantity of the trimeric form of P2X4 to be produced. The homogeneity of protein was unexpected. While the total amount of expressed P2X4 protein increased with longer post infection times, the quality of the expressed protein as assayed by FSEC did not increase beyond 72 hours.
    • Anti-P2X4 Antibodies
  • The disclosure provides anti-P2X4 antibodies that comprise novel antigen-binding fragments. In a particular embodiment, the anti-P2X4 antibody is an anti-P2X4 antibody described herein (e.g., Antibodies 1-48) or a fragment thereof.
  • In general, antibodies can be made, for example, using traditional hybridoma techniques (Kohler and Milstein (1975) Nature, 256: 495-499), recombinant DNA methods (U.S. Pat. No. 4,816,567), or phage display performed with antibody libraries (Clackson, T. and Lowman, H. B. Phage Display—A Practical Approach, 2004. Oxford University Press; (2) Thompson, J. et al. J Mol Biol. 256(1):77-88, 1996; (3) Osbourn, J. K. et al. Immunotechnology, 2(3):181-96, 1996). Exemplary antibodies 35-48 were obtained using hybridoma techniques as described herein. Exemplary antibodies 1-34 were obtained using phage display as described herein. For other antibody production techniques, see also Antibodies: A Laboratory Manual, eds. Harlow et al., Cold Spring Harbor Laboratory, 1988. The invention is not limited to any particular source, species of origin, or method of production.
  • Intact antibodies, also known as immunoglobulins, are typically tetrameric glycosylated proteins composed of two light (L) chains of approximately 25 kDa each and two heavy (H) chains of approximately 50 kDa each. Two types of light chain, designated as the λ chain and the x chain, are found in antibodies. Depending on the amino acid sequence of the constant domain of heavy chains, immunoglobulins can be assigned to five major classes: A, D, E, G, and M, and several of these may be further divided into subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2.
  • The subunit structures and three-dimensional configurations of different classes of immunoglobulins are well known in the art. For a review of antibody structure, see Harlow et al., supra. Briefly, each light chain is composed of an N-terminal variable domain (VL) and a constant domain (CL). Each heavy chain is composed of an N-terminal variable domain (VH), three or four constant domains (CH), and a hinge region. The CH domain most proximal to VH is designated as C H1. The VH and VL domains consist of four regions of relatively conserved sequence called framework regions (FR1, FR2, FR3, and FR4), which form a scaffold for three regions of hypervariable sequence called complementarity determining regions (CDRs). The CDRs contain most of the residues responsible for specific interactions with the antigen. The three CDRs are referred to as CDR1, CDR2, and CDR3. CDR constituents on the heavy chain are referred to as H1, H2, and H3, while CDR constituents on the light chain are referred to as L1, L2, and L3, accordingly. CDR3 and, particularly H3, are the greatest source of molecular diversity within the antigen-binding domain. H3, for example, can be as short as two amino acid residues or greater than 26. In particular embodiments, a heavy chain CDR3 (H3) comprises between about 4 amino acids (see, for example, Ab No. 2) and 22 amino acids (see, for example, Ab Nos. 20 and 34).
  • The Fab fragment (Fragment antigen-binding) consists of the VH-C H1 and VL-CL domains covalently linked by a disulfide bond between the constant regions. To overcome the tendency of non-covalently linked VH and VL domains in the Fv to dissociate when co-expressed in a host cell, a so-called single chain (sc) Fv fragment (scFv) can be constructed. In a scFv, a flexible and adequately long polypeptide links either the C-terminus of the VH to the N-terminus of the VL or the C-terminus of the VL to the N-terminus of the VH. Most commonly, a 15-residue (Gly4Ser)3 peptide is used as a linker, but other linkers are also known in the art.
  • Antibody diversity is a result of combinatorial assembly of multiple germline genes encoding variable regions and a variety of somatic events. The somatic events include recombination of variable gene segments with diversity (D) and joining (J) gene segments to make a complete VH region and the recombination of variable and joining gene segments to make a complete VL region. The recombination process itself is imprecise, resulting in the loss or addition of amino acids at the V(D)J junctions. These mechanisms of diversity occur in the developing B cell prior to antigen exposure. After antigenic stimulation, the expressed antibody genes in B cells undergo somatic mutation.
  • Based on the estimated number of germline gene segments, the random recombination of these segments, and random VH-VL pairing, up to 1.6×107 different antibodies could be produced (Fundamental Immunology, 3rd ed., ed. Paul, Raven Press, New York, N.Y., 1993). When other processes that contribute to antibody diversity (such as somatic mutation) are taken into account, it is thought that upwards of 1×1010 different antibodies could be potentially generated (Immunoglobulin Genes, 2nd ed., eds. Jonio et al., Academic Press, San Diego, Calif., 1995). Because of the many processes involved in antibody diversity, it is highly unlikely that independently generated antibodies will have identical or even substantially similar amino acid sequences in the CDRs.
  • The disclosure provides novel CDRs derived from human immunoglobulin gene libraries. The structure for carrying a CDR will generally be an antibody heavy or light chain or a portion thereof, in which the CDR is located at a location corresponding to the CDR of naturally occurring VH and VL. The structures and locations of immunoglobulin variable domains may be determined, for example, as described in Kabat et al., Sequences of Proteins of Immunological Interest, No. 91-3242, National Institutes of Health Publications, Bethesda, Md., 1991.
  • The amino acid sequences of anti-P2X4 antibodies 1-48, 208, and 287 to 321, including their VH and VL domains are set forth in the Figures and described herein.
  • Anti-P2X4 antibodies may optionally comprise antibody constant regions or parts thereof. For example, a VL domain may have attached, at its C terminus, antibody light chain constant domains including human Cκ or Cλ chains. Similarly, a specific antigen-binding domain based on a VH domain may have attached all or part of an immunoglobulin heavy chain derived from any antibody isotope, e.g., IgG, IgA, IgE, and IgM and any of the isotope subclasses, which include but are not limited to, IgG1 and IgG4. The DNA and amino acid sequences for the C-terminal fragment of are well known in the art (see, e.g., Kabat et al., Sequences of Proteins of Immunological Interest, No. 91-3242, National Institutes of Health Publications, Bethesda, Md., 1991).
  • Certain embodiments comprise a VH and/or VL domain of an Fv fragment from a P2X4 antibody. Further embodiments comprise at least one CDR of any of these VH and VL domains. Antibodies, comprising at least one of the CDR sequences set forth for Antibody Nos. 1-48 are encompassed within the scope of this invention. In one particular embodiment, an antibody of the invention comprises CDR3 of VH.
  • In certain embodiments, the VH and/or VL domains may be germlined, i.e., the framework regions (FRs) of these domains are mutated using conventional molecular biology techniques to match those produced by the germline cells. In other embodiments, the framework sequences remain diverged from the consensus germline sequences.
  • In certain embodiments, the antibodies specifically bind an epitope within the extracellular domain of human P2X4. In certain embodiments, the antibodies specifically bind an epitope within the extracellular domain of human or mouse P2X4, with an affinity of more than 106 M−1, more than 107 M−1, or more than 108 M−1.
  • It is contemplated that antibodies of the invention may also bind with other proteins, including, for example, recombinant proteins comprising all or a portion of the P2X4 extracellular domain.
  • One of ordinary skill in the art will recognize that the antibodies of this invention may be used to detect, measure, and inhibit proteins that differ somewhat from P2X4. The antibodies are expected to retain the specificity of binding so long as the target protein comprises a sequence which is at least about 60%, 70%, 80%, 90%, 95%, or more identical to any sequence of at least 100, 80, 60, 40, or 20 of contiguous amino acids of P2X4 (NCBI Ref. No. Q99571). The percent identity is determined by standard alignment algorithms such as, for example, Basic Local Alignment Tool (BLAST) described in Altshul et al. (1990) J. Mol. Biol., 215: 403-410, the algorithm of Needleman et al. (1970) J. Mol. Biol., 48: 444-453, or the algorithm of Meyers et al. (1988) Comput. Appl. Biosci., 4: 11-17.
  • In addition to the sequence homology analyses, epitope mapping (see, e.g., Epitope Mapping Protocols, ed. Morris, Humana Press, 1996) and secondary and tertiary structure analyses can be carried out to identify specific 3D structures assumed by the disclosed antibodies and their complexes with antigens. An example of such a 3D structure is provided for Antibody No. 11. Such methods include, but are not limited to, X-ray crystallography (Engstom (1974) Biochem. Exp. Biol., 11:7-13) and computer modeling of virtual representations of the presently disclosed antibodies (Fletterick et al. (1986) Computer Graphics and Molecular Modeling, in Current Communications in Molecular Biology, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.).
    • Derivatives
  • This disclosure provides methods for obtaining antibodies specific for P2X4. CDRs in such antibodies are not limited to the specific sequences of VH and VL identified herein, and may include variants of these sequences that retain the ability to specifically bind P2X4. Such variants may be derived from the sequences listed herein by a skilled artisan using techniques well known in the art. For example, amino acid substitutions, deletions, or additions, can be made in the FRs and/or in the CDRs. While changes in the FRs are usually designed to improve stability and immunogenicity of the antibody, changes in the CDRs are typically designed to increase affinity of the antibody for its target. Variants of FRs also include naturally occurring immunoglobulin allotypes. Such affinity-increasing changes may be determined empirically by routine techniques that involve altering the CDR and testing the affinity of the antibody for its target. For example, conservative amino acid substitutions can be made within any one of the disclosed CDRs. Various alterations can be made according to the methods described in Antibody Engineering, 2nd ed., Oxford University Press, ed. Borrebaeck, 1995. These include, but are not limited to, nucleotide sequences that are altered by the substitution of different codons that encode a functionally equivalent amino acid residue within the sequence, thus producing a “silent” change. For example, the nonpolar amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine. The polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine. The positively charged (basic) amino acids include arginine, lysine, and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Substitutes for an amino acid within the sequence may be selected from other members of the class to which the amino acid belongs (see Table 1). Furthermore, any native residue in the polypeptide may also be substituted with alanine (see, e.g., MacLennan et al. (1998) Acta Physiol. Scand. Suppl. 643:55-67; Sasaki et al. (1998) Adv. Biophys. 35:1-24).
  • TABLE 1
    Original Exemplary Typical
    Residues Substitutions Substitutions
    Ala (A) Val, Leu, Ile Val
    Arg (R) Lys, Gln, Asn Lys
    Asn (N) Gln Gln
    Asp (D) Glu Glu
    Cys (C) Ser, Ala Ser
    Gln (Q) Asn Asn
    Gly (G) Pro, Ala Ala
    His (H) Asn, Gln, Lys, Arg Arg
    Ile (I) Leu, Val, Met, Ala, Phe, Norleucine Leu
    Leu (L) Norleucine, Ile, Val, Met, Ala, Phe Ile
    Lys (K) Arg, 1,4-Diamino-butyric Acid, Gln, Asn Arg
    Met (M) Leu, Phe, Ile Leu
    Phe (F) Leu, Val, Ile, Ala, Tyr Leu
    Pro (P) Ala Gly
    Ser (S) Thr, Ala, Cys Thr
    Thr (T) Ser Ser
    Trp (W) Tyr, Phe Tyr
    Tyr (Y) Trp, Phe, Thr, Ser Phe
    Val (V) Ile, Met, Leu, Phe, Ala, Norleucine Leu
  • Derivatives and analogs of antibodies of the invention can be produced by various techniques well known in the art, including recombinant and synthetic methods (Maniatis (1990) Molecular Cloning, A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., and Bodansky et al. (1995) The Practice of Peptide Synthesis, 2nd ed., Spring Verlag, Berlin, Germany).
  • In one embodiment, a method for making a VH domain which is an amino acid sequence variant of a VH domain of the invention comprises a step of adding, deleting, substituting, or inserting one or more amino acids in the amino acid sequence of the presently disclosed VH domain, optionally combining the VH domain thus provided with one or more VL domains, and testing the VH domain or VH/VL combination or combinations for a specific binding to P2X4 or and, optionally, testing the ability of such antigen-binding domain to modulate P2X4 activity, for example, using an electrophysiology assay described herein. The VL domain may have an amino acid sequence that is identical or is substantially identical to a polypeptide of the invention.
  • An analogous method can be employed in which one or more sequence variants of a VL domain disclosed herein are combined with one or more VH domains.
  • A further aspect of the disclosure provides a method of preparing an antigen-binding fragment that specifically binds with P2X4. The method comprises:
      • (a) providing a starting repertoire of nucleic acids encoding a VH domain that either includes a CDR3 to be replaced or lacks a CDR3 encoding region;
      • (b) combining the repertoire with a donor nucleic acid encoding an amino acid sequence substantially as set out herein for a VH CDR3 (i.e., H3) such that the donor nucleic acid is inserted into the CDR3 region in the repertoire, so as to provide a product repertoire of nucleic acids encoding a VH domain;
      • (c) expressing the nucleic acids of the product repertoire;
      • (d) selecting a binding fragment specific for P2X4; and
      • (e) recovering the specific binding fragment or nucleic acid encoding it.
  • Again, an analogous method may be employed in which a VL CDR3 (i.e., L3) of the invention is combined with a repertoire of nucleic acids encoding a VL domain, which either include a CDR3 to be replaced or lack a CDR3 encoding region. The donor nucleic acid may be selected from nucleic acids encoding an amino acid sequence substantially as set out in Antibody Nos. 1-48.
  • A sequence encoding a CDR of the invention (e.g., CDR3) may be introduced into a repertoire of variable domains lacking the respective CDR (e.g., CDR3), using recombinant DNA technology, for example, using methodology described by Marks et al. (Bio/Technology (1992) 10: 779-783). In particular, consensus primers directed at or adjacent to the 5′ end of the variable domain area can be used in conjunction with consensus primers to the third framework region of human VH genes to provide a repertoire of VH variable domains lacking a CDR3. The repertoire may be combined with a CDR3 of a particular antibody. Using analogous techniques, the CDR3-derived sequences may be shuffled with repertoires of VH or VL domains lacking a CDR3, and the shuffled complete VH or VL domains combined with a cognate VL or VH domain to make the P2X4-specific antibodies of the invention. The repertoire may then be displayed in a suitable host system such as the phage display system described herein or as described in WO92/01047 so that suitable antigen-binding fragments can be selected.
  • Analogous shuffling or combinatorial techniques are also disclosed by Stemmer (Nature (1994) 370: 389-391), who describes the technique in relation to a β-lactamase gene but observes that the approach may be used for the generation of antibodies.
  • In further embodiments, one may generate novel VH or VL regions carrying one or more sequences derived from the sequences disclosed herein using random mutagenesis of one or more selected VH and/or VL genes. One such technique, error-prone PCR, is described by Gram et al. (Proc. Nat. Acad. Sci. U.S.A. (1992) 89: 3576-3580).
  • Another method that may be used is to direct mutagenesis to CDRs of VH or VL genes. Such techniques are disclosed by Barbas et al. (Proc. Nat. Acad. Sci. U.S.A. (1994) 91: 3809-3813) and Schier et al. (J. Mol. Biol. (1996) 263: 551-567).
  • Similarly, one or more, or all three CDRs may be grafted into a repertoire of VH or VL domains, which are then screened for an antigen-binding fragment specific for P2X4.
  • A portion of an immunoglobulin variable domain will comprise at least one of the CDRs substantially as set out herein and, optionally, intervening framework regions from the scFv fragments as set out herein. The portion may include at least about 50% of either or both of FR1 and FR4, the 50% being the C-terminal 50% of FR1 and the N-terminal 50% of FR4. Additional residues at the N-terminal or C-terminal end of the substantial part of the variable domain may be those not normally associated with naturally occurring variable domain regions. For example, construction of antibodies by recombinant DNA techniques may result in the introduction of N- or C-terminal residues encoded by linkers introduced to facilitate cloning or other manipulation steps. Other manipulation steps include the introduction of linkers to join variable domains to further protein sequences including immunoglobulin heavy chain constant regions, other variable domains (for example, in the production of diabodies), or proteinaceous labels as discussed in further detail below.
  • Although the embodiments illustrated in the Examples comprise a “matching” pair of VH and VL domains, a skilled artisan will recognize that alternative embodiments may comprise antigen-binding fragments containing only a single CDR from either VL or VH domain. In particular embodiments, the antigen-binding fragment is CDR3 of VH (H3). Either one of the single chain specific binding domains can be used to screen for complementary domains capable of forming a two-domain specific antigen-binding fragment capable of, for example, binding to P2X4. The screening may be accomplished by phage display screening methods using the so-called hierarchical dual combinatorial approach disclosed in WO92/01047, in which an individual colony containing either an H or L chain clone is used to infect a complete library of clones encoding the other chain (L or H) and the resulting two-chain specific binding domain is selected in accordance with phage display techniques as described.
  • Anti-P2X4 antibodies described herein can be linked to another functional molecule, e.g., another peptide or protein (albumin, another antibody, etc.). For example, the antibodies can be linked by chemical cross-linking or by recombinant methods.
  • The disclosed antibodies may also be altered to have a glycosylation pattern that differs from the native pattern. For example, one or more carbohydrate moieties can be deleted and/or one or more glycosylation sites added to the original antibody. Addition of glycosylation sites to the presently disclosed antibodies may be accomplished by altering the amino acid sequence to contain glycosylation site consensus sequences known in the art. Another means of increasing the number of carbohydrate moieties on the antibodies is by chemical or enzymatic coupling of glycosides to the amino acid residues of the antibody. Such methods are described in WO 87/05330 and in Aplin et al. (1981) CRC Crit. Rev. Biochem., 22: 259-306. Removal of any carbohydrate moieties from the antibodies may be accomplished chemically or enzymatically, for example, as described by Hakimuddin et al. (1987) Arch. Biochem. Biophys., 259: 52; and Edge et al. (1981) Anal. Biochem., 118: 131 and by Thotakura et al. (1987) Meth. Enzymol., 138: 350. The antibodies may also be tagged with a detectable, or functional, label. Detectable labels include radiolabels such as 131I or 99Tc, which may also be attached to antibodies using conventional chemistry. Detectable labels also include enzyme labels such as horseradish peroxidase or alkaline phosphatase. Detectable labels further include chemical moieties such as biotin, which may be detected via binding to a specific cognate detectable moiety, e.g., labeled avidin.
  • Typically, an amino acid is substituted by a related amino acid having similar charge, hydrophobic, or stereochemical characteristics. Such substitutions would be within the ordinary skills of an artisan. Unlike in CDRs, more substantial changes can be made in FRs without adversely affecting the binding properties of an antibody. Changes to FRs include, but are not limited to, humanizing a non-human derived or engineering certain framework residues that are important for antigen contact or for stabilizing the binding site, e.g., changing the class or subclass of the constant region, changing specific amino acid residues which might alter the effector function such as Fc receptor binding, e.g., as described in U.S. Pat. Nos. 5,624,821 and 5,648,260 and Lund et al. (1991) J. Immun. 147: 2657-2662 and Morgan et al. (1995) Immunology 86: 319-324, or changing the species from which the constant region is derived.
  • One of skill in the art will appreciate that the modifications described above are not all-exhaustive, and that many other modifications would obvious to a skilled artisan in light of the teachings of the present disclosure.
    • Nucleic Acids, Cloning and Expression Systems
  • The present disclosure provides the amino acid sequence of the disclosed antibodies. Once provided with this information, one of skill in the art could readily obtain nucleic acid molecules encoding the disclosed antibodies. The nucleic acids may comprise DNA or RNA and may be wholly or partially synthetic or recombinant. Reference to a nucleotide sequence encompasses a DNA molecule with the specified sequence, and encompasses a RNA molecule with the specified sequence in which U is substituted for T, unless context requires otherwise.
  • The nucleic acids molecules of the invention comprise a coding sequence for a CDR, a VH domain, and/or a VL domain disclosed herein.
  • The present disclosure also provides constructs in the form of plasmids, vectors, phagemids, transcription or expression cassettes which comprise at least one nucleic acid molecule encoding a CDR, a VH domain, and/or a VL domain disclosed herein.
  • The disclosure further provides a host cell which comprises one or more constructs as above.
  • Also provided are nucleic acids encoding any CDR (H1, H2, H3, L1, L2, or L3), VH or VL domain, as well as methods of making of the encoded products. The method comprises expressing the encoded product from the encoding nucleic acid. Expression may be achieved by culturing under appropriate conditions recombinant host cells containing the nucleic acid. Following production by expression a VH or VL domain, or specific binding member may be isolated and/or purified using any suitable technique, then used as appropriate.
  • Antigen-binding fragments, VH and/or VL domains and encoding nucleic acid molecules and vectors may be isolated and/or purified from their natural environment, in substantially pure or homogeneous form, or, in the case of nucleic acid, free or substantially free of nucleic acid or genes of origin other than the sequence encoding a polypeptide with the required function.
  • Systems for cloning and expression of a polypeptide in a variety of different host cells are well known in the art. For cells suitable for producing antibodies, see Gene Expression Systems, Academic Press, eds. Fernandez et al., 1999. Briefly, suitable host cells include bacteria, plant cells, mammalian cells, and yeast and baculovirus systems. Mammalian cell lines available in the art for expression of a heterologous polypeptide include Chinese hamster ovary cells, HeLa cells, baby hamster kidney cells, NS0 mouse myeloma cells, and many others. A common bacterial host is E. coli. Any protein expression system compatible with the invention may be used to produce the disclosed antibodies. Suitable expression systems include transgenic animals described in Gene Expression Systems, Academic Press, eds. Fernandez et al., 1999.
  • Suitable vectors can be chosen or constructed, so that they contain appropriate regulatory sequences, including promoter sequences, terminator sequences, polyadenylation sequences, enhancer sequences, marker genes and other sequences as appropriate. Vectors may be plasmids or viral, e.g., phage, or phagemid, as appropriate. For further details see, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, 1989. Many known techniques and protocols for manipulation of nucleic acid, for example, in preparation of nucleic acid constructs, mutagenesis, sequencing, introduction of DNA into cells and gene expression, and analysis of proteins, are described in detail in Current Protocols in Molecular Biology, 2nd Edition, eds. Ausubel et al., John Wiley & Sons, 1992.
  • A further aspect of the disclosure provides a host cell comprising a nucleic acid as disclosed here. A still further aspect provides a method comprising introducing such nucleic acid into a host cell. The introduction may employ any available technique. For eukaryotic cells, suitable techniques may include calcium phosphate transfection, DEAE-Dextran, electroporation, liposome-mediated transfection and transduction using retrovirus or other virus, e.g., vaccinia or, for insect cells, baculovirus. For bacterial cells, suitable techniques may include calcium chloride transformation, electroporation and transfection using bacteriophage. The introduction of the nucleic acid into the cells may be followed by causing or allowing expression from the nucleic acid, e.g., by culturing host cells under conditions for expression of the gene.
    • Methods of Use
  • The disclosed anti-P2X4 antibodies are capable of modulating the electrophysiological activity of P2X4. In particular, antibodies provided herein may be used to inhibit or potentiate P2X4 channel conductance. Such antibodies can be used to treat P2X4-associated medical disorders in mammals, especially, in humans. In particular, antibodies that inhibit P2X4 activity are useful for the treatment of neuropathic pain. Antibodies that potentiate P2X4 activity are useful in other therapeutic methods, including but not limited to microglia-mediated diseases and disorders and macrophage-mediated diseases and disorders.
  • Antibodies of the invention can also be used for isolating P2X4 or P2X4-expressing cells.
  • As demonstrated in the Examples, binding of P2X4 with an anti-P2X4 antibody modulates P2X4 biological activity by potentiating or reducing passage of ions through the P2X4 channel.
  • The antibodies or antibody compositions of the present invention are administered in therapeutically effective amounts. Generally, a therapeutically effective amount may vary with the subject's age, condition, and sex, as well as the severity of the medical condition of the subject. The appropriate dose is chosen based on clinical indications by a treating physician.
  • The antibodies may be given as a bolus dose, to maximize the circulating levels of antibodies for the greatest length of time after the dose. Continuous infusion may also be used after the bolus dose.
  • Anti-P2X4 antibodies of the invention may be used to detect the presence of P2X4 in biological samples. Detection methods that employ antibodies are well known in the art and include, for example, ELISA, radioimmunoassay, immunoblot, Western blot, immunofluorescence, and immunoprecipitation. If desired, an anti-P2X4 antibody is modified, for example, with a ligand group (such as biotin) or a detectable marker group (such as a fluorescent group, a radioisotope or an enzyme). If desired, the antibodies of the invention may be labeled using conventional techniques. Suitable detectable labels include, for example, fluorophores, chromophores, radioactive atoms, electron-dense reagents, enzymes, and ligands having specific binding partners. Enzymes are typically detected by their activity. For example, horseradish peroxidase can be detected by its ability to convert tetramethylbenzidine (TMB) to a blue pigment, quantifiable with a spectrophotometer. For detection, suitable binding partners include, but are not limited to, biotin and avidin or streptavidin, IgG and protein A, and the numerous receptor-ligand couples known in the art. Other permutations and possibilities will be readily apparent to those of ordinary skill in the art, and are considered as equivalents within the scope of the invention.
    • Pharmaceutical Compositions and Methods of Administration
  • The invention provides pharmaceutical compositions comprising anti-P2X4 antibodies (e.g., Antibody Nos. 1-48). Such compositions are likely suitable for pharmaceutical use and administration to patients. The compositions typically comprise one or more antibodies of the present invention and a pharmaceutically acceptable excipient. The phrase “pharmaceutically acceptable excipient” includes any and all solvents, dispersion media, coatings, antibacterial agents and antifungal agents, isotonic agents, and absorption delaying agents, and the like, that are compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. The compositions may also contain other active compounds providing supplemental, additional, or enhanced therapeutic functions. The pharmaceutical compositions may also be included in a container, pack, or dispenser together with instructions for administration.
  • A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Methods to accomplish the administration are known to those of ordinary skill in the art. The administration may, for example, be intravenous, intraperitoneal, intramuscular, intracavity, subcutaneous or transdermal. In one embodiment, neuropathic pain is treated by intrathecal administration. It may also be possible to obtain compositions which may be topically or orally administered, or which may be capable of transmission across mucous membranes.
  • Solutions or suspensions used for intradermal or subcutaneous application typically include one or more of the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerin, propylene glycol, or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates; and agents for the adjustment of tonicity such as sodium chloride or dextrose. The pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. Such preparations may be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
  • Pharmaceutical compositions suitable for injection include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. It should be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars; polyalcohols such as mannitol, sorbitol, and sodium chloride in the composition. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyetheylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and/or by the use of surfactants. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate, and gelatin.
  • Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For oral administration, the antibodies can be combined with excipients and used in the form of tablets, troches, or capsules. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches, and the like can contain any of the following ingredients, or compounds of a similar nature; a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
  • Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration may be accomplished, for example, through the use of lozenges, nasal sprays, inhalers, or suppositories. For example, in case of antibodies that comprise the Fc portion, compositions may be capable of transmission across mucous membranes in intestine, mouth, or lungs (e.g., via the FcRn receptor-mediated pathway as described in U.S. Pat. No. 6,030,613). For transdermal administration, the active compounds may be formulated into ointments, salves, gels, or creams as generally known in the art. For administration by inhalation, the antibodies may be delivered in the form of an aerosol spray from pressured container or dispenser, which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.
  • In certain embodiments, the presently disclosed antibodies are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. Liposomal suspensions containing the presently disclosed antibodies can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811.
  • It may be advantageous to formulate oral or parenteral compositions in a dosage unit form for ease of administration and uniformity of dosage. The term “dosage unit form” as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • Toxicity and therapeutic efficacy of the composition of the invention can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50. Compositions that exhibit large therapeutic indices are preferred.
  • The data obtained from electrophysiological experiments and animal studies can be used in formulating a range of dosage for use in humans. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 (i.e., the concentration of the antibody which achieves a half-maximal inhibition of symptoms). Circulating levels in plasma may be measured, for example, by high performance liquid chromatography. The effects of any particular dosage can be monitored by a suitable bioassay. The dosage lies preferably within a range of circulating concentrations with little or no toxicity. The dosage may vary depending upon the dosage form employed and the route of administration utilized.
    • Kits
  • The invention provides kits for modulating P2X4 activity. Antibodies that potentiate P2X4 activity are useful for the treatment of indications mediated by decreased P2X4 activity as described herein. Antibodies that inhibit P2X4 activity are useful for the treatment or prevention of neuropathic pain and/or microglia-mediated diseases and disorders and/or macrophage-mediated diseases and disorders. In one embodiment, the kit includes a therapeutic or prophylactic composition containing an effective amount of an anti-P2X4 antibody that modulates P2X4 activity in unit dosage form.
  • In some embodiments, the kit comprises a sterile container which contains a therapeutic or prophylactic cellular composition; such containers can be boxes, ampules, bottles, vials, tubes, bags, pouches, blister-packs, or other suitable container forms known in the art. Such containers can be made of plastic, glass, laminated paper, metal foil, or other materials suitable for holding medicaments.
  • If desired an antibody of the invention is provided together with instructions for administering the antibody or agent to a subject having or at risk of developing neuropathic pain. The instructions will generally include information about the use of the composition for the treatment or prevention of such indications. In other embodiments, the instructions include at least one of the following: description of the therapeutic agent; dosage schedule and administration for treatment or prevention of an immune disorder or symptoms thereof; precautions; warnings; indications; counter-indications; overdosage information; adverse reactions; animal pharmacology; clinical studies; and/or references. The instructions may be printed directly on the container (when present), or as a label applied to the container, or as a separate sheet, pamphlet, card, or folder supplied in or with the container.
  • The practice of the present invention employs, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry and immunology, which are well within the purview of the skilled artisan. Such techniques are explained fully in the literature, such as, “Molecular Cloning: A Laboratory Manual”, second edition (Sambrook, 1989); “Oligonucleotide Synthesis” (Gait, 1984); “Animal Cell Culture” (Freshney, 1987); “Methods in Enzymology” “Handbook of Experimental Immunology” (Weir, 1996); “Gene Transfer Vectors for Mammalian Cells” (Miller and Calos, 1987); “Current Protocols in Molecular Biology” (Ausubel, 1987); “PCR: The Polymerase Chain Reaction”, (Mullis, 1994); “Current Protocols in Immunology” (Coligan, 1991). These techniques are applicable to the production of the polynucleotides and polypeptides of the invention, and, as such, may be considered in making and practicing the invention. Particularly useful techniques for particular embodiments will be discussed in the sections that follow.
  • The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the anti-P2X4 antibodies in assay, screening, and therapeutic methods of the invention, and are not intended to limit the scope of what the inventors regard as their invention.
    • EXAMPLES Example 1: Production and Isolation of Recombinant P2X4 Proteins
  • Human P2X purinoceptor 4 (Q99571), a natural variant of human P2X purinoceptor 4 with an S to G mutation at position 242 (Corresponds to variant rs25644) and murine P2× purinoceptor 4 (Q9JJX6) proteins were designed with a C-terminal AVI tag (Avidity LLC) and a C-terminal Histidine tag. The constructs were cloned into pFASTBAC1 vectors (Life Technologies). Bacmids were generated in DH10Bac (Life Technologies) E. coli cells. Bacmids were subsequently transfected into Sf9 insect cells (Spodopterafrugiperda Sf9 cells from Life Technologies, cat no 11496-015) for production of recombinant baculovirus particles, which in turn were used to infect Sf9 cells for protein expression.
  • Expression parameters were assessed by monitoring expression level, protein quality and the homogeneity of the receptor using a modified Fluorescence-detection size-exclusion chromatography (FSEC) method described by Backmark et al., (Protein Sci. 22 (2013) 1124-1132). This method is similar to the basic FSEC concept as described by Kawate and Gouaux (Structure 14 (2006) 673-681), but applied a fluorescent probe that specifically interacts with the Histidine tag on the protein. Cells were typically innoculated at a density of 1.0×10e6/mL in SF900II medium. Cells were infected with a multiplicity of infection of 2 at a cell density of 2×10E6 cells/ml. Protein expression was performed at 27° C. and cells were harvested 72 hours post infection. Expression parameters were selected to enhance the quantity of trimer and homogeneity of protein present as trimers. As assayed by fluorescent size exclusion chromatography, the protein preparation contains 50-75% trimer. Although the total amount of receptor increased with longer post infection times, FSEC analysis indicated that protein quality declined when the expression time was increased past 72 hours.
  • Human P2X4 receptor and mouse P2X4 were purified as follows. Membranes were prepared from SF9 cells. Membrane proteins were extracted from the membranes by detergent solubilization, using combinations of detergents, salts, buffers and additives, including n-Dodecyl-beta-D-Maltoside CAS 69227-93-6 (0-2% (w/v)), n-Dodecyl thio-Maltoside CAS 148565-58-6 (0-1% (w/v)), (3-[(3-Cholamidopropyl)-Dimethylammonio]-1-Propane Sulfonate/N,N-Dimethyl-3-Sulfo-N-[3-[[3α,5β,7α,12α)-3,7,12-Trihydroxy-24-Oxocholan-24-yl]Amino]propyl]-1-Propanaminium Hydroxide abbreviated to CHAPS CAS 75621-03-3 (0-0.6% (w/v)), and Cholesteryl Hemisuccinate CAS 102601-49-0 (0-0.12% (w/v)). Without being bound to theory, higher concentrations of the indicated substances as well as alternative detergents support extraction of the protein from the membranes. The proteins underwent standard affinity and size exclusion chromatography purification. The purified protein was formulated in a buffer which contained 50 mM Tris-HCl pH 8.0, 600 mM NaCl, 10% (v/v) glycerol, 0.025 (w/v) % n-Dodecyl-beta-D-Maltoside CAS 69227-93-6, 0.0125% (w/v), n-Dodecyl thio-Maltoside CAS 148565-58-6, 0.0075% (w/v) (3-[(3-Cholamidopropyl)-Dimethylammonio]-1-Propane Sulfonate/N,N-Dimethyl-3-Sulfo-N-[3-[[3α,5β,7α,12α)-3,7,12-Trihydroxy-24-Oxocholan-24-yl]Amino]propyl]-1-Propanaminium Hydroxide abbreviated to CHAPS CAS 75621-03-3, and 0.0015% (w/v) Cholesteryl Hemisuccinate CAS 102601-49-0.
  • The purified protein was formulated under alternative conditions, including phosphate buffers and HEPES buffers 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid buffers CAS 7365-45-9. The pH of the various buffers has ranged from 7.0-8.0. Salt (NaCl) has been varied between 120-600 mM. Glycerol can be excluded from the protein formulation. Various detergents have been used in protein formulation, such as lauryl maltose neopentyl glycol 2,2-didecylpropane-1,3-bis-P3-D-maltopyranoside, decyl maltose neopentyl glycol 2,2-dioctylpropane-1,3-bis-P3-D-maltopyranoside, octyl maltose neopentyl glycol 2,2-dihexylpropane-1,3-bis-P3-D-maltopyranoside, CYMAL-5 5-Cyclohexyl-1-pentyl-P3-D-maltoside CAS 250692-65-0, n-Tetradecylphosphocholine 77733-28-9, n-Decyl-P3-D-Maltopyranoside CAS 82494-09-5, n-octyl-P3-D-glucoside CAS 29836-26-8 and n-nonyl-1-D-glucoside CAS 69984-73-2. Formulations in other detergents are also possible. The concentration of Cholesteryl Hemisuccinate CAS 102601-49-0 can be varied and excluded from the protein formulation as well.
    • Example 2: Purification of Trimeric P2X4 Complexes
  • In vivo, P2X receptors form functional trimeric ion channels. The solubilised and purified P2X4 proteins are typically present in a range of oligomeric states, including monomers, dimers, trimers, and hexamers (i.e., dimers of trimers). This range of oligomeric states is described for example, by references (Backmark et al., Protein Sci. 22 (2013) 1124-1132; Kawate et al., Structure 14 (2006) 673-681; Kawate et al., Nature 460 (2009) 592-598; Nakazawa et al., European Journal of Pharmacology 518 (2005) 107-110; Nicke et al., Mol. Pharmacol. 63 (2003) 243-252). To obtain a stable predominantly trimeric arrangement, solubilization conditions were adjusted.
  • Combinations of detergents, additives, buffers and pH were varied. Optimal conditions were selected to increase the FSEC signature of the trimer while reducing larger order oligomeric arrangements and aggregates. Such undesirable forms were eluted in the void volume of the size-exclusion columns applied. Conditions tested included KPO4-HCl pH 7.4, 600 mM NaCl and 2% (w/v) n-dodecyl-beta-maltopyranoside CAS 69227-93-6. Optimal solubilization was obtained in buffers containing combinations of the detergents including n-Dodecyl-beta-D-Maltoside CAS 69227-93-6, n-Dodecyl thio-Maltoside CAS 148565-58-6, (3-[(3-Cholamidopropyl)-Dimethylammonio]-1-Propane Sulfonate/N,N-Dimethyl-3-Sulfo-N-[3-[[3α,5β,7α,12α)-3,7,12-Trihydroxy-24-Oxocholan-24-yl]Amino]propyl]-1-Propanaminium Hydroxide abbreviated to CHAPS CAS 75621-03-3, and the additive Cholesteryl Hemisuccinate CAS 102601-49-0. The purified protein was formulated in a buffer which contained 50 mM Tris-HCl pH 8.0, 600 mM NaCl, 10% (v/v) glycerol, 0.025 (w/v) % n-Dodecyl-beta-D-Maltoside CAS 69227-93-6, 0.0125% (w/v), n-Dodecyl thio-Maltoside CAS 148565-58-6, 0.0075% (w/v) (3-[(3-Cholamidopropyl)-Dimethylammonio]-1-Propane Sulfonate/N,N-Dimethyl-3-Sulfo-N-[3-[[3α,5β,7α,12α)-3,7,12-Trihydroxy-24-Oxocholan-24-yl]Amino]propyl]-1-Propanaminium Hydroxide abbreviated to CHAPS CAS 75621-03-3, and 0.0015% (w/v) Cholesteryl Hemisuccinate CAS 102601-49-0.
    • Example 3: Anti-P2X4 Specific Antibodies were Isolated Using Phage Display Selection
  • Naïve human single chain Fv (scFv) phage display libraries were cloned into a phagemid vector based on the filamentous phage M13 were used for selections (Lloyd (2009) Protein Eng Des Sel 22, 159-168; Vaughan et al., Nature biotechnology 14, 309-314, 1996). Anti-P2X4 specific antibodies were isolated from the phage display libraries using a series of selection cycles on recombinant human P2X4 (hu P2X4), essentially as previously described by Vaughan et al (Vaughan et al., supra). In brief, human P2X4 in PBS (Dulbecco's PBS, pH7.4) was immobilised onto wells of a MaxiSorpL microtitre plate (Nunc) overnight at 4° C. Wells were washed with PBS then blocked for 1 hour with PBS-Marvel dried skimmed milk (3% w/v). Purified phage in PBS-Marvel (3% w/v) were added to the wells and allowed to bind coated antigen for 1 hour at room temperature. Unbound phage was removed by a series of wash cycles using PBS. Bound phage particles were eluted with trypsin for 30 minutes at 37° C., infected into E. coli TG1 bacteria and rescued for the next round of selection. Alternatively, anti-P2X4 antibodies were isolated as described above except deselection of the purified phage library against the C-terminal peptide huP2X4370-388 (Alomone Labs # APR-002) or phenyl hydrophobic interaction chromatography (HIC) beads was performed prior to selection with the antigen.
    • Example 4: Generation of Rat Anti-Murine P2X4 Antibodies Using Hybridoma Technology
  • Immunisations
  • Purified recombinant murine P2X4 protein and murine P2X4 transfected HEK 293F cells were used to immunise Sprague Dawley rats in three groups. For group 1, rats were immunised with murine P2X4 protein; for group 2, rats were immunised with murine P2X4 transfected HEK 293F cells; and for group 3, rats were immunised by alternating murine P2X4 protein and murine P2X4 transfected HEK 293F cells.
  • A twenty eight day immunization protocol was used with a priming immunization on day 0, followed by four subsequent booster immunizations on days 7, 15, 22 and 24. For group 1, equal volumes of complete Freund's adjuvant and murine P2X4 protein (total protein: 100 μg) were emulsified together, and delivered to the rats subcutaneously at two sites (200 μL per site). For the subsequent three booster injections, the same amount of protein was used, emulsified in Freund's incomplete adjuvant. For group 2, murine P2X4 transfected HEK 293F cells were resuspended at 5E7 cells per mL in PBS and emulsified with equal volumes of complete Freund's adjuvant. As above, the cells were injected into rats at two sites (200 μL per site). For the subsequent three booster injections, the same number of cells was used, emulsified in Freund's incomplete adjuvant. For group 3, the priming immunization was with murine P2X4 protein as per group 1 above, followed by three booster immunizations with murine P2X4 transfected HEK 293F cells, murine P2X4 protein, and murine P2X4 transfected HEK 293F cells.
  • The final boosts were given intraperitoneally on day 24, group 1 and group 3 rats received murine P2X4 protein (400 μL at 50 μg/mL in Tris buffer), and group 2 rats received murine transfected HEK 293F cells (400 μL at 5E7/mL).
  • Tail vein bleeds were obtained from the rats before immunisation, on day 13 after the first immunization, and on day 20 after second immunisation. The IgG titres to anti-murine P2X4 were determined by a cell-based DELFIA (dissociation-enhanced lanthanide fluorescence immunoassay) assay.
  • Assessment of rat immune response to murine P2X4 using a cell-based DELFIA
  • The IgG titres to murine P2X4 in sera were determined by a cell based DELFIA using both mP2X4 transfected HEK 293F and parental HEK cells. In order to reduce anti-HEK 293F cell specific antibodies in sera, before being assayed the serum samples from rats immunised with either cells alone or the alternating protein and cells strategy were incubated with non-transfected HEK 293F cells. The sera from rats immunised with protein were assayed without this pre-adsorption step.
  • Murine P2X4 transfected HEK 293F and parental HEK cells were plated in culture media onto black collagen coated 96 well microtitre plates at a density of 30,000 cells per well. After overnight incubation at 37° C. in a 5% CO2 incubator, the culture supernatant was removed and the cells were fixed with 3.7% formaldehyde solution at 50 μL per well. All subsequent incubations were carried out at room temperature. After 5 minutes fixation, the formaldehyde solution was discarded and replaced with 200 μL of 3% marvel/PBS blocking buffer. After one hour, the blocking buffer was removed and the serum samples added in a 3-fold dilution series (50 μL per well starting from a 1:200 dilution). After incubating for one hour, the wells were washed gently three times with PBS supplemented with 0.05% (v/v) Tween 20. A biotinylated polyclonal goat anti-rat IgG Fc gamma specific secondary antibody (diluted 1:500 in marvel/PBS) was added then at 50 μL per well. Following a further one hour incubation and three gentle washes as above, Eu-N1-labeled streptavidin (Perkin Elmer) was added to the wells (diluted to 100 ng/mL in marvel/PBS, 50 μL per well). After 30 minutes incubation time, the wells were gently washed five times and DELFIA enhancement solution was added. The reaction was allowed to develop for 10 minutes, and then the plate was then read using a PerkinElmer EnVision 2103 multilabel plate reader. The TRF (time-resolved fluorescence) signal in each well was measured (excitation 340 nm, emission 615 nm).
  • The serum titration curves for murine P2X4 transfected HEK 293F cells and parental HEK 293F cells were plotted and the respective area under the curves (AUC) calculated. For rats immunized with murine P2X4 transfected HEK 293F cells, specific mP2X4 IgG titres were derived by subtracting the AUC values from parental HEK cells from the AUC values for the murine P2X4 transfected cells.
  • Monoclonal Rat IgG Isolation
  • Four days after the final boost, lymph nodes were aseptically harvested and cells were isolated by mechanical disruption and counted. These cells were mixed with SP2/0 myeloma cells and fused using an electrofusion apparatus. The resultant fusions were mixed with a methylcellulose-based semi-solid media and plated out into OmniTray plates. The semi-solid media comprised CloneMatrix and DMEM supplemented with 20% FCS, 10% BM Condimed H1, 1 mM sodium pyruvate and OPI media supplement, 2% hypoxanthine azaserine and FITC conjugated goat anti-rat IgG. The cells in semi-solid media were cultured for 13 days at 37° C. in a 5% CO2 incubator. During this incubation period, clonal colonies are formed from a single progenitor hybridoma cell. These colonies secrete IgG that is trapped in the vicinity of the colony by the FITC conjugated anti-IgG present in the semi-solid media. The resultant immune complex formation can be observed around the cell as a fluorescent ‘halo’ when visualised by ClonePix FL colony picker (Molecular Devices). These haloed colonies are then picked into 96 well microtitre plates.
  • After 3-5 days in culture, the supernatants of the picked colonies were harvested and screened for murine P2X4 specificity by comparing binding to murine P2X4 transfected HEK 293F cells and parental HEK 293F cells by a cell-based fluorornetric microvolumne assay technology (FMAT) assay.
  • DNA Sequencing of Rat IgG
  • Messenger RNA (mRNA) was extracted from cells using magnetic oligo (dT) particles and converted into cDNA. PCR amplification was performed using poly-C and constant region VH/VL primers.
    • Rat IgG Purifications
  • Prior to purification, the hybridomas were tested by ELISA using a goat anti-rat IgG2a coated microtitre plate to determine which clones secreted Rat IgG2a, as this isotype is purified using a different purification matrix to rat IgG1, IgG2b and IgG2c isotypes.
  • Cells were propagated in 24 well plates and overgrown in serum free HL-1 medium supplemented with HyperZero and glutamine. After 10 days, the supernatants were transferred to 96 well masterblocks and rat IgG1, IgG2b and IgG2c isotypes were purified on 20 L Phytips containing ProPlus resin (Phynexus). Rat IgG2a antibodies were purified on custom packed Phytips containing CaptureSelect IgG-Fc multiple species resin (Lift Technologies) using Perkin Elmer Minitrack. The captured rat IgGs were eluted with 75 μL of 100 mM HEPES, 140 mM NaCl pH 3.0 then neutralised with an equal volume of 200 mM HEPES pH 8.0. The purified IgGs were quantified using an absorbance reading at 280 nm in UV-Star 384 well plate.
    • Reformatting of Rat IgGs to Human IgG1
  • Rat hybridoma IgG clones were molecularly reformatted to generate chimeric constructs expressing rat VH and VL domains and human IgG1 constant domains essentially as described by Persic et al., 1997 (Gene 187, 9-18) with the following modifications. An OriP fragment was included in the expression vectors to facilitate use with CHO-transient cells and to allow episomal replication. The VH domain was cloned into a vector (pEU1.4) containing the human heavy chain constant domains and regulatory elements to express whole IgG1 heavy chain in mammalian cells. This constant region contained the triple mutations (TM) L234F/L235E/P331S resulting in an effector null human IgG1 (Oganesyan et al., (2008) Acta Crystallogr D Biol Crystallogr. 64, 700-704). Similarly, the VL domain was cloned into a vector (pEU4.4) for the expression of the human light chain (lambda) constant domains and regulatory elements to express whole IgG light chain in mammalian cells. To obtain IgGs, the heavy and light chain IgG expressing vectors were transfected into CHO-transient mammalian cells. IgGs were expressed and secreted into the medium. Harvests were filtered prior to purification, then IgG was purified using Protein A chromatography. Culture supernatants were loaded on a column of appropriate size of Ceramic Protein A (Pall 20078-036) and washed with 50 mM Tris-HCl pH 8.0, 250 mM NaCl. Bound IgG was eluted from the column using 0.1 M Sodium Citrate (pH 3.0) and neutralised by the addition of Tris-HCl (pH 9.0). The eluted material was buffer exchanged into PBS using Nap 10 columns (GE Lifesciences 17-0854-02) and the concentration of IgG was determined spectrophotometrically using an extinction coefficient based on the amino acid sequence of the IgG (Pace et al., (1995) Protein Sci. 4, 2411-23). The purified IgG were analysed for purity using SDS-PAGE.
    • Example 5: Identification of Human P2X4 Binding Antibodies from Phage Display Selections
  • ScFv antibodies identified from the phage display method described in Example 3 were expressed in bacteria and screened as unpurified bacterial periplasmic extracts (which contain scFv), prepared in: 0.2M HEPES buffer pH7.4, 0.5 mM EDTA and 0.5 M sucrose. Alternatively, the heavy and light chain variable regions were amplified by PCR and cloned into a vector for expression as human IgG1 antibodies in HEK293F cells.
  • For screening of bacterial scFv samples, 5 μl of bacterial extract was added to a 384 well assay plate (Corning 3655). Assay buffer was prepared as follows: 1× Hanks Balanced Salt Solution (HBSS) (Sigma H8264), 0.1% (v/v) BSA (PAA K05-013), 20 mM HEPES (Gibco 15630) and 1 U/ml Apyrase (Sigma A6535) and 5 μl added to the assay plate with the bacterial scFv extract. Anti-myc detection reagent (Serotec MCA2200) and anti-mouse DyLight649 (Jackson Immuno Research Labs 115-495-071) were diluted in assay buffer to 15.6 nM and 24 nM respectively in the same solution and 5 μl added to the assay plate with the scFv sample. HEK293F cells expressing human P2X4 (huP2X4) (Q99571, ENSP00000336607) were diluted to 2.6e5 cells/ml in assay buffer and 15l added to the assay plate. In parallel scFv samples were also tested for binding to HEK293F cells that did not express huP2X4.
  • For screening of the HEK293F expressed IgG samples, 2.5 μl of cell culture supernatant was added to the 384 well assay plate (Corning 3655). Assay buffer was prepared as described above and 7.5 μl was added to the assay plate with the IgG sample. Anti-human AlexaFluor 647 (Life Technologies A21445) was diluted in assay buffer to 6 nM and 10 μl added to the assay plate with the IgG sample. HEK293F cells expressing huP2X4 (Q99571, ENSP00000336607) were diluted to 4e5 cells/ml in assay buffer and 10l added to the assay plate. In parallel IgG samples were also tested for binding to HEK293F cells that did not express huP2X4. Assay plates set up to screen both types of samples were sealed with a Topseal plate sealer (Perkin Elmer 6005250) and incubated at room temperature for at least 4 hours before reading on the Fluorescence Microvolume Assay Technology (FMAT), a fluorescence based platform that detects fluorescence localized to bead or cells settled at the bottom of a microwell (Dietz et al., Cytometry 23:177-186 (1996), Miraglia et al., J. Biomol. Screening 4:193-204 (1999)). Data was analysed using the FMAT analysis software and events were gated based on fluorescence 0-10,000 FL1 counts, colour typically 0.15 to 0.40 and size 10-60. A minimum count of 20 events was set as a threshold before data was reported for each well. ScFv showing binding to the HEK293F huP2X4 cells, but not to the control HEK293F cells were selected for further testing if the FL1 count was above 1000 on the huP2X4 cells, IgG samples showing a specific huP2X4 binding signal of greater than 200 FL1 counts were identified as hits and characterised further.
  • ScFv or IgG samples which showed a specific binding signal to HEK293F huP2X4 cells as unpurified samples were subjected to DNA sequencing (Vaughan et al. supra, Nature Biotechnology 14: 309-314), (Osbourn 1996; Immunotechnology. 2, 181-196). Unique scFvs were expressed in bacteria and purified by affinity chromatography (as described by Bannister et al (2006) Biotechnology and bioengineering, 94. 931-937). Those scFv that confirmed binding to human P2X4 were generated as full IgGs and expressed and purified as described in Example 4. Purified IgG antibodies were tested for functional activity in the electrophysiology assay and for binding to cells expressing mouse and cynomologus P2X4 using the same method described for the human P2X4 cells described above except a titration of purified IgG sample was used. Results of electrophysiology assays are provided at FIGS. 3 and 4.
    • Example 6: Identification of Hybridoma IgGs that Bind Specifically to Murine P2X4
  • Supernatants generated from the immunisations were screened to identify IgGs with specific binding to mP2X4. Briefly supernatants were diluted 10 fold into assay buffer (HBSS, 0.1% (v/v) BSA, 20 mM HEPES and 1 U/ml Apyrase) and 5 μl added to the assay plate. Anti-rat detection antibody labeled with Alexa Fluor 647 (Jackson Immuno Research labs) was diluted to 6 nM and 10 μl added to the assay plate. HEK293F cells expressing mP2X4 were diluted to 2.6e5/ml and 15 μl added to the assay plate. IgG samples were also tested for non-specific binding in parallel by testing the samples for binding to HEK293F cells. IgGs demonstrating specific binding to mP2X4 and no binding to HEK293F cells were identified as hits and selected for antibody purification and analysis by electrophysiology. Results of the electrophysiology screen are provided in FIG. 7 together with the binding results for these samples against human and cyno P2X4 expressing cell lines using the same assay described previously
    • Example 7: Generation of Human P2X4 Variants and Expression by Transient Transfection in HEK293F Cells
  • To determine the epitope to which the P2X4 functional antibodies bind the following mutations were generated in human P2X4; E95Q, V105M, G114D, A122V, S131N, A151P, G154R, L303P, N306K. DNA vectors containing huP2X4 sequences with these changes were generated using standard molecular biology techniques. DNA vectors were transfected into HEK293F cells using 293-fectin (Life Technologies 12347019) following the manufacturers guidelines. Cells expressing the huP2X4 variants were incubated with Antibody Nos. 1, 11, 29, and 33 together with the anti-human AlexaFluor 647 (Life Technologies A21445) detection reagent. Binding was measured using the FMAT plate reader. Variant S131N was shown to be important for the binding of Antibody Nos. 11, 29, and 33. FIGS. 1A-1D show the results of FMAT assays characterizing binding of P2X4 antibodies to HEK293F cells expressing variants of human P2X4.
    • Example 8: Electrophysiological Characterization of Monoclonal Antibodies to P2X4
  • Methods for Phage Display Derived mAbs:—FIGS. 3 & 4
  • HEK 293F cells stably expressing human P2X4, mouse P2X4 or cynomolgus P2X4 were harvested at 50% confluency using accutase. Cells were then resuspended in 10 ml Freestyle 293F media supplemented with HEPES (10 mM)+apyrase (1 U/ml, ATPase/ADPase activity=1) at a density of 2-3e6 cells/ml. P2X4 function was assayed using the automated electrophysiology platform QPatch 16X (Sophion) in population patch configuration. Composition of QPatch extracellular buffer (QEB) was (in mM) NaCl (140), KCl (2), MgCl2 (1) CaCl2) (2), HEPES (10). Final composition of compound plate extracellular buffer (CPEB1) was NaCl (137.6), KCl (2.2), MgCl2 (0.66), CaCl2 (1.3), HEPES (6.6), KH2PO4 (0.49), NaH2PO4 (2.66). pH of extracellular buffers was adjusted to 7.4 with NaOH (1 M), osmolarity was adjusted to 300 mOsm with sucrose and the solutions were 0.2 m filtered. Compound plate extracellular buffer was supplemented with 0.1% bovine serum albumin. The QPatch intracellular buffer contained (in mM) CsF (140), NaCl (10), EGTA (1), HEPES (10). pH of the intracellular buffer was adjusted to 7.3 with CsOH (1 M) and the solution was 0.2 μm filtered. IgGs were titrated to pH 7.4 with NaOH (1 M).
  • After obtaining whole cell configuration, cells were voltage clamped at −50 mV with 70% series resistance compensation employed. The ligand agonist adenosine 5′-triphosphate disodium salt (ATP, 3 μM) in CPEB1 was applied for 3 seconds every 5 minutes for 20 minutes resulting in 4 control agonist responses. Each agonist response was washed off with CPEB1+apyrase (1 U/ml). 4 additional agonist responses were then measured every 5 minutes in the continued presence of the test IgG or an isotype control IgG (NIP 228). Exemplar traces showing the effect of inhibitory IgGs 5 mins after IgG application can be seen in FIG. 8A whereas an example of a potentiating IgG can be seen in FIG. 8D. Electrophysiology data presented in FIG. 3 and FIG. 4 were leak subtracted by subtracting the current in the absence of ligand and the magnitude of the P2X4 response measured as the peak inward current in the presence of ligand. Peak inward current in the presence of IgG+ATP after 5 minutes IgG incubation was expressed as a fraction of the 4th control ATP response. Data were subsequently normalised to a time and concentration matched isotype control antibody response using the equation Inorm=IIgG*(1/Iisotype) where IIgG=fraction of control current for the test IgG and Iisotype=fraction of control current for the isotype control IgG. Six IgGs were found to significantly inhibit human P2X4 currents; Antibody Nos. 5, 8, 11, 18, 29, and 33 (FIGS. 3, 4, 8A). Inhibition of P2X4 currents was rapid, occurring at the first time point following IgG addition, whereas the isotype control IgG NIP 228 had no significant effect. IgGs were subsequently tested for function against mouse and cynomolgus P2X4 (FIGS. 3, 4) and data reported as a mean of n=3-4 experiments.
  • Sequences for phage display antibodies are provided in FIG. 2. Results of cross reactivity for phage display antibodies between human, cynomolgus monkey, and mouse are provided in FIG. 3. FIG. 9 provides a structural analysis of the epitope/paratope interface. FIG. 10 provides the sequence of the predicted P2X4 epitope.
  • Methods for Hybridoma Derived mAbs.—FIGS. 5, 7 & 8
  • HEK 293F cells stably expressing either mouse P2X4 (Uniprot # Q9JJX6) or human P2X4 (Uniprot # Q99571) were harvested at 50% confluency using accutase. Cells were then resuspended in 10 ml Freestyle 293F media supplemented with HEPES (10 mM)+apyrase (1 U/ml, ATPase/ADPase activity=1) at a density of 2-3e6 cells/ml. P2X4 function was assayed using the automated electrophysiology platform QPatch 16X (Sophion) in population patch configuration. Composition of QPatch extracellular buffer (QEB) was (in mM) NaCl (140), KCl (2), MgCl2 (1) CaCl2 (2), HEPES (10). Final composition of compound plate extracellular buffer (CPEB2) was NaCl (115.5), KCl (1.3), MgCl2 (0.66), CaCl2 (1.32), HEPES (56.1). pH of extracellular buffers was adjusted to 7.4 with NaOH (1 M) and the solutions were 0.2 μm filtered. The QPatch intracellular buffer contained (in mM) CsF (140), NaCl (10), EGTA (1), HEPES (10). pH of the intracellular buffer was adjusted to 7.3 with CsOH (1 M) and the solution was 0.2 μm filtered. IgGs were titrated to pH 7.4 with NaOH (1 M). After obtaining whole cell configuration, cells were voltage clamped at −50 mV with 70% series resistance compensation employed. The ligand agonist adenosine 5′-triphosphate disodium salt (ATP) (6 μM for mouse P2X4, 3 μM for human P2X4) in QEB was applied for 3 seconds then washed off with QEB+apyrase (1 U/ml). CPEB2+IgG was then incubated for 3 minutes followed by a second ATP addition. Data were leak subtracted by subtracting the current in the absence of ligand and the magnitude of the P2X4 response measured as the peak inward current in the presence of ligand. The ATP response after IgG addition was expressed as a fraction of the ATP response prior to IgG addition. The hIgG1 NIP 228 TM was used as a control antibody to determine the cutoff for defining functional antibodies. IgGs were initially screened in duplicate (FIG. 5, First screen and FIG. 7) at mP2X4 and expressed as mean of n=1-2 experiments. The control antibody NIP 228 TM had a fraction of control current of 1.08+/−0.27 (Mean+/−S.D), n=49. From these data the cutoff for defining functional inhibitory antibodies was set at <0.5 (>˜2 standard deviations from the mean). Functional antibodies from the first screen were repeated with a larger sample set (n=3-4) and data reported as mean+/−SD (FIG. 5).
  • Results of cross reactivity for hybridoma antibodies between human and mouse are provided at FIGS. 5 and 7. Sequences for hybridoma antibodies are provided at FIGS. 6 and 13.
    • Example 9: In Vivo Testing of Monoclonal Antibodies to P2X4 in Seltzer Model of Neuropathic Pain
  • 50 female C57BL/6 mice were used for the studies. All mice underwent insertion of transponders for identification purposes at least 5 days before the start of the study. Mechanical hyperalgesia was determined using an analgysemeter (Randall & Selitto 1957) (Ugo Basile). An increasing force was applied to the dorsal surface of each hind paw in turn until a withdrawal response was observed. The application of force was halted at this point and the weight in grams recorded. Data was expressed as withdrawal threshold in grams for ipsilateral and contralateral paws. Following the establishment of baseline readings mice were divided into 2 groups with approximately equal ipsilateral/contralateral ratios which underwent surgery to partially ligate the sciatic nerve or served as sham operated controls. Operated mice were anaesthetised with isoflurane. Following this approximately 1 cm of the left sciatic nerve was exposed by blunt dissection through an incision at the level of the mid thigh. A suture (9/0 Virgin Silk: Ethicon) was then passed through the dorsal third of the nerve and tied tightly. The incision was then closed using glue and the mice were allowed to recover for at least six days prior to commencement of testing. Sham operated mice underwent the same protocol but following exposure of the nerve the mice were sutured and allowed to recover.
    Mice were tested for onset of hyperalgesia on days 7 and 10 post surgery. Any mice showing an ipsilateral/contralateral ratio of greater than 80% were classed as non-responders and removed from the study. Following testing on day 10 mice were further sub-divided into groups giving the final treatment groups;
  • A. Group 1: Sham operated+NIP 228 TM 5 μg per mouse intra-thecal (N=10)
  • B. Group 2: Nerve ligated+NIP 228 TM 5 μg per mouse intra-thecal (N=10)
  • C. Group 3: Nerve ligated+Antibody No. 208 5 μg per mouse intra-thecal (N=10)
  • D. Group 4: Nerve ligated+Antibody No. 38 5 μg per mouse intra-thecal (N=10)
  • Mice were administered NIP 228 TM (Isotype control) or test molecules on day 13 and were re-tested for changes in mechanical hyperalgesia at 4 hrs post dose and also on 1, 2, 4 and 7 days post dose. For dosing mice were anaesthetised with isoflurane. Intra-thecal administration was carried out manually into the L4-L6 area of the spinal cordNIP 228 TM and all test compounds were supplied as 1.02 mg/ml=solutions=1 μg per μl=5 μg per mouse.
    Ipsilateral and contralateral readings were taken for each animal at each test time and were entered into EXCEL for calculation of ipsilateral/contralateral ratios. Summary data was transferred into PRISM for graphical and statistical analysis. Results were analysed using 2-way ANOVA. Pairwise comparisons where appropriate were made using Tukey's test.
    Analysis of the results showed that partial ligation of the sciatic nerve caused a mechanical hyperalgesia which manifested as a significant reduction in the ipsilateral/contralateral ratio on day 7 and 10 when compared to sham operated controls. Following treatment with NIP228, operated mice did not show any change in the level of mechanical hyperalgesia from pre-dose levels indicating a lack of effect of the isotype control on mechanical hyperalgesia. The administration of Antibody No. 208 produced a significant reversal which was significant for up to 4 days post dose after which the response returned to baseline levels. Similar effects were seen with Antibody No. 38 (FIG. 13).
    • Example 10: Generation of Mouse Anti-Human P2X4 Antibodies by Hybridoma Technology
  • Methods for Mouse Anti-Human P2X4 Antibody Generation were Carried Out in the Same Way as Described in the Previous Section of Rat Anti-Murine P2X4 Antibody Generation, Other than the Following Differences:
    • Immunisations
  • Human P2X4 (hP2X4) transfected HEK 293F and XS63 cells were used to immunise CD1 mice in three groups. In group 1, mice were immunised with hP2X4 transfected HEK 293F cells, group 2 mice were immunised with hP2X4 transfected XS63 cells, and group 3 mice were immunised by alternating hP2X4 transfected XS63 cells and hP2X4 transfected HEK 293F cells. hP2X4 transfected cells were re-suspended at 1E8/mL and emulsified with equal volumes of complete Freund's adjuvant, and injected into mice at two sites, 100 μL per site. For the subsequent 3 injections, the same number of cells was emulsified in Freund's incomplete adjuvant and injections were performed as above. The last boost was carried out on day 24, injecting 200 μL of transfected cells at 1E8/mL intraperitoneally.
    Assessment of Mouse Immune Response to hP2X4 Using a Cell-Based DELFIA
    The serum IgG titres to hP2X4 were determined by a cell-based time-resolved fluorescence assays (DELFIA) using parental HEK 293F cells and hP2X4 transfected HEK 293F cells.
    • Monoclonal Mouse IgG Isolation
  • Lymphoid cells isolated from spleens and lymph nodes were fused with SP2/0 myeloma cells using an electrofusion method. The fusions were plated out into semi-solid selection media containing FITC conjugated goat anti-mouse IgG.
    • Cell Binding Assay for Mouse IgGs
  • Supernatants were initially screened for IgGs that specifically bound to hP2X4 using both the hP2X4 expressing HEK 293F and XS63 cells, and parental HEK 293F cells. The IgGs that showed specific binding to hP2X4, and no binding to parental HEK293F cells, were selected for further specificity testing on mouse P2X4 (mP2X4) HEK 293F cells. IgGs which specifically bound to hP2X4 or to both hP2X4 and mP2X4 were selected for antibody purification and functional analysis by electrophysiology.
    • DNA Sequencing and Purification of Mouse IgGs
  • Messenger RNA (mRNA) was extracted from hybridoma cells using magnetic oligo (dT) particles and reverse transcribed into cDNA. Polymerase chain reaction (PCR) amplification was performed using poly-C and constant region VH or VL primers specific to all mouse IgG subclasses.
    Mouse IgGs of all subclasses (IgG1, IgG2a, IgG2b and IgG3) were purified from overgrown cell culture supernatants on ProPlus resin (Phynexus).
    • Functional Screening by Electrophysiology
  • HEK 293F cells stably expressing human P2X4 (Uniprot # Q99571) were harvested at 50% confluency using accutase. Cells were then resuspended in 10 ml Freestyle 293F media supplemented with HEPES (10 mM)+apyrase (1 U/ml, ATPase/ADPase activity=1) at a density of 2-3e6 cells/ml. P2X4 function was assayed using the automated electrophysiology platform QPatch 16X (Sophion) in population patch configuration. Composition of QPatch extracellular buffer (QEB) was (in mM) NaCl (140), KCl (2), MgCl2 (1) CaCl2 (2), HEPES (10). Final composition of compound plate extracellular buffer (CPEB2) was NaCl (115.5), KCl (1.3), MgCl2 (0.66), CaCl2 (1.32), HEPES (56.1). pH of extracellular buffers was adjusted to 7.4 with NaOH (1 M) and the solutions were 0.2 μm filtered. The QPatch intracellular buffer contained (in mM) CsF (140), NaCl (10), EGTA (1), HEPES (10). pH of the intracellular buffer was adjusted to 7.3 with CsOH (1 M) and the solution was 0.2 m filtered. IgGs were titrated to pH 7.4 with NaOH (1 M). After obtaining whole cell configuration, cells were voltage clamped at −50 mV with 70% series resistance compensation employed. The ligand agonist adenosine 5′-triphosphate disodium salt (ATP, 3 μM) in QEB was applied for 3 seconds then washed off with QEB+apyrase (1 U/ml). CPEB2+IgG was then incubated for 3 minutes followed by a second ATP addition. Data were leak subtracted by subtracting the current in the absence of ligand and the magnitude of the P2X4 response measured as the peak inward current in the presence of ligand. The ATP response after IgG addition was expressed as a fraction of the ATP response prior to IgG addition. The hIgG1 NIP 228 TM was used as a control antibody to determine the cutoff for defining functional antibodies. Antibody sequences are provided in FIG. 13.
    • Example 11: Affinity Maturation of Antibody 11
  • Antibody No. 11 was optimised for affinity via two approaches either; targeted or random mutagenesis followed by affinity-based phage display selections. In the targeted approach, large scFv-phage libraries derived from the lead clone were created by oligonucleotide-directed mutagenesis of the variable heavy (VH) complementarity determining regions 3 (CDR3) and light (VL) chain CDR3 using standard molecular biology techniques as described (Clackson, T and Lowman, H. B. Phage Display A Practical Approach, 2004. Oxford University Press). The libraries were subjected to affinity-based phage display selections in order to select variants with higher affinity for human P2X4. The selections were performed essentially as described previously in Example 3 with the exception of lowering the concentration of immobilised human P2X4 over four rounds of selection (10 μg/ml-1.25 μg/ml). Antibodies with improved affinity were identified in a competition assay based on Antibody 11 binding to huP2X4 expressing cells (described in Example 12). To generate further affinity improvement, CDR mutations from improved antibodies were recombined into new scFvs using standard molecular biology techniques.
  • Antibody 11 was also optimised using a random mutagenesis approach to identify key residues within the entire variable domain that may improve binding to human P2X4. Such a technique is described by Gram et al. [Gram et al., 1992, Proc. Natl. Acad. Sci., USA, 89:3576-3580], who used error-prone PCR. In some embodiments one or two amino acid substitutions are made within an entire variable domain or set of CDRs. The generated library was subjected to affinity-based selections as described for the targeted selections outlined above.
    Exemplary antibodies from this selection method are disclosed herein as Antibodies 287 to 315, and an alignment of their sequences is shown in FIG. 12.
    • Example 12: Identification of Higher Affinity Antibodies Against Human P2X4
  • Phage display selection outputs described in example 11, were screened for activity in a competition assay based on Antibody 11 binding to huP2X4 expressing cells. Briefly Antibody 11 IgG was labelled with DyLight® 650 using a Lightning-Link® Rapid DyLight® 650 conjugation kit following the manufacturer's instructions (Innova Biosciences Ltd). Bacterially expressed scFv were collected into 0.2M HEPES buffer pH7.4, 0.5 mM EDTA and 0.5 M sucrose as peri plasmic extracts and added to the assay plate (Corning® 3655) together with assay buffer (HBSS, 0.1% BSA, 1 U/ml apyrase, either with or without 20 mM HEPES). Antibody 11-Dylight® 650 was added to each well except the wells used to define the background binding, to a final concentration of 2 nM. HEK293F huP2X4 cells were added to each well at a final density of approximately 2000 cells per well. Plates were covered and incubated at room temperature for 2 to 3 hours before reading on a Mirrorball® plate reader (TTP Labtech, Ltd) and determining the total FL3 fluorescence per well (Median (mean intensity) fluorescence multiplied by the number of objects). Individual events were gated on size and fluorescence and a minimum object number of greater than 25 was used to determine wells with sufficient events to report a FL3 total value. % specific binding was calculated for each well using the following equation, maximal FL3 total values were defined from wells that did not receive any scFv but did receive peri plasmic sample buffer:
  • % specific binding = sample FL 3 total - background FL 3 total maximal FL 3 total - background FL 3 total × 100
  • Samples where the binding signal was lower than 85% specific binding were selected for sequencing and sequence unique hits were generated as purified scFv.
    To confirm the inhibition of these scFv antibodies, purified scFv antibodies were diluted in assay buffer described above to generate a dilution series and the diluted samples were added to the assay plate before the addition of Antibody 11-DyLight® 650 to a final concentration of 2 nM, followed by approximately 2000 HEK293F huP2X4 cells per well. Plates were incubated at room temperature for 2 to 3 hours before being read on the Mirrorball® plate reader. Data was analysed as described above and scFv clones showing inhibition were generated as full IgG antibodies.
    • Example 13: Identification of Antibodies with Improved Potency Against Human P2X4 Using the Human P2X4 1321N1 Cell Line FLIPR® Assay
  • Antibodies identified in the Antibody 11 competition assay described in example 12 were generated as purified IgG and titrated to generate a dilution series. These antibodies were diluted in assay buffer containing HBSS and 0.1% BSA and pre-incubated with 1321N1 cells expressing huP2X4 for 30 mins where the cells had previously been loaded with Fluo-4 NW calcium dye (Molecular Probes™, Life Technologies) following the manufacturer's instructions. P2X4 was activated by the addition of 1 μM ATP diluted in assay buffer and the resulting rise in intracellular calcium was detected by the calcium dye and measured by an increase in fluorescence using the FLIPR® Tetra plate reader (Molecular Devices, LLC). Data was calculated to determine the maximum fluorescence observed over the background fluorescence for the duration of the assay. These data were then analysed to determine % maximal response over the buffer response alone seen in wells where ATP was omitted, using the following equation:
  • % maximal response = sample response - buffer response total response - buffer response × 100
  • Data was analysed in Prism (GraphPad Software, Inc) to determine IC50 values using the following equation:

  • Y=Bottom+(Top−Bottom)/(1+10{circumflex over ( )}((LogIC50−X)*HillSlope))
  • To enable ranking of antibodies the top and bottom of the curves were constrained to 100 and 0 respectively. Geometric means of the IC50 values for the antibodies tested are listed in FIG. 15 and an example of the IC50 curves for two antibodies are shown in FIG. 19 together with an isotype control antibody
    • Example 14: Identification of Antibodies with Improved Potency Against Human P2X4 Using the HEK 293F huP2×4 Cell Line on the Automated Electrophysiology Platform Qpatch 16X
  • HEK 293F cells stably expressing human P2X4, were harvested at 50% confluency using accutase. Cells were then resuspended in 10 ml Freestyle 293F media supplemented with HEPES (10 mM)+apyrase (1 U/ml, ATPase/ADPase activity=1) at a density of 2-3e6 cells/ml. P2X4 function was assayed using the automated electrophysiology platform QPatch 16X (Sophion) in population patch configuration. Composition of QPatch extracellular buffer (QEB) was (in mM) NaCl (140), KCl (2), MgCl2 (1) CaCl2 (2), HEPES (10). pH of extracellular buffers was adjusted to 7.4 with NaOH (1 M), osmolarity was adjusted to 300 mOsm with sucrose and the solutions were 0.2 μm filtered. The QPatch intracellular buffer (QIB) contained (in mM) CsF (140), NaCl (10), EGTA (1), HEPES (10). pH of the intracellular buffer was adjusted to 7.3 with CsOH (1 M) and the solution was 0.2 m filtered. IgGs were titrated to pH 7.4 with NaOH (1 M).
  • For determination of the potency of optimized variants of Antibody 11, IgGs were serially diluted in QEB+0.1% bovine serum albumin and tested for function on Qpatch 16X in population patch configuration. Extracellular buffer was QEB, intracellular buffer was QIB and ATP wash buffer was QEB+apyrase (1 U/ml). In this assay, ATP (3 μM) was applied every 10 mins for 3 s with a total of 5 applications per experiment. The first two ATP additions (ATP 1 & ATP 2) were preceded by preincubation for 5 mins with QEB buffer+0.1% BSA whereas the following three ATP additions were preceded by 5 mins incubation with ascending doses of IgG. Log and half log doses of IgG were interleaved in post analysis to generate 6 point dose response curves (dose range 100-0.3 nM). Data were leak subtracted by subtracting the current in the absence of ligand and the magnitude of the P2X4 response measured as the peak inward current in the presence of ligand. The peak inward current in response to ATP was expressed as fraction of control current (ATP2) and labeled as I/Ibasal. Data were fit in Prism using a log (inhibitor) vs. response−Variable slope (four parameters) equation. Y=Bottom+(Top−Bottom)/(1+10{circumflex over ( )}((LogIC50−X)*HillSlope)). The top of the IgG dose response curves was defined by the response to 0.3 nM NIP 228 and constrained to this value. The bottom of the curve was constrained such that it was greater than zero. See FIG. 14-15.
    • Example 15 Potency Determination of Hybridoma Derived Antibodies at Mouse and Human P2X4
  • HEK 293F cells expressing P2X4 were handled as in example 8. Potency of hybridoma derived IgGs was assayed on Qpatch 16X in population patch configuration. For determination of IgG potency, IgGs were serially diluted in PBS+0.1% bovine serum albumin and tested for function on Qpatch 16X in population patch configuration. IgGs were then diluted 1:3 in QEB+0.1% BSA resulting in a final buffer composition of NaCl (137.6), KCl (2.2), MgCl2 (0.66), CaCl2 (1.3), HEPES (6.6), KH2PO4 (0.49), NaH2PO4 (2.66), BSA (0.1%) equivalent to CPEB1. Extracellular buffer was QEB, intracellular buffer was QIB and ATP wash buffer was QEB+apyrase (1 U/ml). In this assay, ATP (3 μM) was applied every 10 mins for 3 s with a total of 5 applications per experiment. The first two ATP additions (ATP 1 & ATP 2) were preceded by preincubation for 5 mins with CPEB1+0.1% BSA whereas the following three ATP additions were preceded by 5 mins incubation with ascending doses of IgG. Log and half log doses were interleaved in post analysis to generate 6 point dose response curves. Data were leak subtracted by subtracting the current in the absence of ligand and the magnitude of the P2X4 response measured as the peak inward current in the presence of ligand. The peak inward current in response to ATP was expressed as fraction of control current (ATP2). Data were fit in Prism using a log (inhibitor) vs. response−Variable slope (four parameters) equation. Y=Bottom+(Top−Bottom)/(1+10{circumflex over ( )}((LogIC50−X)*HillSlope)). The top of the IgG dose response curves was constrained to 1 whereas the bottom of the curve was constrained such that it was greater than zero. See FIG. 16.
    • Example 16 Efficacy of Mouse Reactive Antibodies at Native Mouse Microglial P2X4 Culture of Mouse Microglia:
  • Primary mouse microglia were cultured from C57 neonatal pups, P2. Brains were removed from the skulls of mice and kept in media (DMEM+10% FCS+pen/strep). They were then rolled across filter paper to remove the sticky vasculature and meninges before placing in 20 ml fresh media and triturating to give a single cell suspension. Cells were then filter sterilised through a 40 μm cell strainer then centrifuged at 1200 rpm for 5 min. Cells were then resuspended in 40 ml media per flask at 4 brains per T175 flask and cultured for 1 week. After this, the media was supplemented with GM-CSF (5 ng/ml) and the cells cultured for a further week. Microglia were removed by shaking overnight in an orbital shaker incubator (no CO2) with HEPES supplemented in the media (20 mM). Purified microglia were centrifuged at 1200 rpm for 5 mins and resuspended in 20 ml DMEM+10% FCS+pen/strep growth media. Cells were counted and seeded in ultra low bind T75 cell culture flasks (Corning) at 7e6 cells/flask. Microglia were then maintained in culture for 1-7 days before being used for Qpatch 16X electrophysiology assays or FLIPR calcium imaging assays.
    • Cell Handling Qpatch:
  • 1×T75 flask was washed twice with dPBS and cells were harvested using accutase treatment for 5-10 mins. Cells were then resuspended in 293F Freestyle media+20 mM HEPES+1 U/ml accutase (10 ml) and spun down at 800 rpm for 5 mins. Cells were then resuspended in 3 ml 293F Freestyle media+20 mM HEPES+1 U/ml accutase and 1 ml of cell suspension used per experiment.
    Qpatch 16X was used in population patch configuration and cells voltage clamped at −70 mV. Cells were perfused with either a control antibody or test antibody for 5 minutes before ATP (30 μM) was applied. Current in the absence of ATP was subtracted from all data. Inward current in response to ATP was measured (see FIG. 15). External buffer was QEB and internal buffer was QIB. See FIGS. 17 & 18.
    • FLIPR:
  • Microglia were plated in Cell Coat Poly-D-Lysine coated 384 well plates (black, uclear) with 30 μl per well and cultured in a humidified incubator at 37° C. for 48 hours.
    Media was removed and replaced with 20 ul per well of HBSS buffer+20 mM HEPES+0.1% BSA, supplemented with Screen Quest™ Fluo-8 No Wash Calcium Assay Kit (AAT Bioquest, Inc.) as per the manufacturers instructions. Cells were then incubated at 37° C. for 30 mins then returned to room temperature for 15 mins before assaying on FLIPR (Molecular devices). Ivermectin (12 μM) was made up in a further 384 well compound plate (Compound plate 1). IgGs were made up in PBS+0.1% BSA (compound plate 2). ATP (30 uM) was made up in HBSS+20 mM HEPES+0.1% BSA in a separate 384 well compound plate (Compound plate 3). Fluo-8 was excited at a wavelength of 470-495 nm and the emitted light measured at a wavelength of 515-575 nm. Camera gain was adjusted to give 1000 counts at rest with an exposure of 0.4 s. 10 ul of solution from compound plate 1 was added to the cells and the fluorescence measured. After 5 mins incubation, 10 ul of solution from compound plate 2 was added. 15 min later, ATP (5 uM final) was added and the peak end fluorescence measured between 200-300 sec post ATP addition. Fluorescence counts were normalised to the ATP response in the absence of antibody (minus background fluorescence) and plotted as % of ATP response (See FIG. 21). 10 point dose response curves for each IgG were constructed from duplicate wells and the data fit in Prism using a log (inhibitor) vs. response−Variable slope (four parameters) equation. Y=Bottom+(Top−Bottom)/(1+10{circumflex over ( )}((LogIC50−X)*Hill Slope)). See FIG. 20.
    • Example 17: Functional Effect of P2X4 Antibodies on Human Monocyte Derived Macrophages Cell Culture
  • Human monocytes were isolated from the mononuclear fraction of peripheral blood by centrigugation on a Ficoll-Paque gradient. Cells were then purified by incubating in a T175 cell culture flask in cell culture media in the absence of serum for 1 hour. Non-adherent cells were removed and the remaining cells grown in RPMI Glutamax I media supplemented with 10% FCS (HI/GI)+1% P/S+100 ng/ml M-CSF for 7 days. Cells were fed on day 2-3 by adding an additional 10 ml of media. Macrophage were harvested by accutase treatment for 10 mins followed by cell scraping and replated in ultra-low bind T75 flasks at 6e6 cells per flask. Cells were then cultured for a further 1-10 days before being used for electrophysiological recording. On the day of experiment, cells were harvested with accutase and resuspended in 3 ml CHO ACF media+20 mM HEPES. 1 ml of cell suspension was used per experiment on Qpatch 16X in population patch configuration. Qpatch 16X assay parameters were as described for example 16. Nippon antagonist refers to 1H-naphtho[1,2-b][1,4]diazepine-2,4(3H,5H)-dione (described in Patents WO-2010/093061 and EP2397480A1 See FIGS. 21 & 22.
    • OTHER EMBODIMENTS
  • From the foregoing description, it will be apparent that variations and modifications may be made to the invention described herein to adopt it to various usages and conditions. Such embodiments are also within the scope of the following claims.
  • The recitation of a listing of elements in any definition of a variable herein includes definitions of that variable as any single element or combination (or subcombination) of listed elements. The recitation of an embodiment herein includes that embodiment as any single embodiment or in combination with any other embodiments or portions thereof.
  • All patents and publications mentioned in this specification are herein incorporated by reference to the same extent as if each independent patent and publication was specifically and individually indicated to be incorporated by reference.

Claims (20)

What is claimed is:
1. An antibody or antigen binding fragment thereof that specifically binds a human P2X4 polypeptide and modulates channel activity.
2. The antibody of claim 1, wherein the antibody is a P2X4 potentiator.
3. The antibody of claim 1, wherein the antibody is a P2X4 antagonist.
4. The antibody of claim 1, wherein the antibody binds an epitope comprising human P2X4 amino acids 110-166.
5. The antibody of claim 4, wherein the antibody binds an epitope comprising one or more human P2X4 amino acids selected from the group consisting of amino acids 118, 122-139, 145, 159, 180, 183, 184, 231, and 244.
6. The antibody of claim 1, wherein the antibody or fragment thereof comprises:
a. a heavy chain variable region CDR1 comprising a sequence:
(SEQ ID NO: 1009) X1X2X3X4X5,
wherein
X1 is G, N, S, D, or R;
X2 is Y, A, H, F, or S;
X3 is A, W, Y, S, G, F, W, E, D, or P;
X4 is M, I, W, L, I, F, or V;
X5 is S, G, T, H, or N; and/or
b. a heavy chain variable region CDR2 comprising a sequence:
(SEQ ID NO: 1010) X1X2X3X4X5X6X7X8X9X10X11X12X13X14X15X16,
wherein
X1 is A, R, I, T, E, S, A, V, W, N, G, E, R, or Y;
X2 is I or M;
X3 is S, K, Y, D, N, W, or I;
X4 is S, D, G, H, N, R, Y, or V;
X5 is G, D, S, F, N, R, F, D, or T;
X6 is G, S, N, or T;
X7 is S, T, D, Y, N, A, E, M, F, or D;
X8 is T, I, K, or A;
X9 is Y, D, R, N, G, Q, E, H, or K;
X10 is Y, Q, S, or V;
X11 is A, S, N, or V;
X12 is D, A, P, R, or Q;
X13 is S, P, K, or N;
X14 is V, F, L, or A;
X15 is K, Q, or E;
X16 is G, S, A, or D;
wherein the heavy chain variable region CDR2 optionally comprises an insertion of 1-3 amino acids, XaXbXc between amino acids X3 and X4, wherein
Xa is G, S, P, W, Y, E, A, R, or N; and
XbXc are KT, respectively
and/or
c. a heavy chain variable region CDR3 comprising a sequence:
(SEQ ID NO: 1011) X1X2X3X4X5X6X7X8,
X1 is E, N, D, R, K, G, S, A, Y, V, P, or H;
X2 is E, L, R, Q, T, G, F, P, Y, K, A, S, V, or F;
X3 is R, A, T, G, V, S, M, W, Y, D, H, N, E, L, or I;
X4 is G, L, R, D, T, G, Y, S, E, F, Q, C, I, M, V, N, K, or P;
X5 is S, G, Y, D, W, T, S, N, I, D, V, E, or C;
X6 is Y, A, S, W, T, L, G, E, F, K, V, I, or D;
X7 is D, E, or G; and
X8 is Y, S, V, L, M, Q, I, S, I, H, F, or D;
wherein the heavy chain variable region CDR3 optionally comprises an insertion of 1-14 amino acids Xa-Xn (SEQ ID NO: 1012), wherein
Xa is F, R, S, Y, L, D, G, V, I, T, or A;
Xb is G, R, Y, F, T, D, S, G, V, M, D, or R;
Xc is F, W, A, G, T, I, S, F, Y, C, L, V, R, or N;
Xd is S, F, M, G, Y, L, S, A, D, L, R, V, C, or S;
Xe is G, Y, S, T, P, F, Y, R, A, E, G, Q, N, or L;
Xf is Y, N, G, T, R, F, A, M, W, P, or V;
Xg is Y, M, S, V, F, A, P, S, D, R, H, P, E, or R
Xh is Y, G, M, F, G, P, V, F, H, T, or G,
Xi is T, I G, R, or F;
Xj is Y, G, H, or E;
Xk is Y, G, F, or N;
X1 is F, or N;
Xm is Y; and
Xn is F.
7. The antibody of claim 1, wherein the antibody or fragment thereof comprises,
a. a light chain variable region CDR1 comprising a sequence:
(SEQ ID NO: 1013) X1X2X3X4X5X6X7X8X9X10X11,
wherein
X1 is T, G, R, S, or Q;
X2 is G, A, or L;
X3 is S, T, D, or H;
X4 is S, N, K, A, Q, T, or V;
X5 is G, I, L, S, or D;
X6 is A, G, R, P, I, D, S, E, or T;
X7 is G, N, M, D, K, S, R, Y, or T;
X8 is Y, K, F, Q, S, N, Y, D, H, or R;
X9 is D, N, Y, W, F, M, G, or S;
X10 is V, A, L, I, G, or P;
X11 is H, T, S, Y, A, Q, Y, N, or F;
wherein the light chain variable region CDR1 optionally comprises an insertion of between 1 and 3 amino acids Xa-Xc between X4 and X5, wherein
Xa is S or G;
Xb is N, D or S; and
Xc is I or V;
b. a light chain variable region CDR2 comprising a sequence:
(SEQ ID NO: 1014) X1X2X3X4X5X6X7,
wherein
X1 is G, Y, Q, K, N, D, R, A, or E;
X2 is N, D, K, A, V, G, or T;
X3 is N, S, T, I, K, Y, or D;
X4 is N, D, Y, K, E, T, N, S, or Q;
X5 is R, or L;
X6 is P, E, A, S, or Q;
X7 is S, P, or T; and/or
c. a light chain variable region CDR3 comprising a sequence:
(SEQ ID NO: 1015) X1X2X3X4X5X6X7X8X9,
wherein
X1 is Q, N, A, G, D, S, or L;
X2 is S, V, A, Q, T, L, or H;
X3 is Y, W, R, A, S, Q, T, or G;
X4 is D, Y, I, N, M, or H;
X5 is T, M, S, N, D, R, G, or K;
X6 is N, T, S, G, F, L, or D;
X7 is L, T, G, P, A, I, or N;
X8 is K, W, V, I, P, G, L, R, or Y; and
X9 is V, L, or T;
wherein the light chain variable region CDR3 optionally comprises an insertion of between 1 and 3 amino acids Xa-Xc between X7 and Xs, wherein
Xa is D, N, A, T, S, I or H;
Xb is H, Y, G, A, R, L, S, or P; and
Xc is S.
8. The antibody of claim 1, wherein the antibody or fragment thereof comprises a VH comprising:
a. a heavy chain variable region CDR1 comprising the sequence: SX1AMS (SEQ ID NO: 1016) where X1 is Y or F;
b. a heavy chain variable region CDR2 comprising the sequence: AISGSG XISTYYADSVKG (SEQ ID NO: 1017) where X1 is S or G;
c. a heavy chain variable region CDR3 comprising the sequence:
X1X2DX3WSX4X5X6X7X8TAFDL (SEQ ID NO: 1018), where X1 is H, D or Q; X2 is W, M, F, H, or R; X3 is W, Y or F; X4 is T, N, G, or P; X5 is R, A, S, G, or Y; X6 is S, P, N or T; X7 is G, S, R, or K: X8 is P, M, A or L.
optionally in combination with a VL comprising
a. a light chain variable region CDR1 comprising the sequence SGDALPRQYAY (SEQ ID NO: 1019)
b. a light chain variable region CDR2 comprising the sequence KDSX1RPS (SEQ ID NO: 1020) where X1 is E or F.
c. a light chain variable region CDR3 comprising the sequence QSADSSGTYXIV (SEQ ID NO: 1021), where X11s V or A.
9. The antibody of claim 8, wherein the antibody or fragment thereof comprises a VH comprising:
a. a heavy chain variable region CDR1 comprising the sequence: SFAMS (SEQ ID NO: 813);
b. a heavy chain variable region CDR2 comprising the sequence: AISGSG GSTYYADSVKG (SEQ ID NO: 814);
c. a heavy chain variable region CDR3 comprising the sequence:
(SEQ ID NO: 815) QFDYWSTYSGPTAFDL;
in combination with a VL comprising
a. a light chain variable region CDR1 comprising the sequence SGDALPRQYAY (SEQ ID NO: 822)
b. a light chain variable region CDR2 comprising the sequence KDSERPS (SEQ ID NO: 823)
c. a light chain variable region CDR3 comprising the sequence QSADSSGTYVV (SEQ ID NO: 824).
10. The antibody of claim 1, wherein the antibody or fragment thereof comprises:
a. a heavy chain variable region CDR1 comprising a sequence:
(SEQ ID NO: 1022) X1X2X3X4X5,
wherein
X1 is S, N, D, T, or R;
X2 is G, Y, or F;
X3 is Y, H, S, G, D, or F;
X4 is D, V, or I;
X5 is N, H, C, R, S or is absent;
wherein the heavy chain variable region CDR1 optionally comprises amino acids X6 and X7, which are V and S, respectively;
b. a heavy chain variable region CDR2 comprising a sequence:
(SEQ ID NO: 1023) X1X2X3X4X5X6X7X8X9X10X11X12X13X14X15X16,
wherein
X1 is M, V, L, I, A, G, or T;
X2 is G or I;
X3 is Y, W, N, or C;
X4 is Y, G, D, or W;
X5 is S, D, or E;
X6 is G or D;
X7 is S, Y, N, or I;
X8 is T, P, or K;
X9 is N, A, G, D, or V;
X10 is Y or F;
X11 is N;
X12 is P, S, or E;
X13 is S, A, or N;
X14 is L or F;
X15 is K;
X16 is S, G, or N;
wherein the heavy chain variable region CDR2 optionally comprises an insertion of amino acids Xa and Xb between X3 and X4, wherein Xa is I or P and Xb is S;
c. a heavy chain variable region CDR3 comprising a sequence:
(SEQ ID NO: 1024) X1X2X3X4X5X6X7X8,
wherein
X1 is G, S, A, or R;
X2 is M, G, Y, S, L, R, or V;
X3 is M, D, I, V, H, M, or S;
X4 is V, Y, M, W, or S;
X5 is L, Y, S or absent;
X6 is I, D, V, T, G, S, Y, or absent;
X7 is P, G, D, S, or A; and
X8 is N, Y, or T;
wherein the heavy chain variable region CDR3 optionally comprises an insertion of between 1 and 6 amino acids of Xa-Xf (SEQ ID NO: 1025) between X6 and X7, wherein
Xa is G, T, D, or Y;
Xb is S, A, G, or F;
Xc is Y, V, P, or F;
Xd is Y or F;
Xe is Y; and
Xf is E, F, or G.
11. The antibody of claim 1, wherein the antibody or fragment thereof comprises:
a. a light chain variable region CDR1 comprising a sequence:
(SEQ ID NO: 1026) X1X2X3X4X5X6X7X8X9X10X11,
wherein
X1 is K, Q, or R;
X2 is A or T;
X3 is S, R, or N;
X4 is K or Q;
X5 is S, D, R, N, L, or I;
X6 is I or S;
X7 is T, G, V, or N;
X8 is N, S, H, or K;
X9 is Y or W;
X10 is L, M, or I;
X11 is A, S, or Y;
b. a light chain variable region CDR2 comprising a sequence:
(SEQ ID NO: 1027) X1X2X3X4X5X6X7,
wherein
X1 is S, D, E, or Y;
X2 is G, A, or T;
X3 is S or T;
X4 is T, S, K, or A;
X5 is L;
X6 is Q, A, or V;
X7 is S or D;
c. a light chain variable region CDR3 comprising a sequence:
(SEQ ID NO: 1028) X1X2X3X4X5X6X7X8X9,
wherein
X1 is Q, L, or H
X2 is Q or K;
X3 is Y, A, W, or T;
X4 is Y, H, S, or D;
X5 is E, S, R, T, or N;
X6 is K, N, T, L, or H;
X7 is P;
X8 is Y, W, L, N, P, or R;
X9 is T.
12. A polynucleotide encoding the antibody or antigen binding fragment thereof of claim 1.
13. A host cell comprising a vector comprising the polynucleotide of claim 12.
14. A method for treating neuropathic pain, the method comprising administering to a patient in need thereof an effective amount of an antibody of claim 1 or antigen binding fragment thereof.
15. A method for the large scale production of a recombinant P2X4 polypeptide, the method comprising expressing a human P2X4 protein in an SF9 cell at 27° C. for 72 hours;
extracting the P2X4 protein by solubilizing in a buffer comprising n-Dodecyl-beta-D-Maltoside, n-Dodecyl thio-Maltoside, CHAPS, and the Cholesteryl Hemisuccinate;
then isolating the solubilized protein.
16. A pharmaceutical composition comprising one or more antibodies or antigen binding fragment thereof according to claim 1 and a pharmaceutically acceptable excipient.
17. A pharmaceutical composition comprising one or more antibodies or antigen binding fragment thereof according to claim 8 and a pharmaceutically acceptable excipient.
18. A polynucleotide encoding the antibody or antigen binding fragment thereof of claim 8.
19. A host cell comprising a vector comprising the polynucleotide of claim 18.
20. A method for treating neuropathic pain, the method comprising administering to a patient in need thereof an effective amount of an antibody of claim 8 or antigen binding fragment thereof.
US16/840,910 2014-05-02 2020-04-06 P2x4 antibodies & uses thereof Abandoned US20200247885A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/840,910 US20200247885A1 (en) 2014-05-02 2020-04-06 P2x4 antibodies & uses thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461987929P 2014-05-02 2014-05-02
PCT/EP2015/059633 WO2015166105A2 (en) 2014-05-02 2015-05-02 Ion channel modulators and uses thereof
US201615308294A 2016-11-01 2016-11-01
US16/840,910 US20200247885A1 (en) 2014-05-02 2020-04-06 P2x4 antibodies & uses thereof

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US15/308,294 Continuation US10654926B2 (en) 2014-05-02 2015-05-02 P2X4 antibodies and uses thereof
PCT/EP2015/059633 Continuation WO2015166105A2 (en) 2014-05-02 2015-05-02 Ion channel modulators and uses thereof

Publications (1)

Publication Number Publication Date
US20200247885A1 true US20200247885A1 (en) 2020-08-06

Family

ID=53055033

Family Applications (2)

Application Number Title Priority Date Filing Date
US15/308,294 Active US10654926B2 (en) 2014-05-02 2015-05-02 P2X4 antibodies and uses thereof
US16/840,910 Abandoned US20200247885A1 (en) 2014-05-02 2020-04-06 P2x4 antibodies & uses thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US15/308,294 Active US10654926B2 (en) 2014-05-02 2015-05-02 P2X4 antibodies and uses thereof

Country Status (8)

Country Link
US (2) US10654926B2 (en)
EP (2) EP3137501B1 (en)
JP (2) JP2017515473A (en)
AU (1) AU2015254558B2 (en)
BR (1) BR112016025450A2 (en)
CA (1) CA2946669A1 (en)
ES (1) ES2899754T3 (en)
WO (1) WO2015166105A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11266690B2 (en) * 2018-02-01 2022-03-08 Nanjing Iaso Biotherapeutics Co., Ltd. Chimeric antigen receptor (CAR) binding to BCMA, and uses thereof
WO2020186158A2 (en) * 2019-03-13 2020-09-17 Ulmert Hans David Staffan Prame binding molecules and uses thereof
WO2021041194A1 (en) * 2019-08-23 2021-03-04 Unm Rainforest Innovations Non-opioid compositions and therapies for pain management
MX2022005983A (en) * 2019-11-18 2022-09-07 Janssen Biotech Inc Anti-cd79 chimeric antigen receptors, car-t cells, and uses thereof.
CA3195817A1 (en) * 2020-10-16 2022-04-21 Brian Scott GARRISON Chimeric receptors and methods of use thereof
CN114685657A (en) * 2020-12-31 2022-07-01 康诺亚生物医药科技（成都）有限公司 Development and application of function-enhanced antibody blocking agent
WO2023114962A1 (en) * 2021-12-16 2023-06-22 Unm Rainforest Innovations Humanized non-opioid composition and therapies for pain management

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11214622B2 (en) * 2013-04-03 2022-01-04 Roche Glycart Ag Antibodies specific for DR5 and methods of use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS63502716A (en) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー How to enhance glycoprotein stability
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6242216B1 (en) * 1997-11-14 2001-06-05 Abbott Laboratories Nucleic acids encoding a functional human purinoreceptor P2X2 and P2X4, and methods of production and use thereof
AUPP991199A0 (en) * 1999-04-21 1999-05-13 University Of Sydney, The Methods for diagnosing pre-cancerous and cancerous conditions
AUPR201500A0 (en) * 2000-12-11 2001-01-11 Biosceptre Pty Ltd Methods for identifying pre-neoplastic and neoplastic states in mammals
US20050074819A1 (en) 2003-10-01 2005-04-07 Japan Health Sciences Foundation Screening method of drug for treatment of neuropathic pain
JPWO2005107804A1 (en) * 2004-05-06 2008-03-21 小野薬品工業株式会社 Respiratory disease treatment
KR101727761B1 (en) 2009-02-16 2017-04-17 닛뽕 케미파 가부시키가이샤 Diazepinedione derivative

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11214622B2 (en) * 2013-04-03 2022-01-04 Roche Glycart Ag Antibodies specific for DR5 and methods of use

Also Published As

Publication number Publication date
AU2015254558B2 (en) 2021-02-25
EP3137501A2 (en) 2017-03-08
AU2015254558A1 (en) 2016-12-08
EP4001310A2 (en) 2022-05-25
JP2020018307A (en) 2020-02-06
ES2899754T3 (en) 2022-03-14
BR112016025450A2 (en) 2017-12-12
JP2017515473A (en) 2017-06-15
WO2015166105A2 (en) 2015-11-05
CA2946669A1 (en) 2015-11-05
EP4001310A3 (en) 2022-08-10
WO2015166105A3 (en) 2015-12-30
EP3137501B1 (en) 2021-09-29
US20170166634A1 (en) 2017-06-15
US10654926B2 (en) 2020-05-19

Similar Documents

Publication Publication Date Title
US20200247885A1 (en) P2x4 antibodies &amp; uses thereof
WO2020200196A1 (en) Anti-claudin 18.2 antibody and application thereof
US10894833B2 (en) Agents, uses and methods for treatment
US20210347899A1 (en) Anti-klrg1 antibodies
US20230118983A1 (en) Tetravalent FZD and WNT Co-receptor Binding Molecules and Uses Thereof
CN112334484A (en) anti-CD 3 epsilon antibodies and methods of use thereof
JP2022527372A (en) Anti-integrin antibodies and their use
CN117295766A (en) Antibodies specific for sialic acid binding IG-like lectin 15 and uses thereof
CN114478771A (en) OX40 antibodies and medical uses thereof
KR20220050182A (en) Anti-CD22 Antibodies and Uses Thereof
US20240228631A9 (en) Tetravalent FZD and WNT Co-receptor Binding Antibody Molecules and Uses Thereof
WO2024022478A1 (en) Antibody binding to cannabinoid receptor cb1 and use thereof
WO2023074888A1 (en) NOVEL Nav1.7 MONOCLONAL ANTIBODY
KR20240026496A (en) Anti-nectin4 antibody and multispecific protein complex containing the same
WO2023250402A2 (en) Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof
KR20210158693A (en) Anti pcsk9 antibody and use thereof
KR20230158526A (en) Therapeutic binding molecule that binds to CCR9
CN116082513A (en) Isolated antigen binding proteins and uses thereof
KR20240091042A (en) Isolated antigen binding proteins and uses thereof
EA044828B1 (en) MONOCLONAL ANTIBODY AGAINST NERVE GROWTH FACTOR, GENE ENCODING ITS AND ITS APPLICATION

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

AS Assignment

Owner name: ASTRAZENECA AB, SWEDEN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SNIJDER, HARM JAN;REEL/FRAME:053036/0741

Effective date: 20161130

Owner name: MEDIMMUNE LIMITED, UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ASTRAZENCA AB;REEL/FRAME:053036/0706

Effective date: 20161207

Owner name: MEDIMMUNE LIMITED, UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WILLIAMS, WENDY A.;JONES, CLARE;BUTTON, JAMES;AND OTHERS;SIGNING DATES FROM 20161130 TO 20161201;REEL/FRAME:053036/0855

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION